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11.1 PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder, 
characterized by a wide range of motor and nonmotor symptoms (Lees, Hardy, and 
Revesz 2009) (see Box 1.1). Despite the invariably progressive character of PD, the life 
expectancy of people with PD is only modestly influenced by the disease (de Lau et 
al. 2005). Most people with PD live for many years with their disease; although with 
progressive reductions in quality of life. PD is relatively common: the reported 
prevalence in the general population is around 0.3%, but this rises rapidly with age – 
up to 1.4% for over 55s (Kowal et al. 2013), with an average age at diagnosis of 70.5 years 
(Van Den Eeden et al. 2003). The prevalence of PD in 2040 is estimated to be be twice 
as high as in 2015 (Dorsey et al. 2007; Dorsey et al. 2018; Dorsey et al. 2020); in part 
as a result of the aging of the population, but also because of exposure to abundantly 
present environmental toxins, such as pesticides or trichloroethylene (Dorsey et al. 
2007; Dorsey et al. 2018; Dorsey et al. 2020). Both the incidence and prevalence seem to 
be higher in men than in women (Georgiev et al. 2017). 
 
Box 1.1: Symptoms of Parkinson’s disease
Besides the four traditional motor symptoms of Parkinson’s disease (tremor, 
bradykinesia, rigidity and postural instability), many other motor and non-motor 
symptoms may occur, resulting in a complex phenotype that requires a comprehen-






- Masked facial expression
- Speech disturbances 




- Stooped posture 
- Shuffling, short-stepped gait










- Pain and sensory disturbances
- Dermatologic findings (seborrhea)












1Apart from being seamless, the care for people with PD also needs to be sustainable. 
Sustainable healthcare implies that the level of care can be maintained through time, 
and that the care is efficient and does not unnecessary drain finite resources (Jeurissen, 
Maarse, and Tanke 2018) (Box 1.2). Since life expectancy of the general population is 
rising, people use more care and for a longer period. This causes pressure on healthcare 
costs, which are rising globally (Xu et al. 2018). PD is no exception, since the incidence 
of PD increases dramatically over the age of 60 (Tysnes and Storstein 2017).
1.3  MANY PEOPLE WITH PD DO NOT RECEIVE OPTIMAL 
 CARE
Regrettably, the current care provision for people with PD is often far from seamless 
and sustainable. First, the care people with PD receive varies much between persons, 
thus not ‘consistent’, ‘coherent’ or ‘uniform in quality’. For example, approximately 
only half of the Europeans with PD regularly visit a neurologist (Bloem and Stocchi 
2015). In the USA, forty-two percent of the people with PD over 65 years of age do 
not see a neurologist at all, and this percentage can be as high as 100% in some rural 
areas (Willis et al. 2011). Such variation in accessibility of neurologists also affects 
the utilization of other healthcare services. For example, neurologist visits seem to 
be an important driver for rehabilitation therapy use among elderly with PD in the 
USA (Fullard et al. 2017). Referrals to allied healthcare providers also vary between 
different countries (Stocchi and Bloem 2013). Besides, allied healthcare services are 
inappropriately allocated: a survey among Dutch people with PD in 2004 revealed that 
41% of those requiring a referral to a physiotherapist did not receive physiotherapy. 
In contrast, half of the people with PD who did not require physiotherapy received 
it anyway (Keus et al. 2004). Suboptimal allocation of physiotherapy resources can 
lead to more complications, such as hip fractures, among people with PD (Bloem et 
al. 2017). Potentially avoidable complications not only affect the involved people with 
PD, but ultimately also society, as these often require costly treatments, affecting the 
sustainability of care.
There is currently no cure for PD; nor can the disease progression be slowed down. 
The treatment of PD is therefore entirely symptomatic, and aims to optimize the 
person’s quality of life by reducing the symptom burden, and avoiding PD-related 
complications such as falls and fractures. Treatment includes pharmacotherapy, 
various allied healthcare treatments and several device-aided treatments, including 
deep brain stimulation and two types of pump therapies (Hijdra, Koudstaal, and 
Roos 2016). The costs of these treatments are substantial: in the Netherlands, the 
healthcare costs of the approximately 40,000 people with PD were estimated to be at 
least € 204.1 million in 2017 (National Institute of Public Health and the Environment 
2019a, 2019c). This figure does not include the costs of PD-related complications or 
comorbidities; neither does it include the secondary economic costs of the disease (for 
example: loss of productivity of the people with PD or their family members)(National 
Institute of Public Health and the Environment 2019b). Therefore, the total costs of PD 
are undoubtedly even considerably higher.
1.2  SEAMLESS AND SUSTAINABLE CARE FOR PEOPLE  
 WITH PD
To achieve the best results from the previously mentioned treatments, the care for 
people with PD needs to be well organised and coordinated. This is often referred to 
as ‘seamless’ care (Hammond 2010). Seamless care is care which is consistent and 
coherent, marked by an orderly, logically and aesthetically consistent relation of 
parts, without discontinuities or disparities, uniform in quality and combined in an 
inconspicuous way (Hammond 2010) (Box 1.2). Key objectives are continuity of care, 
multiple uses of healthcare data, and collaborative partnerships between healthcare 
providers (Hammond 2010; Howitt 2011). The concept of seamless care is applied 
when there is a transition of a patient from one healthcare provider to another, most 
notably from the hospital to the persons’ own home (Spehar et al. 2005; Knight et 
al. 2013). Such transitions are very common in the overall management process for 
people living with PD, with involvement of multiple healthcare providers who work 
in different echelons of healthcare. Even people with relatively mild PD regularly visit 
general practitioners, neurologists, specialized nurses, physiotherapists, occupational 
therapists and speech-language therapists. In the more advanced stage, dieticians, 
psychologists, other medical specialists and nursing home facilities often also become 
involved (Bloem et al. 2010a). The number of different healthcare providers increases 
even more when complications occur, such as a hip fracture. Regrettably, these many 
providers rarely work together as a team; and indeed, many providers do not well know 
what others can offer to the overall management process. Sharing of information is 
generally poor, which hampers effective care delivery. These considerations highlight 
the importance of ascertaining a more seamless care delivery for people living with PD.
Box 1.2: Definitions of seamless and sustainable care
Seamless care: care which is consistent and coherent, marked by an orderly, logically 
and aesthetically consistent relation of parts, without discontinuities or disparities, 
uniform in quality and combined in an inconspicuous way (Hammond 2010).
Sustainable care: care which can be maintained through time, and that is efficient 












1Studying these elements of PD care might result in suggestions for improvements, 
and thereby contribute to more seamless and sustainable care. We will analyse these 
elements from the perspective of the person with PD, as well as the perspective of 
society. 
1.4 TOWARDS SEAMLESS AND SUSTAINABLE CARE FOR  
 PEOPLE WITH PD
Initiatives have been taken to make the care for people with PD more seamless and 
sustainable. Some examples are the Centers of Excellence network of the Parkinson’s 
Foundation (Parkinson's Foundation 2019a, 2019b), the World Parkinson’s Program 
(Worlds Parkinson's Program 2019), and the UK Parkinson’s Excellence Network 
(Parkinson's UK 2019). All these initiatives enhance seamless and sustainable care 
by researching and improving expertise and multi-disciplinary collaboration of 
healthcare providers involved in PD.
Since this thesis is conducted in the Dutch care setting, it is important to assess the 
Dutch situation. In the Netherlands, the initiative with the greatest impact on PD care 
is ParkinsonNet, a not-for-profit healthcare organisation exclusively for people with 
PD or a form of atypical parkinsonism (Bloem and Munneke 2014). Founded in 2004, 
the ParkinsonNet approach strives to improve the care for people with PD by improving 
multi-disciplinary collaboration, by enhancing PD-specific knowledge among both 
healthcare providers and people with PD, and by stimulating patient-centeredness. 
To achieve this, ParkinsonNet has created regional networks of a limited number of 
highly motivated and well-trained healthcare providers, who each treat large numbers 
of people with PD. These regional networks include neurologists, physiotherapists, 
occupational therapists, speech & language therapists, dieticians, specialised 
Parkinson nurses, elderly care specialists, rehabilitation specialists, psychiatrists, 
psychologists, pharmacists, social workers, and sex therapists (Bloem and Munneke 
2014; Bloem et al. 2017). These providers receive special training based on national and 
international clinical guidelines; this includes both a three-day basic training course 
and annual follow-up training courses. Expertise is further enhanced by raising the 
caseload per provider. Additionally, different ICT innovations have been implemented 
to support both providers and people with PD. Examples of these are web-based 
communities, ParkinsonTV (a web-based educational television programme) and 
a web-based search engine to readily identify specialised ParkinsonNet providers 
(Bloem and Munneke 2014). An overview of the key components of ParkinsonNet is 
provided in Table 1.2. 
Today, ParkinsonNet consists of 70 regional networks with over 3,200 specialised 
healthcare providers (ParkinsonNet 2019). The approach has been evaluated in 
Second, many studies show that the current care for people with PD is not ‘marked 
by an orderly, logically and aesthetically consistent relation of parts’. In a European 
survey, forty-five percent of respondents with PD regarded the diagnostic process as 
‘poor' or 'very poor' (Bloem and Stocchi 2012). Dutch people with PD reported lack of 
emotional support from their healthcare providers (van der Eijk, Faber, Al Shamma, et 
al. 2011). Additionally, people with PD often feel not involved in treatment decisions. 
Although in the above-mentioned European survey 63% of respondents with PD 
were satisfied with the attention from healthcare providers, just 12% felt involved in 
treatment decisions (Bloem and Stocchi 2015). While many people with PD desire more 
active involvement in treatment decisions, they lack sufficient tools and information 
to do so (van der Eijk, Faber, Al Shamma, et al. 2011). Thus, they receive care focussed 
on pharmacological suppression of symptoms, and not on what really matters for the 
quality of life of the individual person with PD (van der Eijk, Faber, Al Shamma, et al. 
2011; Findley and Baker 2002; Grosset and Grosset 2005). 
Third, financial issues in current healthcare systems might stand in the way of 
seamless and sustainable care delivery. Separate payment systems between different 
echelons of the healthcare sector – e.g., between hospital care, long-term care or 
primary care – frustrate continuity of care, hamper a shared use of healthcare data, 
and interfere with an effective collaboration between healthcare providers (Jeurissen, 
Maarse, and Tanke 2018). In addition, the dominant fee-for-service system harms 
sustainability by inducing healthcare providers to increase their volumes; i.e., the 
number of treatments they can claim. More care delivery does not necessarily mean 
better care: incentivising volume can result in overuse of more or less expensive 
treatments that are not in line with what people with PD desire (Jeurissen, Maarse, 
and Tanke 2018). Fee-for-service can also frustrate a more home-based care approach, 
since healthcare providers usually lose income when facilitating such care (Landers et 
al. 2016). 
Finally, the caseload for PD is generally low per individual healthcare provider. The 
care for people with PD is typically delivered by scattered healthcare providers who 
each manage only very few people with PD, with possible adverse effects. Specifically, 
this lack of concentration of care might harm seamless care delivery in two ways. 
First, it might prevent adequate coordination and multidisciplinary collaboration, 
and lead to lack of alignment between different treatments (Nijkrake et al. 2009; van 
der Eijk, Faber, Al Shamma, et al. 2011). Second, the knowledge about and expertise 
in PD might fall short. Many people with PD indeed encounter difficulties in finding 
healthcare providers with an adequate level of expertise in PD (Keus et al. 2004; van der 
Eijk, Faber, Al Shamma, et al. 2011). Several surveys among allied healthcare providers 
confirm concerns about a lack of expertise among physiotherapists, occupational 












1TABLE 1.3 | General research question and sub questions
 
We will answer these questions in the following chapters:
•  When aiming for seamless and sustainable care, it is important to know what care 
people with PD use. In chapter 2 we will reconstruct the sex-specific ‘journey’ 
travelled by a person with PD through the healthcare system during the first five 
years of the disease course, based on claims data. 
•  In chapter 3 we searched for elements that are missing in the care from the per-
spective of the person with PD, using the Voice of the Customer interview method. 
•  In chapter 4 we present an overview of payment models in healthcare that include 
a financial incentive based on outcomes of care (outcome-based payment models, 
OMPMs) and their effects on the quality and costs. Since there are no experiments 
with OBPMs in specific PD situations, we made a comprehensive systematic review 
of all the literature about OBPMs in healthcare.
•  Chapter 5 analyses the density of provider networks and its effect on health 
outcomes and costs. This can be seen as an indication of volume efficiencies for 
chronic care.
•  In chapter 6 we discuss how recent innovations can bring the care for people with 
PD closer to home. 
•  The results of the previous chapters are discussed in chapter 7, which also gives the 
answers to our research questions. 
TABLE 1.2 | Key components of the ParkinsonNet approach (Bloem and Munneke 2014)
multiple studies (Nijkrake et al. 2010; Munneke et al. 2010; Beersen et al. 2011; van der 
Marck, Munneke, et al. 2013; Wensing et al. 2011; Canoy et al. 2015; van der Eijk, Bloem, 
et al. 2015; Sturkenboom et al. 2015; Sturkenboom et al. 2014; Ketelaar et al. 2013; 
Ypinga et al. 2018; Bloem et al. 2017). There is ample evidence that ParkinsonNet leads 
to a better quality of care, as reflected by a greater knowledge of PD among providers 
(Nijkrake et al. 2010a), better adherence to guidelines (Nijkrake et al. 2010; Munneke 
et al. 2010; Beersen et al. 2011), and a higher caseload per provider (Nijkrake et al. 2010; 
Munneke et al. 2010). 
There is also evidence that ParkinsonNet enhances sustainability. Studies report 
better health outcomes and fewer PD-related complications (Beersen et al. 2011; 
Sturkenboom et al. 2014; Ypinga et al. 2018); and thereby reduced healthcare costs 
(Munneke et al. 2010; Beersen et al. 2011; Ypinga et al. 2018). Costs are also reduced 
by the greater efficiency of care, because therapists can do with fewer treatment 
sessions (Ypinga et al. 2018). Following the successful implementation process in the 
Netherlands, and stimulated by the demonstrated cost-effectiveness, other countries 
have also expressed an interest in introducing a similar type of network care. In the 
past few years, elements of the Dutch ParkinsonNet approach have successfully 
been introduced in the USA (ParkinsonNet 2014), Norway (ParkinsonNet 2016), 
Luxembourg, Germany and Czech Republic (Gal et al. 2017).
1.5 AIMS OF THIS THESIS
In this thesis, we seek to unravel certain important elements for seamless and 
sustainable care. We first analyse the current situation from the perspective of the 
person with PD, and identify the actual patients’ needs. We then investigate potential 
innovations. Given that the organisation of PD care requires improvements in specific 










Development of mono- and multidisciplinary guidelines
Inclusion of a restricted number of participants 
Preferred referral to ParkinsonNet participants to increase caseload
Baseline training for participants and knowledge exchange structures 
Stimulating adherence to guidelines 
Open source publication of outcomes 




How can we achieve seamless and sustainable care for 
people with PD? 
•  What does the current patient journey of people with PD look like? 
(chapter 2)
•  What are the current seams in the care for people with PD?  
(chapter 3)
•  Can outcome-based payment models contribute to seamless and 
sustainable care for people with PD?  
(chapter 4)
•  Can the density of provider networks contribute to seamless and 
sustainable care for people with PD?  
(chapter 5)
•  How can we organise seamless and sustainable care for people 
with PD at the patient’s home?  
(chapter 6)
CHAPTER 2
Sex-specific patient journeys 
in early Parkinson’s disease 
in the Netherlands
F.P. Vlaanderen, Y. de Man, J.H. Krijthe, M.A.C. Tanke, A.S. Groenewoud, 
P.P.T. Jeurissen, S. Oertelt-Prigione, M. Munneke, B.R. Bloem and M.J. Meinders, 
‘Sex-Specific Patient Journeys in Early Parkinson's Disease in the Netherlands’. 
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2.1 INTRODUCTION
During the course of the disease, a patient with Parkinson’s disease (PD) visits many 
different healthcare providers from different disciplines.(Radder et al. 2018) This 
‘journey through the healthcare system’ varies per individual because of heterogeneity 
of symptoms, differences in disease progression rate, and the occurrence of PD-related 
complications. One important source of this variation might be sex differences in the 
presentation of PD. (Georgiev et al. 2017) For example, numerous studies confirm that 
the incidence and prevalence of PD is higher in men,(Baldereschi et al. 2000; Alves 
et al. 2009; Kovács et al. 2016; Georgiev et al. 2017; Marras et al. 2018) that the disease 
starts at an earlier age in men (Haaxma et al. 2007; Georgiev et al. 2017) and that the 
disease progresses faster in men.(Haaxma et al. 2007; Scott et al. 2000) In women, PD 
tends to be more often tremor-dominant,(Georgiev et al. 2017; Haaxma et al. 2007; 
Solla et al. 2012) while in men it is more often the akinetic-rigid type. (Georgiev et al. 
2017; Baba et al. 2005; Picillo et al. 2017)
We do not know if these sex differences translate to different patient journeys 
between men and women with PD. But when striving for optimal patient-centered 
and integrated care, it is vital to understand what the patient journeys look like. 
As shown for other diseases(Kuo et al. 2015; Mehta et al. 2017; Hibbard, Mahoney, 
and Sonet 2017; Laveau et al. 2017) such insights can be used to improve access 
and optimize coordination of care. In this paper, we use medical claims data to 
reconstruct the sex-specific journey for Dutch people with PD during the first five 
years after diagnosis. 
In the Netherlands, the patient’s journey starts when a general practitioner makes a 
referral to a neurologist when symptoms of Parkinson’s appear. Neurologists, all 
located in hospitals, make the diagnosis. Thereafter, a person with PD visits the 
hospital every three months, to see their neurologist, who is supported by nurses 
or nurse specialists. The nurse and neurologist work in close collaboration with 
allied healthcare professionals in the community, including, e.g., physiotherapists, 
occupational therapists and speech & language therapists. Hospital care is covered 
by the compulsory health insurance, whereas allied healthcare services are covered 
by additional insurance package, which is not compulsory but taken up by over 80% 
of the Dutch people. In addition, the Netherlands stands out with comparatively low 
out-of-pocket payments.(Maarse, Jeurissen, and Ruwaard 2016) This probably reduces 
any possible selection bias due to differences in price responsiveness among people 
with PD. In the analysis, we therefore focus on the most frequently involved healthcare 
disciplines (neurologists, allied healthcare therapists and general practitioners) 
and on recognized clinical milestones (PD-related complications, nursing home 
admission and death). 
ABSTRACT
Objective: To reconstruct a sex-specific patient journey for Dutch people with Parkinson’s 
disease (PD) during the first five years after diagnosis.   
Method: We analyzed a national administrative medical claims database containing data 
of all patients newly diagnosed with PD between 2012 and 2016 in the Netherlands. We 
performed time-to-event analysis to identify the moments when patients received care 
from neurologists, allied healthcare therapists or general practitioners. We also extracted 
relevant clinical milestones: unexpected hospitalization for PD, pneumonia, orthopedic 
injuries, nursing home admission and death. Using these data, we constructed the patient 
journey stratified for sex.
Results: We included claims data of 13,518 men and 8,775 women with newly diagnosed PD 
in the Netherlands. While we found little difference in neurologist consultations, women 
visited general practitioners and physiotherapists significantly earlier and more often (all 
p-values <0.001). After five years, 37.9% (n=3,326) of women had visited an occupational 
therapist and 18.5% (n=1,623) a speech & language therapist at least once. This was 33.1% 
(n=4,474) and 23.7% (n=3,204) for men. Approximately two years after diagnosis, PD-
related complications (pneumonia, orthopedic injuries and PD-related hospitalization) 
occurred for the first time (women: 1.8 years; men: 2.3 years), and after five years, 72.9% 
(n=6,397) of women and 68.7% (n=9,287) of men had experienced at least one. 
Discussion: Considering the strengths and limitations of our methods, our findings 
suggest that women experience complications and access most healthcare services 
sooner after diagnosis and more frequently than men. The identified sex differences 
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This method deals with differences in length of follow-up between patients. The 
follow-up length was calculated for every patient as the number of days from diagnosis 
till death or till December 31st 2016, i.e., the last data point in the dataset. The median 
values of the time-to-event analysis were plotted on a timeline, representing the 
journey of the average person with PD. We constructed one timeline for men, and one 
for women. We chose median values over mean values because of the considerable 
differences in length of follow-up in our sample. Sex differences were statistically 
analyzed using log rank tests. 
Standard Protocol Approvals, Registrations, and Patient Consents
This study was approved by the institutional review board of the Radboud University 
Medical Center with a waiver of consent for participants in the study.
Data Availability Policy
All data, published or not published within the article, is accessible through Vektis. 
Analyses were performed in SAS.
2.3 RESULTS
We included medical claims data of all 22,293 newly diagnosed patients in the 
analyses. As shown in Table 2.1, the population consists mainly of elderly individuals, 
a minority of whom lives in a nursing home before diagnosis. 
TABLE 2.1 | General characteristics of the population (n=22,293)
Healthcare utilization
Figure 2.1 shows two timelines representing the sex-specific patient journey of men 
and women with PD. Table 2.2 shows the inter quartile ranges (IQRs).
2.2  MATERIALS AND METHODS
To reconstruct the PD patient journey, we used medical claims data of all people 
with PD diagnosed between 2012 and 2016 in the Netherlands. The dataset was made 
available through Vektis, a not-for-profit organization that combines claims data of 
all Dutch healthcare insurance companies.(Vektis 2018) Since all Dutch citizens are 
obliged by law to have a healthcare insurance, the Vektis database contains the claims 
data of approximately 99.8% of the Dutch population(Zorgwijzer 2019) (17.3 million 
people (CBS 2018)). The claims database contains data on primary care, emergency 
care and hospital care, plus nursing home residency. The dataset was anonymized by 
Vektis, making available only the sex, year of birth, and a unique random identifier for 
each individual. The key to the identifiers was not available to the researchers. 
Similar to a recent paper using similar Dutch claims data in PD,(Ypinga et al. 2018) we 
included only patients who had at least one diagnosis-related group code (DRG code) 
for PD. In the Netherlands, PD can only be diagnosed by a neurologist. We therefore 
regarded the first PD-related neurology DRG as the moment of diagnosis and, as such, 
as the starting point of the journey.
To reconstruct the patient journey, we included the professionals most frequently 
involved in the treatment of PD. These are neurologists (together with specialized 
PD nurses, since both claim their activities under the DRG code of the hospital), 
physiotherapists, occupational therapists, speech & language therapists, and general 
practitioners. For every included claim, we calculated how many days after the first 
diagnosis the activity had occurred. Next, we selected the 1st, 10th, 20th, and 30th visit to the 
general practitioner and the allied healthcare therapists. Unlike these disciplines, claims 
related to hospital care are defined in a DRG model, rather than by a pay-per-visit model. 
The first PD-related DRG includes at least one visit to a neurologist, but the actual number 
of visits may be higher. A subsequent PD-DRG can only start 90 days after the initial 
PD-DRG, and contains at least one visit to a neurologist or specialized PD nurse. Third 
and subsequent PD-DRGs can only start 365 days after the previous one. Consequently, 
the maximum number of PD-DRGs within the first five years after diagnosis is six. We 
therefore selected the first six PD-DRGs to assess utilization of neurologist. In a similar 
way, we identified the time after diagnosis until five clinical milestones in the patient’s 
journey had been reached, using a methodology previously used in a comparable 
analysis:(Bjornestad et al. 2017) nursing home admission, hospitalization for three 
PD-related complications (unexpected hospitalization for PD, pneumonia, orthopedic 
injuries)(Ypinga et al. 2018; Muzerengi et al. 2016) and, finally, death. 
We used event history analysis with Kaplan-Meyer estimators to determine after how 
many days the average patient received specific care or reached a clinical milestone. 
Men (n = 13,518; 60.6%) Women (n = 8,775; 39.4%)
Age at diagnosis (mean, in years) 71.6 (SD: 9.9) 72.5 (SD: 10.2)
Early onset PD (<50 years at  
diagnosis, n (%))
421 (3.1%) 278 (3.2%)
Length of follow-up (mean) 2.5 years (SD: 1.4) 2.5 years (SD: 1.4)
Living in a nursing home at time  
of diagnosis (n (%))
673 (5.0%) 729 (8.3%)
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TABLE 2.2 | Time (in days, since diagnosis) till relevant provider contacts and clinical 
milestones during the patient journey, by sex
Approximately one month after diagnosis, patients first visited their general 
practitioner (women after 31 days; men after 41). Thereafter, women saw their general 
practitioner approximately once every six weeks (43 days). Men saw their general 
practitioner less often: approximately once every eight to nine weeks (59 days). For 
both sexes the frequency declined after the 20th visit (median >5 years for 30th visit). In 



































































































Median (1st – 3rd quartile)
Men
Median (1st – 3rd quartile)
P-value
Provider contact
1st neurology DRG 0 (0 – 0) 0 (0 – 0) 0.270
2nd neurology DRG 90 (90 – 240) 90 (90 – 210) 0.079
3rd neurology DRG 455 (360 – >1826) 455 (330 – 1454) 0.040
4th neurology DRG 820 (575 – >1826) 820 (575 – >1826) 0.280
5th neurology DRG 1185 (935 – >1826) 1185 (935 – >1826) 0.348
6th neurology DRG 1545 (1180 – >1826) 1430 (1180 – >1826) 0.333
1st general practitioner visit 31 (8 – 87) 41 (11 – 116) <0.001
10th general practitioner visit 428 (231 – 824) 574 (301 – 1112) <0.001
20th general practitioner visit 863 (505 – 1605) 1178 (659 – >1826) <0.001
30th general practitioner visit >1826 (830 – >1826) >1826 (1082 – >1826) <0.001
1st physiotherapist visit 140 (16 – 826) 229 (38 – 1303) <0.001
10th physiotherapist visit 460 (136 – >1826) 679 (177 – >1826) <0.001
20th physiotherapist visit 877 (268 – >1826) 1202 (341 – >1826) <0.001
30th physiotherapist visit >1826 (415 – >1826) >1826 (530 – >1826) <0.001
1st occupational therapist visit >1826 (986 – >1826) >1826 (1247 – >1826) <0.001
1st speech & language therapist 
visit
>1826 (>1826 – >1826) >1826 (>1826– >1826) <0.001
Clinical milestones
Nursing home admission >1826 (1571 – >1826) >1826 (>1826 – >1826) <0.001
1st PD-related complication
  pneumonia >1826 (661 – >1826) >1826 (686 – >1826) 0.879
  orthopedic injuries 1114 (347 – >1826) >1826 (527 – >1826) <0.001
  hospitalization >1826 (>1826 – >1826) >1826 (>1826 – >1826) 0.359
  All PD-related complications 646 (179 – >1826) 828 (214 – >1826) <0.001
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. 
FIGURE 2.2 | Kaplan-Meyer curve of the time-to-event analysis for PD-related complications 
 
2.4 DISCUSSION
The reconstruction of the Parkinson patient’s journey through the Dutch healthcare 
sector during the first five years after diagnosis, reveals quantitative information 
about healthcare utilization and the occurrence of clinical milestones over time. It 
also reveals sex differences: in the Netherlands, women visit most of the included 
healthcare professionals sooner after diagnosis and more frequently. In addition, 
PD-related complications occur earlier in women than in men. A sizeable subgroup 
of patients is admitted to nursing homes within five years after diagnosis. Again, this 
happens more frequently in women. Finally, 14.6% of the women and 18.3% of the 
men died within five years after the diagnosis.
Relation with previous findings
Our findings confirm and extend earlier work, from both inside and outside the 
Netherlands. The characteristics of our population are comparable to earlier work 
when it comes to general incidence(Hijdra, Koudstaal, and Roos 2012) and the male 
predomination of the disease.(Baldereschi et al. 2000; Alves et al. 2009; Kovács et al. 
Three months after diagnosis, many patients saw their neurologist or specialized PD 
nurse again (both for men and women median = 90 days). However, a substantial part 
of the population also visited their neurologist or specialized PD nurse much later 
for the second time, i.e., not before eight to nine months after diagnosis (75th quartile 
value = 210 days (men) and 240 days (women)). After the second visit, the frequency 
of claimed neurology DRGs was about once a year for both sexes, i.e. they visited a 
neurologist or specialized PD nurse at least once a year. Except for the third visit, 
where men used neurologist services slightly earlier than women, no significant sex 
differences were found.
Women with PD started their physiotherapy treatment approximately five months 
after diagnosis (median = 140 days). Their first twenty physiotherapy sessions took 
place about once every five to six weeks. Men started to visit a physiotherapist later 
after the diagnosis then women: eight months after diagnosis (median = 229 days), and 
with a lower frequency: once every seven to eight weeks. For both sexes the frequency 
declined after the 20th session (median >5 years for 30th physiotherapy sessions). In 
all analyses, women used physiotherapist services significantly earlier and within a 
shorter timespan than men (p-values <0.001). 
For occupational therapists and speech & language therapists, the median values for 
the first visits were not reached within the follow-up time of five years. Therefore, 
they are not displayed in Figure 2.1. After five years, 37.9% of the women (n=3,326) and 
33.1% of the men (n=4,474) had visited an occupational therapist at least once. This was 
18.5% for women (n=1,623) and 23.7% for men (n=3,204) for the first visit to speech & 
language therapist. These differences were statistically significant (p-values <0.001)
Clinical milestones
Approximately two years after diagnosis, the first PD-related complication occurred. 
For women the median value was 1.8 years (IQR= 0.5 - >5 years); for men this was 
2.3 years (IQR= 0.6 - >5 years; p-value <0.001). We added the Kaplan-Meyer curve of 
this analysis in Figure 2.2. As shown in Table 2.2, orthopedic injuries were the most 
common complication, and occurred earlier in the course of the disease in women 
(p-value <0.001). Five years after diagnosis, the percentage of patients that had 
experienced at least one PD-related complication was 72.9% in women (n=6,397) and 
68.7% in men (n=9,287). The percentage of women admitted to a nursing home rose 
from 8.3% (n=728) before diagnosis to 27.5% (n=2,413) after five years of PD. In men this 
increase is from 5.0% (n=676) to 22.5% (n=3,042) (p<0.001). During the first five years 
after diagnosis, significantly fewer women died (14.6%) than men (18.3%, p-value = 
<0.001). 
Time in days
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However, since our population characteristics matched well with previous reports, 
we do not think that all these factors affected our data on a large scale. Moreover, it 
is unlikely that this diagnostic error affected men and women differentially. Another 
strength is that our study is based on highly standardized claims data. And we only 
used items that, although self-reported by healthcare professionals, are known to be 
reliably completed.(Vektis 2017) 
As claims data don’t include detailed information about the clinical status of the 
patients, we were not able to correct for factors that confound and/or modify the 
relationship between sex and complications.(Bloem et al. 2018) This holds particularly 
true for co-morbidity and PD-related complications that are more frequently asso-
ciated to female sex (e.g., dyskinesia, motor and non-motor complications).(Picillo 
et al. 2017) Also, the sex-difference in the occurrence of orthopedic injuries might 
be explained by the female predominance in osteoporosis. Therefore, our findings 
require confirmation in other, independent datasets. 
Finally, our findings might be difficult to extrapolate to other countries with another 
organization of the healthcare system. For example, duration of visits and treatment 
intensity can differ between countries. Moreover, the presence of ParkinsonNet in the 
Netherlands contributed to the quality and role of allied health care professionals, and 
stimulated access to specialized and multidisciplinary Parkinson care.(Bloem et al. 
2017)
Practical implications
Comparable work on other diseases suggests that our reconstruction of the patient 
journey may lead to better patient-centered care delivery. Specifically, it provides 
healthcare professionals an overview of where and when particular physicians get 
involved, which might reveal errors in providers’ perspectives.(Tan et al. 2017) It 
might act as a useful tool to gain insight in patient experiences,(Tan et al. 2017; Kuo et 
al. 2015) to reveal barriers to access,(Kelly et al. 2017; Mehta et al. 2017) to detect gaps 
in care delivery,(Thrift-Perry et al. 2018; Roughead, Semple, and Rosenfeld 2016) and 
to improve coordination and quality of care.(Kelly et al. 2017; Crepaz and Curry 2013) 
The identified sex differences might contribute to the debate about differences in PD 
between men and women, extending earlier work on different phenotypes to now 
include contrasts in healthcare utilization as well. We hope these insights can lead to 
better and more personalized care for people with PD of both sexes. 
 
2016; Georgiev et al. 2017; Marras et al. 2018) Comparable values for age at diagnosis 
and percentage of early-onset PD were also found before.(Van Den Eeden et al. 2003) 
However, while most studies found a faster disease progression in men,(Haaxma et 
al. 2007; Scott et al. 2000) our findings suggest a more rapid disease progression in 
women, since they visited their healthcare professionals sooner and experienced 
orthopedic injuries earlier and more often after diagnosis. However, there might 
be other explanations for this observation. First, the included women were living 
relatively more often in a nursing home before diagnosis, indicating that they were 
probably in a worse physical condition at the outset. This might make them more prone 
to develop complications and also explain the more intense healthcare utilization. 
Patients living in nursing homes might also have easier access to the in-house allied 
health therapists. Second, the findings can indicate a doctor or patient delay in the 
diagnostic process in women, meaning that women receive the diagnosis relatively 
late in the course of the disease. This has been found earlier.(Saunders-Pullman et 
al. 2011) Alternatively, women might find their way to healthcare professionals more 
effectively (or faster). This has been observed for other diseases(Addis and Mahalik 
2003; Cohen 2009) but not previously for PD. 
What surprised us was the high mortality rate and that patients experienced their 
first PD-related complication already two years after the diagnosis. No PD-specific 
literature is available to compare these results with. The average age at onset of 72 years 
is in line with other population-based cohort studies.(Darweesh et al. 2017; Savica et 
al. 2016; de Lau and Breteler 2006) The finding that 5.08.3% of the patients are living 
in a nursing home at diagnosis, which is are relatively high, can be understood when 
considering that the Netherlands has relatively one of the largest long term care 
sectors in the world.(Mosca et al. 2016) Given that patients living in a nursing home are 
likely more vulnerable, this might explain the mortality and complication rates.  
Strengths and limitations 
Our methods have strengths and limitations. An important strength is that our dataset 
contained all newly diagnosed patients in the country over a period of five consecutive 
years. This reduces a potential selection bias. However, some selection may have 
resulted from our inclusion criteria. Since we included all patients with a first PD 
DRG, there might be some cases where the initial diagnosis of PD was wrong. PD is 
hard to diagnose, with reported diagnostic error rates of >10%.(Skinner, Scott, and 
Martin 2016) Therefore, we cannot exclude that some patients had other conditions, in 
particular one of the forms of atypical parkinsonism.(Hijdra, Koudstaal, and Roos 2012) 
Our sample most likely included people who were incorrectly diagnosed. A review of 
the literature, including 11 studies, concluded that the validity of clinical diagnosis of 
PD Is not satisfying, which was the case for both non-experts and movement disorder 
specialists.(Rizzo et al. 2016) We were not able to correct for this error in our analysis. 
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3.1 INTRODUCTION
To improve the care for patients with chronic neurological conditions like Parkinson’s 
disease, identifying the core needs of patients is crucial (Kleiner-Fisman, Gryfe, 
and Naglie 2013). Usually, these needs are assessed by interviews, focus groups or 
questionnaires among patients or healthcare professionals. Kaiser Permanente, 
an American not-for-profit health plan, developed the Voice of the Customer (VoC) 
approach to assess the needs of their members from a person-centered perspective. 
This method, which was borrowed from the field of industry to probe the clients’ needs, 
applies sets of qualitative research methods (including semi-structured interviews, 
video ethnography and participatory observations) to identify the needs of end-users, 
i.e. patients, family, clinicians and staff. Kaiser Permanente used these methods 
successfully to develop quality improvement programs and to improve existing 
programs to better meet people’s needs and deliver better outcomes (Neuwirth et al. 
2012; Kaiser Permanente 2016).
In June 2015, we applied the VoC approach for the first time outside of the Kaiser 
Permanente system, and also for the first time in the field of Parkinson’s disease. The 
VoC approach, as described in this paper, aimed to identify the needs of Dutch patients 
with Parkinson’s disease, in order to further optimize the care they receive.
3.2 METHODS
The VoC approach consisted of three steps: (1) capturing patient needs by means of 
semi-structured interviews with patients, relatives and healthcare providers in 
their private environment; (2) preparing a comprehensive summary of the contents 
discussed in the interviews; and (3) prioritizing needs in a consensus meeting, in 
which all parties participate. 
For the first step, all Parkinson patients visiting one of the two hospitals in Nijmegen, 
the Netherlands, were identified using the hospital information systems. There were 
two inclusion criteria. First, patients needed to be diagnosed with Parkinson’s disease. 
For this purpose, the diagnosis in all participants was verified by a neurologist with 
experience in movement disorders, based on accepted international criteria. Second, 
patients had to live in one of three representative suburbs of the city of Nijmegen, the 
Netherlands. All identified patients fulfilling the inclusion criteria then received a 
recruitment letter with information about the VoC approach. 
Participants completed the informed consent form. They were asked which healthcare 
professionals they normally visited. All identified healthcare professionals who were 
working in the three suburbs were then invited for an interview. To adequately capture 
ABSTRACT
Introduction: To improve the care for patients with chronic neurological conditions like 
Parkinson’s disease, identifying the core needs of patients is crucial. 
Methods: In this article, we present the Voice of the Customer approach (originally 
developed in the field of industry to probe the clients’ needs), a novel methodology to 
identify these needs. A group of 12 discussants carried out in depth interviews to patients 
(n=20), relatives (n=12) and healthcare professionals (n=11). The interviewers combined 
the most informative quotations into a comprehensive video, which was used as feedback 
to the interviewees. The interviewees then identified the most important needs in a 
consensus meeting. 
Results: The approach revealed that patients were more concerned about the impact of 
Parkinson’s disease on their daily lives than about the bio-medical aspects of the disease. 
Their top unmet needs were: (1) more self management; (2) better interdisciplinary 
collaboration between different healthcare professionals; (3) more time to discuss the 
future and possible scenarios; and (4) a healthcare professional acting as a single point 
of access, acting as personal case manager, either to solve problems directly or to direct 
patients to the professional best equipped to address the problem at hand. 
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the patient needs by allocating a maximum of three points to each of the different 
needs. They could allocate all their points to one need or divide these between two or 
three needs. The total number of points represented the importance of the topic.
The study was not presented to the institutional review board for ethical approval. 
The Voice of the Customer approach was part of a larger quality improvement program 
for Parkinson patients, for which in the Netherlands no approval by an institutional 
review board is required. Even though this was not formally required, we did obtain 
our own informed consent from every participant, after the purpose of the project and 
the patients’ contribution was carefully explained.
3.3 RESULTS
In total, 89 patients were invited, of whom 23 agreed to participate (26% participation 
rate). Twenty of them were interviewed, of which nine had an interview together with 
their spouse. For three other patients, a close relative participated in the interview 
instead. Additionally, 81 healthcare professionals were invited for an interview. Eleven 
healthcare professionals were included (14% participation rate), leading to a total 
number of 34 interviews. Each interview lasted approximately 70 minutes. See Table 
3.1 for more detailed information about the respondents. 
TABLE 3.1 | Overview of interviewed individuals
the voice of the patient, we aimed for inclusion of 24 patients and 12 healthcare 
professionals. These numbers were based on the prior experiences of Kaiser 
Permanente, where answers saturated when these sample sizes were used. 
The recruited patients, sometimes accompanied or represented by their relatives, 
and the healthcare professionals were subjected to a semi-structured interview of 
approximately one hour. Interviews were always performed by two interviewers. 
During the interviews, the interviewers positioned the interviewee in an expert 
role. The interviewers posed questions, listened and observed, while creating an 
atmosphere that facilitated an open conversation and avoided socially acceptable 
answers. Interviewers were instructed to probe for clarification and examples when 
desirable. All respondents were asked about their positive and negative experiences 
with current care, and their opinion on which aspects needed improvement. The 
interviewed healthcare professionals were asked to answer these questions, both from 
their own perspective and from the perspective of their patient. The interviews took 
place at the home of the patient or the practice of the healthcare professional, and all 
were recorded on video. 
To maintain focus and accelerate the analysis, all interviews were scheduled within 
one week. This required a relatively large pool of 12 interviewers. To diminish inter-
rater bias, we developed specific interview guides for interviews with patients, 
relatives of patients and healthcare professionals. These guides were based on the 
experiences of Kaiser Permanente. Besides instructions for the interviewers, the 
guides did not contain a topic list. This was left out to let the interviews proceed 
as open as possible. They were presented and discussed in a training session for 
the interviewers. Subsequently, the interviewers carried out a test interview, to 
complement the preparation phase. 
For the second step, the interviewers translated the completed interviews into 
patient needs. At the end of each day of the interview week, the interviewers came 
together to review their videos and discuss their findings. During these meetings, the 
interviewers drew conclusions as to the most frequently expressed patient needs. 
After the interview period, the interviewers made a comprehensive video that showed 
the main conclusions, combined with illustrative quotations by the interviewees. This 
video formed a comprehensive outline of the patient's story, and aimed at serving as a 
tool to generate ideas for future improvement projects.
The third step was to prioritize the identified patient needs. During a consensus 
meeting with the interviewed patients and healthcare professionals, the most 
frequently expressed patient needs were presented on posters. After discussing the 
posters and viewing the comprehensive video, the patients and relatives prioritized 
N Patients (n=20) and relatives (n=12) 
20 Patients, of whom nine were accompanied by their relative during the interview
1 Spouse of patient
1 Son of patient
1 Friend of patient
Healthcare professionals (n=11)




1 Speech and language therapist
1 General practitioner
1 Elderly care physician
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The interviewers extracted the 10 most frequently expressed patient needs from the 
interviews, which were subsequently prioritized during a consensus meeting. Patients 
were generally more concerned about the impact of Parkinson’s disease on their daily 
lives than about the bio-medical aspects of their disease. Their top unmet needs were: 
(1) more self management; (2) better interdisciplinary collaboration between different 
healthcare professionals; (3) more time to discuss the future and possible scenarios; 
and (4) one healthcare professional as a single point of access, acting as a personal case 
manager, either to solve problems directly or to direct patients to the professional best 
equipped to address the problem at hand (see Table 3.2). 
3.4 DISCUSSION
The VoC approach is an innovative, person-centered and relatively fast way to reveal 
the most important needs of Parkinson patients. We found that the most urgent patient 
needs, report by themselves, concern the social, emotional or domestic domain of the 
patient. 
Some of our findings confirm the results of previous research: a large European 
survey among 2068 patients revealed that only 11.6% of patients feels involved in 
treatment decisions(Bloem and Stocchi 2015). This is in line with the desire for more 
self-management, similar to what we found, which includes the involvement in 
decision making. However, most other studies found different needs: the main results 
of the previously mentioned European survey found unmet needs in the diagnostic 
process(Bloem and Stocchi 2012), the diagnosis delivery(Bloem and Stocchi 2012) and 
access to allied healthcare professionals and specialized nurses(Stocchi and Bloem 
2013). Other studies reported a lack of information provision, emotional support, and 
multidisciplinary collaboration of healthcare professionals(van der Eijk, Faber, Al 
Shammaa, et al. 2011; Buetow et al. 2008). The differences in identified patient needs 
may be due to the fact that most of the existing literature consists of the standard 
type of questionnaires that focus on the biomedical domain or the professional-
patient relation. In contrast, the VoC method is a deep interviewing method that 
really places the patient in the expert role. This may have led to an accentuation 
of the social, emotional or domestic domain. For example, a key issue such as the 
desire to have one easily approachable healthcare provider who can act as a personal 
case manager, has not been described before. Sharing such personal matters with a 
stranger (an interviewer whom patients did not know) requires an open dialogue and 
an environment in which the interviewee feels sufficiently safe to share his or her 
deepest feelings. This might be the area where the VoC approach can add the greatest 
value, compared to more traditional methodologies like surveys or focus groups. 
TABLE 3.2 | Top 10 priorities of patient needs, as retrieved by the VoC approach.
Item Points Illustrative quotes (translated to English)
1 Desire for self- 
management
22 “The three of us met: the neurologist, the nurse and I. They were talking to 
each other using technical terms, while I was just sitting there. I became a 
bit angry: they were talking about me, so I would like to understand what 
they were saying.” 
“Going to the hospital was compulsory; not because we felt the need to go 
at that moment.”
“I want to decide myself if I need care. That is what I call self-manage-
ment.” 
2 Better collaboration 
between my different 
healthcare professionals
21 “I am seeing a cardiologist. I noticed this was not communicated to my 
neurologist. That makes me question: ‘This is about my life, and two people 
in the hospital are individually working on it. Why are they not working 
together?’”
“I think specialists are named ‘specialists’ because they work in their own 
work field, of which they know almost everything, but they are very isolat-
ed from each other.” 
3 More time for discussing 
the future
20 “I fear the future. I notice that I am thinking a lot about how the disease 
will progress: how will it be? How will my life look like?”
“I have it for five years now. The neurologist told me: ‘up to now it seems 
that the disease progresses quite slowly. We can expect this trend to con-
tinue in the future.’ I feel the need to know this type of information.”
4 One healthcare provider 
who can act as a person-
al case manager
18 “Sometimes I have panic attacks. It helps if I can contact the nurse to talk 
about it. But if I call and I get an appointment in two weeks, it is useless. 
Then I do not need it anymore.” 
“I have a good relationship with the specialized nurse. She knows me quite 
well by now. I call this ‘warm care’. She has patience for me, and she recog-
nizes me when we coincidently encounter outside the hospital.”
“It would certainly help if there was somebody who said: ‘I want to help 
you during the whole process. You will encounter this and that.’ This makes 
you feel prepared.” 
5 More knowledge of the 
disease
11 “Often home care nurses lack specific knowledge of Parkinson’s.”
“Pharmacists lack detailed knowledge of the different types of medication.”
6 More support from my 
pharmacist
10 “There are three different brands of Madopar, so things sometimes go 
wrong when ordering medication. The attitude of pharmacists regarding 
this is frustrating.”
7 Increased focus on the 
needs of my spouse
9 “You do not have Parkinson’s alone. The whole family has Parkinson’s. It 
would be nice if this issue was given some attention.”
8 More contact with  
other patients 
7 “I strongly feel the need to talk to people in the same situation.”
“That is the best that can happen to you: you encounter someone who also 
has the disease. Then you do not need many words to explain what is going 
on.”
9 More provision of  
information
6 “If I look back, I think it would have been useful to be explained things 
straight away. Like, ‘okay, your father is diagnosed with Parkinson’s disease. 
Let’s sit down together with all the involved healthcare providers and 
explain what this will mean for you as a family member of a Parkinson 
patient.’”
10 Less fragmentation  
of healthcare 
6 “It would be nice if I could see the same neurologist every time; the same 
nurse, the same therapist. They should then sit together once in a while 
and discuss my case as their mutual patient. If they had more contact with 
each other and did this, they would know who I am.” 
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An important limitation of our research is the low participation rate of invited 
patients (26%) and healthcare professionals (14%), which might lead to inclusion bias. 
Additionally, no neurologist or movement specialist participated in the interviews. 
Since the VoC approach was performed as a quality improvement program without the 
primary intention to conduct research, no data about those who did not participate 
were collected.
The VoC approach used here revealed that the perception of "being healthy" is broader 
than simply achieving an acceptable level of symptoms. It also includes the ability to 
maintain a social life and participate in society. These new results should now be used 
to further optimize the care for patients with Parkinson’s disease. 
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ABSTRACT
Introduction: Outcome-based payment models (OBPMs) might solve the shortcomings 
of fee-for-service or diagnostic related group (DRG) models by using financial incentives 
based on outcome indicators of the provided care. This review provides an analysis of the 
characteristics and effectiveness of OBPMs, in order to determine which models lead to 
favourable effects.
Methods: We first developed a definition for OBPMs. Next, we searched four data 
sources to identify the models: 1) scientific literature databases; 2) websites of relevant 
governmental and scientific agencies; 3) the reference lists of included articles; and 4) 
experts in the field. We only selected studies that examined the impact of the payment 
model on quality and/or costs. A narrative evidence synthesis was used to link specific 
design features to effects on quality of care or healthcare costs.
Results: We included 88 articles, describing 12 OBPMs. We identified two groups of 
models based on differences in design features: narrow OBPMs (financial incentives based 
on quality indicators) and broad OBPMs (combination of global budgets, risk sharing, and 
financial incentives based on quality indicators). Most (5 out of 9) of the narrow OBPMs 
showed positive effects on quality, the others had mixed (2) or negative (2) effects. The 
effects of narrow OBPMs on healthcare utilization or costs, however, were unfavourable 
(3) or unknown (6). All broad OBPMs (3) showed positive effects on quality of care, while 
reducing healthcare cost growth. 
Discussion: Although strong empirical evidence on the effects of OBPMs on healthcare 
quality, utilization, and costs is limited, our findings suggest that broad OBPMs may be 
preferred over narrow OBPMs. 
4.1 INTRODUCTION
In most developed countries, policy makers are searching for payment systems which 
stimulate the quality of care and reduce healthcare costs. The predominant fee-
for-service and diagnosis related group (DRG) models incentivize volume, and are 
therefore widely considered to be an important reason for rising costs in healthcare 
(Orszag and Ellis 2007). While incentivizing volume can lead to reduced waiting 
times and better access to healthcare, fee-for-service and DRG models lack incentives 
for improving quality: providers are paid for the quantity of care they deliver, not for 
the impact on the health status of their patients (Tai, Kalanithi, and Milstein 2014). 
Since the start of this century, pay-for-performance (P4P) models became popular as a 
response. In P4P models, reimbursement of healthcare providers explicitly depends on 
meeting predefined quality targets, which to date have largely been based on process 
and structure indicators (Nicholson et al. 2008). Though models based on these 
indicators have been studied extensively, evidence that these P4P models are (cost-)
effective is limited (Eijkenaar et al. 2013; Milstein and Schreyoegg 2016). Additionally, 
it is still unclear whether the results of initially effective P4P models are sustainable 
(Eijkenaar et al. 2013; Milstein and Schreyoegg 2016; Ryan, Nallamothu, and Dimick 
2012). Many authors emphasize the important influence of adequate design features, 
including the selection of incentivised indicators, on the effectiveness of P4P models 
(Roland and Campbell 2014; Conrad and Perry 2009; Eijkenaar et al. 2013; Eijkenaar and 
Schut 2015; Eijkenaar 2013; Jha 2013; Mehrotra, Sorbero, and Damberg 2010; Rosenthal 
and Dudley 2007; Werner and Dudley 2009; Roland 2012).
Over the last decade, the different shortcomings of P4P models based on structure and 
process indicators have been addressed by an increased incorporation of outcome 
indicators. The question is if this increased focus on outcomes has resulted in better 
quality of care and/or reduced cost growth, or if there are other design features that are 
(more) important. 
However, a comparative evaluation of payment models with an increased focus on 
outcomes is lacking. Therefore, we conducted a systematic review of the literature 
on the effects of these new models. Our objective is to synthesize the evidence of the 
effects on quality of care, healthcare utilization and healthcare costs. This will lead to 
better understanding of the consequences of these models, and will help to determine 
which design features lead to favourable effects, and why. In addition, it might lead to 
further development and implementation of effective payment models.
In this paper, we use the term ‘outcome-based payment models’ (OBPMs) to denote 
payment models with a substantial reliance on outcome indicators. Although this 
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in incentive structures that might exist across sectors. There was also no restriction 
in study design; qualitative studies, quantitative studies, and reviews were all eligible 
for inclusion. However, articles describing only simulated or expected effects were 
excluded. Because we expected that many evaluations of OBPMs are not published 
in scientific peer-reviewed journals, we included governmental and other research 
reports (provided that they matched our inclusion and exclusion criteria) to ensure 
a complete inclusion of information. Letters, editorials and viewpoints that did not 
contain primary research were excluded.
Search strategy 
We used four data sources to ensure a comprehensive search. Firstly, we searched three 
databases with scientific literature (Medline, the Cochrane Library, and EMBASE), 
using the keywords listed in Appendix 4.1. Secondly, we consulted websites of relevant 
governmental and/or scientific agencies (see Appendix 4.2). Thirdly, we searched 
through the references of the yielded documents. Finally, we consulted several experts 
in the field, all of whom responded (see Appendix 4.3).
Selection procedure
Titles and abstracts of the documents yielded by the three scientific databases were 
checked for duplicates and remaining articles were screened for relevance. Full-texts 
of seemingly relevant articles were subjected to the inclusion and exclusion criteria. To 
determine if a model matched our definition of an OBPM, we sometimes searched for 
additional information about the model on the Internet via Google, using programme-
specific keywords. The selection procedure was done independently by two reviewers. 
Meetings were held to minimise interobserver bias. Differences were resolved in a 
discussion between the reviewers, if necessary after consultation of a third reviewer. 
Next, articles found on websites of the consulted agencies, articles that were brought 
to our attention by the consulted experts, and articles retrieved from references of 
included documents were subjected to the inclusion and exclusion criteria. 
Data extraction 
To extract and summarize the data, we developed an extraction form. This form 
contained the three elements: 
- Name, country, and period in which the model was operating.
- Design features of the payment model 
- Effects on quality of care, healthcare utilization and healthcare costs. 
A methodological challenge was the fact that payment models tend to change over 
time, sometimes on an annual basis, e.g. indicators were added or removed, payment 
structure changed. To address this, we searched for additional information about 
de Ven, and Schut 2012; Hayen et al. 2013). For example, there is no standard about the 
minimum use of outcome indicators, while only a few models use outcome indicators 
exclusively. When creating a definition for OBPMs, we noted that in P4P models 
outcome indicators typically contribute less than 10% to the performance-related 
incentive payments (see the examples in (Eijkenaar, van de Ven, and Schut 2012; 
Eijkenaar and Schut 2015; Hayen et al. 2013; Eijkenaar 2012)). Based on this finding and 
on expert opinions in the field (Appendix 4.3), we choose for a pragmatic approach 
to consider programmes OBPMs if at least 10% of the performance -related incentive 
payment is determined by scores on outcome indicators. We adopted the following 
definition:  
An outcome-based payment model is a payment model in healthcare in which the 
performance-related incentive payments for the healthcare providers depend for at least 
10% on outcomes of the provided care, and which is designed to stimulate favourable effects 
in terms of quality of care or healthcare costs.
We address the following questions: 1) What are the design features of OBPMs and to 
what extent do they differ from each other? 2) What are the effects of OBPMs on quality 
of care, healthcare utilization, and healthcare costs? 
4.2 METHODS
Inclusion and exclusion criteria 
Included articles had to describe the effects on quality of care, healthcare utilization 
or healthcare costs of at least one OBPM that matched the definition mentioned in 
the introduction. In this article quality of care is assessed by the scores on quality 
indicators according to the donabedian framework (structure, process and outcome 
indicators) (Donabedian 1988). ‘Outcome’ is defined as ’the effects of care on the health 
status of patients and populations’ (Donabedian 1988). We do not distinguish between 
intermediate outcomes (e.g. blood pressure values), final outcomes (e.g. mortality, 
complication rates, and hospital readmissions) and patient-reported outcomes. 
’Healthcare costs’ are defined according to the definition of the OECD: ‘the sum of 
expenditure on activities that – through application of medical, pharmaceutical, and 
nursing knowledge and technology – have certain healthcare related objectives’ ((OECD) 
2014).
Articles written in English and published between January 2000 and October 2016 
were included. We only included effects that were achieved in OECD countries ((OECD) 
2011), since the aims and contexts of programmes in other countries are too different 
to allow a useful comparison. To be as comprehensive as possible, we did not focus 














FIGURE 4.1 | Search flow and results
 
Based on the general characteristics (Table 4.1) and the design features (Table 4.2), we 
identified two types of OBPMs. We called the first group ‘narrow OBPMs’. The models 
comprising this group focus exclusively on explicit financial incentives for objectively 
measured quality, with the incorporation of relatively many outcome indicators (i.e. 
pertaining to >10% of performance-related reimbursement). In these models, providers 
earn bonuses and/or suffer penalties based on their scores on a predefined set of indicators. 
These models typically target one provider type (e.g. hospitals, primary care physicians) 
and/or specific clinical areas (e.g. care for acute myocardial infarction). The other group of 
models is called ‘broad OBPMs’. These models encompass the entire provider payment by 
combining global budgets and shared savings incentives with explicit financial incentives 
for quality indicator scores. This group of models generally targets multidisciplinary 
provider groups providing different types of care for their patient population.
the changes in programme design over time. If due to these changes the model did 
not meet our definition of OBPM in a specific year, the results achieved in that year 
were not taken into account. The process of data extraction was performed by two 
independent reviewers. 
Study appraisal
To appraise the methodological quality of the included quantitative studies, we used 
the generic and widely applied method described by Downs & Black (Downs and Black 
1998). In the Downs & Black method, articles receive points on 27 items covering four 
domains: reporting, external validity, internal validity and power. The more points an 
article receives, the higher the methodological quality of the article. The maximum 
number of points is 32 (Downs and Black 1998). We chose this generic appraisal method 
because of the expected heterogeneity of the included study designs, e.g. interrupted 
time series, observational cohort studies, and cross-sectional studies. To determine 
the methodological quality of included qualitative studies and reviews, we used 
the Critical Appraisal Skills Programme checklists ((CASP) 201787). These appraisal 
methods have been used in other systematic reviews of the effects of payment models 
in healthcare (van Herck et al. 2010; Gillam, Siriwardena, and Steel 2012; Eijkenaar et 
al. 2013).
The study appraisal was performed by one reviewer; a second reviewer then did an 
independent review of all qualitative studies and reviews, plus a random selection 
of 10% of the included quantitative studies. Meetings were held to minimise inter-
observer bias. Differences were resolved in a discussion between the reviewers, if 
necessary after consultation of a third reviewer.
4.3 RESULTS
Included studies
Figure 4.1 summarizes the search flow. The 88 included articles contained 75 
quantitative studies, 8 qualitative studies, 3 research reports, and 2 reviews. All 
quantitative studies had a quasi-experimental design (difference-in-difference and 
case-control design). They had an average Downs & Black score of 11.7 (out of 32) and a 
standard deviation of 1.9 (Appendix 4.4). Most points were lost on items about internal 
validity and statistical power. 
One quantitative study contained results for two OBPMs, and one policy report 
contained results of three OBPMs. The rest of the yielded documents described only 
one model. In total, we identified 29 OBPMs (Appendix 4.5), of which 12 could be 
included for our analysis. Table 4.1 and Table 4.2 provide the general characteristics 
and the design features of the 12 included OBPMs.
Initial search result through databases: 3143
articles
Duplications: 821 articles
Excluded articles after reading title and abstract:
1823 articles
Total number of relevant articles: 499
Websites of consulted agencies:
7 additional articles
Expert consulting: 2 additional articles
Total number of relevant articles: 508
(116 potential OBPM's)
Excluded models that did not eet our definition of 
an OBPM: 87 models (400 articles)
OBPM's that were excluded due to lack of effect 
studies: 17 models (27 articles)
Included articles: 81
(12 OBPM's)
Search through reference lists: 7 additional articles
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TABLE 4.1 | Characteristics of the 12 included outcome-based payment models




Targeted care Targeted  
healthcare pro-
viders
Outcome indicators and 
their contribution (in 
%) to the performance- 
related payment size: 
Alternative Quality  
Contract (AQC)
USA; Since 2009 
(Song et al. 2011; Song et 
al. 2012; Eijkenaar and 
Schut 2015; Eijkenaar, van 
de Ven, and Schut 2012)
Blue Cross Blue 
Shield (BCBS) 
private; HMO
All care for BCBS 
insured
Integrated care 
model: all providers 
involved in targeted 
care
Cholesterol levels; HbA1c 
levels; blood pressure  
(35,3%)*
Commissioning for Quali-
ty & Innovation (CQUIN)
UK
Since 2010 
(Eijkenaar and Schut 2015; 





Acute care,  
ambulance service, 
mental health care, 
and home care for 
NHS
Multiple provider 
model: all providers 
involved in targeted 
care
Unknown: differs locally 
(usually >10%) 




and Freiberg 2008; Ep-
stein, Jha, and Orav 2014; 
Eijkenaar and Schut 2015; 
Eijkenaar, van de Ven, and 
Schut 2012)
Centers for Medicare 
& Medicaid Services 
(CMS)
public
Hospital care for 
Medicare insured 
(= USA citizens of 
65+ age) in 5 clinical 








sion rate; post-ok haemor-





USA; since 2012 
(Kahn et al. 2015; Mellor, 
Daly, and Smith 2016)
Centres for Medicare 
& Medicaid Services 
(CMS)
public









sions for acute myocardial 
infarction, heart failure, 




USA; Since 2004 
(Chien et al. 2012)
Hudson Health Plan 
private; non-profit
Primary care for 
diabetes patients 
enrolled in Hudson 
Health Plan
Single provider 
model: primary care 
physicians
Hba1C levels; blood 




quired Condition Program 
(Maryland HACP)
USA; Since 2009 




Hospital care of 





Hospital acquired  
conditions
(100%) 




(Eijkenaar and Schut 2015; 
(CMS) 2016)
Centres for Medicare 
& Medicaid Services 
(CMS)
public





el: all participating 
providers involved in 
targeted care
Blood pressure; HbA1C 
levels; cholesterol levels
(18,2%)
Palo Alto Medical Clinic 
P4P Program (PAMC P4P) 
USA; Since 2007 
(Chung, Palaniappan, 
Wong, et al. 2010; Chung, 
Palaniappan, Trujillo, et 
al. 2010)
Palo Alto Medical 
Foundation (PAMF)
private; non-profit
Primary care of all 
patients who visit 
targeted providers
Single provider 
model: primary care 
physicians
Blood pressure; HbA1C 
levels; cholesterol levels 
(20,0%)




Targeted care Targeted  
healthcare pro-
viders
Outcome indicators and 
their contribution (in 
%) to the performance- 
related payment size: 
Pioneer Accountable Care 
Organizations (Pioneer 
ACO) USA; since 2012
(Eijkenaar and Schut 2015; 
(CMS) 2016)
Centres for Medicare 
& Medicaid Services 
(CMS)
public
All care for all 




el: all participating 
providers involved in 
targeted care
Blood pressure; HbA1C 
levels; cholesterol levels
(18,2%)
Quality and Outcomes 
Framework (QOF)
UK; Since 2004
(Campbell, McDonald, and 
Lester 2008; Doran et al. 
2006; Doran, Fullwood, et 
al. 2008; Doran et al. 2011; 
(HSCIC) 2014;  





All primary care for 
NHS insured (= all 
UK citizens)
Single provider 
model: primary care 
physicians
Blood pressure, HbA1C 
levels; cholesterol levels; 
lithium levels
(20,8%)
Value Based Purchasing 
(VBP)
USA; since 2012
(Eijkenaar and Schut 2015; 
(CMS) 2017)
Centres for Medicare 
& Medicaid Services 
(CMS)
public
Hospital care for 
CMS insured (= USA 




30-day mortality, catheter 
associated urinary tract 
infections, central line 
associated blood stream 
infections, surgical site 
infections, MRSA or C. Diffi-
cile infections and elective 
deliveries.
(2013: 0%; 2014: 25%; 2015: 
30%; 2016: 50%; 2017: 
50%)
Value Incentive Program 
(VIP)
Korea; since 2007
(Kim et al. 2012; Eijkenaar, 
van de Ven, and Schut 
2012; Yang et al. 2016)
National Health 




Hospital care of 
NHIK insured (= all 
Korean citizens) in 3 
clinical areas: Acute 
Myocardial Infarc-
tion (AMI), Caesar 








































































Type of indicators 
usedA
No. of indicators
 (of which out-
come indicators)B
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Effects of OBPMs
Most articles (58) describe effects on quality of care only, 9 articles on healthcare 
utilization or healthcare costs and 21 articles on both quality and utilization/costs. The 
follow-up period varies from 9 months to 7 years. Table 4.3 summarizes the effects of 
OBPMs on quality of care and healthcare utilization/costs.
 
TABLE 4.3 | Effects of OBPMs on quality of care and healthcare utilization/costs
Effects are regarded positive when at least 65% of the articles find that a significant improvement in quality of 
care or reduced health care costs. When the majority of studies found that the quality of care did not improve (or 
worsened) or healthcare costs increased, we considered the effect negative.
? = unknown
*  After 3 years, the HQID adopted some design changes. In the first phase quality of care improved, the second 
phase was less successful.
** One of the aims of this programme was to increase the income of general practitioners substantially.
 
Effects on quality of care
Regarding the effects of the models on quality of care, evidence is available for all 12 
models. Of the 88 included studies, 79 targeted quality of care. 
Incentivised indicators
All three broad OBPMs showed improvements on the incentivised indicators. Process 






























































































































































































































































































































































Type of indicators 
usedA
No. of indicators
 (of which out-
come indicators)B





































































































































































































































































Downs & Black 
score: mean (SD)
Narrow OBPMs
CQUIN + ? 3 9,0 (1,0)
HQID   mixed* - 13 11,4 (1,6)
HRRP + ? 2 9,0 (1,0)
Hudson Health Plan Mixed - 2 13,0 (0)
Maryland HACP + ? 1 10,0 (0)
PAMC P4P - ? 2 10,5 (2,5)
QOF +    -** 43 11,9 (1,9)
VBP - ? 9 11,5 (2,3)
VIP + ? 3 12,0 (2,0)
Broad OBPMs
AQC + + 10 12,4 (1,1)
MSSP + + 2 11,0 (0)
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improve (Chien et al. 2012; Figueroa et al. 2016; Ryan et al. 2015; Serumaga et al. 2011; 
Simpson et al. 2011), the mortality rate in particular remaining unaffected (in HQID, 
QOF, and VBP) (Epstein, Jha, and Orav 2014; Jha et al. 2012; Mehrotra et al. 2009; Ryan 
2009; Figueroa et al. 2016; Ryan et al. 2015; Ryan et al. 2016).
While the effects of broad OBPMs on quality of care increased over time (Song et al. 
2011; Song et al. 2012; Song et al. 2014; Eijkenaar and Schut 2015), positive effects of 
narrow OBPMs tended to be short-lived. In two broad OBPMs (AQC and Pioneer ACO), 
effects on the incentivised indicators increased over the years (Song et al. 2011; Song 
et al. 2012; Song et al. 2014; Eijkenaar and Schut 2015). In contrast, two narrow OBPMs 
(HQID and QOF) showed ceiling effects. For HQID this occurred after a significant 
revision of the incentive structure (Eijkenaar and Schut 2015; Ryan et al. 2012; Shih 
and Dimick 2013; Werner et al. 2011), while for QOF diabetes and asthma indicators 
already reached a ceiling after the first year (Campbell et al. 2009). For most of the 
other indicators in the QOF, ceiling effects emerged after year two or three (Doran et 
al. 2011; Lee et al. 2011), when many GP practices exceeded the quality thresholds for 
maximum incentive payments (Fleetcroft et al. 2012). However, the percentage of 
hospital emergency admissions continued to decrease as a result of the QOF (Harrison 
et al. 2014).
Relevant provider and patient characteristics
Private providers and providers with low baseline quality scores improved their 
performance the most (Hudson Health plan, MSSP, Pioneer ACO, QOF, VBP, VIP) (Chien, 
Li, and Rosenthal 2010; Nattinger et al. 2016; Greene, Hibbard, and Overton 2015; 
Vaghela et al. 2009; Chatfield 2016; Zhao et al. 2015; Kim et al. 2012; Yang et al. 2016), 
although some studies concerning the VBP report relatively poor performance of 
initially low-scoring providers, and in HQID safety net hospitals performed relatively 
poorly (Eijkenaar and Schut 2015; Ryan et al. 2012; Shih and Dimick 2013; Jha et al. 2012; 
Figueroa et al. 2016; Gilman et al. 2015; Ryan et al. 2015). Among the narrow OBPMs, 
three models (HQID, Hudson Health plan, QOF) show that large providers outperform 
smaller ones (Bhattacharyya, Mehta, and Freiberg 2008; Chien, Li, and Rosenthal 2010; 
Wang et al. 2006). In the VBP model, this scale effect is mixed (Chatfield 2016; Ramirez 
et al. 2016; Zhao et al. 2015).
It remains unclear if high-need patients benefit more from OBPMs than other patients. 
In the AQC, children with special needs benefitted more than others from preventive 
paediatric care (Chien et al. 2014). In the QOF, quality of care for diabetics with co-
morbidities improved more than for those without co-morbidities (Millett, Bottle, et 
al. 2009). In contrast, mental health centres (AQC), nursing homes (QOF) and hospitals 
with more Medicare and Medicaid patients (VBP) showed significantly lower quality 
scores after introduction of a OBPM (Barry et al. 2015; Stuart et al. 2016; Shah et al. 2011; 
2014; Eijkenaar and Schut 2015; Barry et al. 2015; Chien et al. 2014), while improvement 
of outcome indicators was only found for diabetes and vascular care in one study (AQC) 
(Barry et al. 2015). No improvement was found in outcome indicators for substance use 
disorder patients (Stuart et al. 2016), emergency department use (both AQC) (Sharp et 
al. 2013) or hospital readmissions (Pioneer ACO) (McCarthy 2015).
For the narrow OBPMs, five out of nine models showed positive results on the 
incentivised indicators (CQUIN, HRRP, Maryland HACP, QOF, VIP) (Shlebak et al. 
2016; Mellor, Daly, and Smith 2016; Doran et al. 2006; Fleetcroft et al. 2012; Millett, 
Gray, Saxena, Netuveli, Khunti, et al. 2007; Strong, South, and Carlisle 2009; Kim et al. 
2012; Lee et al. 2012; Yang et al. 2016; Doran et al. 2011; Calikoglu, Murray, and Feeney 
2012), one showed mixed results (Hudson health plan) (Chien et al. 2012; Chien, Li, 
and Rosenthal 2010) and in two models no significant effect was found (PAMC, VBP) 
(Chung, Palaniappan, Trujillo, et al. 2010; Gilman et al. 2015; Figueroa et al. 2016; Ryan 
et al. 2015; Chee et al. 2016). In the remaining model (HQID), some improvements 
were observed in the first phase of the programme (first three years), but after some 
alterations in the design these improvements did not last (Eijkenaar and Schut 2015; 
Mehrotra et al. 2009; Werner et al. 2011; Epstein, Jha, and Orav 2014; Jha et al. 2012; 
Ryan 2009). 
As in the broad OBPMs, process indicators showed larger improvements than outcome 
indicators. Five out of nine programmes (CQUIN, HQID, Hudson Health plan, QOF, VIP) 
reported improvements in certain process indicators (Shlebak et al. 2016; Eijkenaar 
and Schut 2015; Mehrotra et al. 2009; Werner et al. 2011; Chien, Li, and Rosenthal 2010; 
Doran et al. 2006; Fleetcroft et al. 2012; Millett, Gray, Saxena, Netuveli, Khunti, et al. 
2007; Strong, South, and Carlisle 2009; Campbell et al. 2009; Lee et al. 2011; Vaghela 
et al. 2009; Millett, Saxena, et al. 2009; Kim et al. 2012; Lee et al. 2012; Yang et al. 2016; 
Doran et al. 2011), while four (HRRP, Maryland HACP, QOF, VIP) showed improvements 
in outcomes (Mellor, Daly, and Smith 2016; Alshamsan et al. 2012; Millett, Gray, 
Saxena, Netuveli, Khunti, et al. 2007; Millett, Saxena, et al. 2009; Vaghela et al. 2009; 
Yang et al. 2016; Harrison et al. 2014; Kasteridis et al. 2016; Calikoglu, Murray, and 
Feeney 2012). Two of these could not show improvements in process indicators 
because these models only included outcome indicators (HRRP and Maryland HACP). 
Outcome indicators that showed improvements were hospital readmissions after 
acute myocardial infarction (HRRP) (Mellor, Daly, and Smith 2016), hospital acquired 
conditions (Maryland HACP) (Calikoglu, Murray, and Feeney 2012), blood pressure and 
lab results for diabetes and renal disease (both QOF) (Alshamsan et al. 2012; Millett, 
Gray, Saxena, Netuveli, Khunti, et al. 2007; Millett, Saxena, et al. 2009; Vaghela et al. 
2009), mortality after stroke (VIP) (Yang et al. 2016), emergency hospital admissions 
(QOF) (Harrison et al. 2014) and homecare placements for patients with dementia 
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In broad OBPMs, the cost containment effects increased over time. Several studies 
reported no or small cost reductions in the first years of the AQC programme (Chien 
et al. 2016; Sharp et al. 2013; Song et al. 2011), while these reductions increased after 
one or two years (McWilliams, Landon, and Chernew 2013; Song et al. 2012; Song et al. 
2014). For the Pioneer ACO programme, one study found similar effects (Eijkenaar and 
Schut 2015), but another study reported the opposite (McCarthy 2015). For the narrow 
OBPMs, no longitudinal evaluation studies were available with respect to the impact 
on costs. 
Of the narrow OBPMs, costs increased in all three models for which results are 
available. This is due to the bonus payments (Ryan 2009; Kruse et al. 2012; Chien, Li, 
and Rosenthal 2010; Doran, Fullwood, et al. 2008b; Ryan et al. 2016). The HQID does not 
report any significant effect on healthcare costs, but in the calculation the $17 million 
that was spent on bonus payments was not taken into account (Ryan 2009; Kruse et 
al. 2012). Hudson Health Plan, a relatively small programme, spent over $1 million 
on bonus payments (Chien, Li, and Rosenthal 2010). In the QOF (where a substantial 
income increase for general practitioners was one of the objectives), over £5 billion 
was spent in the first seven years of the programme (Doran, Fullwood, et al. 2008b; 
Ryan et al. 2016), resulting in a 26-40% increase of income for general practitioners 
(Campbell et al. 2009; Whalley, Gravelle, and Sibbald 2008). 
Unintended consequences
For four models (AQC, HQID, Maryland HACP, and QOF), studies were available about 
effects on non incentivised indicators. For broad OBPMs, data are only available for 
the AQC. The included studies for this model showed no obvious effect (positive nor 
negative) on non-incentivised indicators (Chien et al. 2014; McWilliams, Landon, and 
Chernew 2013). In contrast, for the narrow OBPMs some signs of negative effects exist: 
while HQID shows no effects on not included indicators (Mehrotra et al. 2009; Ryan et 
al. 2012), in the Maryland HACP the incidence of non incentivised hospital acquired 
conditions increased (Calikoglu, Murray, and Feeney 2012). In the QOF there was no 
change in mortality for either incentivised or non incentivised diseases (Ryan et al. 
2016), but (non-incentivised) continuity of care decreased (Campbell et al. 2009). 
Another study regarding the QOF showed an initial improvement in non incentivised 
indicators for asthma, diabetes, and vascular diseases, but after two years these effects 
decreased to below baseline level (Doran et al. 2011).
In three narrow models (HQID, Hudson Health plan, QOF), the effects on ethnic and 
social disparities were analysed, finding little to no improvement, and sometimes a 
deterioration. In HQID, the existing gap on process quality closed between blacks and 
whites, but differences in mortality remained (Epstein, Jha, and Orav 2014). In the 
Hudson Health Plan, existing disparities in immunisation rates remained (Chien, Li, 
Zhao et al. 2015). In the Hudson Health Plan, there was no change in quality of care for 
patients both with and without co-morbidities (Chien et al. 2012).
Effects on healthcare utilization and costs
Regarding the effects on healthcare utilization and healthcare costs, three (out of nine) 
narrow OBPMs are included (13 studies) in the analysis. Of the broad OBPMs, all three 
models were included (17 studies). 
Healthcare utilization
For five models (AQC, HQID, Hudson Health Plan, Pioneer ACO and QOF), data were 
available about effects on healthcare utilization. Two out of three narrow OBPMs 
showed an increase in healthcare utilization. Prescription of preventive drugs 
increased (antibiotics in HQID (Mehrotra et al. 2009) and antihypertensive drugs in 
the QOF (Karunaratne et al. 2013)). Moreover, the number of newly diagnosed diabetics 
who started with medication increased (QOF) (Gallagher et al. 2014). In the Hudson 
Health Plan, no significant change in healthcare utilization was found (Chien et al. 
2012). 
Contrary to the narrow OBPMs, the two broad OBPMs showed a reduction in healthcare 
utilization. For the AQC, reductions among Medicare patients were reported in 
emergency department use, the use of outpatient care, office visits, minor procedures, 
imaging and diagnostic tests (McWilliams, Landon, and Chernew 2013). This is in line 
with the reduction of healthcare utilization found four years after the introduction 
of the AQC (Song et al. 2014). However, there was no significant impact on the use of 
pharmaceuticals (Afendulis et al. 2014), while small increases were reported for the 
use of mental health services (Barry et al. 2015) and emergency departments (Sharp et 
al. 2013). For the Pioneer ACO programme, a reduction in inpatient services was found 
(McCarthy 2015).
Healthcare costs
All three broad OBPMs (AQC, MSSP, Pioneer ACO) showed a cost saving based on the 
incentives of the programme (McWilliams, Landon, and Chernew 2013; Song et al. 
2011; Song et al. 2012; Song et al. 2014; Eijkenaar and Schut 2015; McCarthy 2015). The 
MSSP led to a cost saving of about $385 million within one year, while the Pioneer 
ACO reached a comparable cost reduction after two years (Eijkenaar and Schut 2015; 
McCarthy 2015). For the third model (AQC), two out of six studies did not find an effect 
on healthcare costs (Chien et al. 2014; Sharp et al. 2013), while four studies that were 
performed later found savings of 1.9%, 3.3%, and 6.8% after 1, 2, and 4 years after 
introduction, respectively (McWilliams, Landon, and Chernew 2013; Song et al. 2011; 
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Explanations and comparisons to the existing literature
In both groups of OBPMs, process indicators showed larger improvements than 
outcome indicators. In a way this may be considered disappointing as it raises the 
question what the value is of focussing financial incentives on outcomes. One 
explanation is that outcomes are generally more difficult to influence by providers 
than processes. Another explanation is that improvements in processes may precede 
improvements in outcomes, especially in the short-term. However, although 
some studies suggest that the link between processes and outcomes is often not 
straightforward (Mant 2001). Finally, the improvements on indicator scores could be 
due to ‘signalling power’: the implementation of a payment model can lead to increased 
attention to the incentivised indicators. This attention, rather than the design features 
of the payment model, could lead to improvements on easy to influence (process) 
indicators. Nonetheless, the fact that processes improve is positive, given that many 
earlier evaluations of P4P programmes (which have focused mainly on processes) 
show mixed effects on process indicators (Eijkenaar et al. 2013). 
The broad OBPMs showed increasing improvements on quality indicators over 
time, while the effects of the narrow OBPMs tend to be short-lived. This may be due 
to broad OBPMs generally being less prone to ceiling effects due to a design in which 
explicit incentives based on objectively measured indicators are combined with more 
general payment mechanisms (i.e. global budgets with risk sharing arrangements). 
Additionally, the finding that relatively poor performers improve more is another 
indication of the existence of ceiling effects, which are reported in some of the 
included models (Eijkenaar and Schut 2015; Ryan et al. 2012; Shih and Dimick 2013; 
Werner et al. 2011; Campbell et al. 2009; Doran et al. 2011; Lee et al. 2011; Fleetcroft et 
al. 2012). 
We also found that cost savings in broad OBPMs tend to increase over time. In addition, 
narrow OBPMs typically show increases in healthcare utilization, while broad OBPMs 
show reductions. These effects might be explained by the additional focus on cost 
containment in broad OBPMs (i.e. global budgets and risk sharing), while narrow 
OBPMs focus on quality alone. 
Literature on P4P models shows results comparable to our findings on narrow OBPMs: 
there is evidence that both types of models increase (process) quality of care, although 
results are mixed and there is no evidence that non-incentivised indicators improve 
(Eijkenaar et al. 2013). This might be due to similarities in the design: despite the 
incorporation of more outcome indicators, the working mechanism of narrow OBPMs 
is often analogous to that of P4P models (i.e. bonuses or penalties for achieving 
predefined targets with respect to explicitly measured quality indicators). 
and Rosenthal 2010). For QOF, seven out of nine studies found no effects on existing 
social or ethnic disparities (Doran et al. 2006; Millett, Gray, Saxena, Netuveli, Khunti, et 
al. 2007; Lee et al. 2011; Alshamsan et al. 2012; Crawley et al. 2009; Millett, Gray, Saxena, 
Netuveli, and Majeed 2007; Millett et al. 2008). One study showed a decrease between 
deprived and not deprived patients (Doran, Fullwood, et al. 2008b), while another 
noticed an increasing gap between socio-economic groups (Simpson et al. 2011).
For the HQID, the HRRP and the QOF (all narrow OBPMs), several studies examine 
whether or not providers have been trying to abuse the model by directly or indirectly 
manipulating the performance scores (gaming). In general, there is little evidence 
that this occurred on a large scale. For HQID and HRRP, no evidence was found that 
hospitals delay readmissions, alter discharge statuses, limit the access for high-risk 
patients, or focus on the most profitable measures (Mellor, Daly, and Smith 2016; 
Nicholas, Dimick, and Iwashyna 2011; Epstein et al. 2014). In the QOF, the generally low 
levels of exception reporting suggest that large-scale gaming is uncommon (Doran et 
al. 2006; Serumaga et al. 2011; Doran, Fullwood, Reeves, et al. 2008; Doran et al. 2012; 
Gravelle, Sutton, and Ma 2010; McDonald and Roland 2009), although some suspect 
variations in performance scores were noticed (Doran, Fullwood, Reeves, et al. 2008; 
Doran et al. 2012).
4.4 DISCUSSION
Summary of principal findings
This review provides an evidence synthesis of the characteristics and effectiveness 
of twelve OBPMs. Based on differences in design features, two groups of OBPMs 
were distinguised: narrow OBPMs, which only contain explicit financial incentives 
for objectively measured quality performance; and broad OBPMs, which combine 
global budgets and risk sharing for multidisciplinary provider groups with explicit 
financial incentives for quality. Although only three broad OBPMs could be included 
in this review, their effects on both quality of care and healthcare utilization/costs are 
particularly favourable when compared to the narrow OBPMs. In addition, these effects 
improved over time in the broad OBPMs, while the effects of narrow OBPMs tended 
to be short-lived. We also found that process indicators showed larger improvements 
than outcome indicators in both groups of OBPMs. Other findings were: larger private 
providers and providers with initially poor quality scores tended to score better than 
other providers; high-need patients did not seem to benefit more from OBPMs than 
other patients; broad OBPMs had little effect on non-incentivised indicators, while 
there are signs that non-incentivised indicators may deteriorate in the narrow OBPMs; 
narrow OBPMs did not seem to decrease social or ethnic disparities; and narrow OBPMs 
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included OBPMs when the information at our disposal consistently confirmed that 
the model matched our definition and that there were no major differences in specific 
regions or care settings. This was the case for all five aforementioned OBPMs. 
Third, we acknowledge that incentives emanating from payments linked to good 
scores on outcome indicators might be weaker in included OBPMs with small total 
incentive payment sizes (e.g. the HRRP) than in excluded models with relatively large 
total incentive payments but in which less than 10% of these payments are linked to 
outcomes. However, incorporating the size of these payments into the definition of 
OBPMs is practically impossible and would lead to an unworkable definition, since 
the required information is often not available, especially in payment models with 
complex designs.
A final limitation of our review concerns the generalisation of our findings. First, 
comparing different outcome measures, used in different OBPMs, is not ideal. Some 
outcome indicators may have more improvement potential than others, and the 
existence of clear guidelines can increase this potential. Furthermore, some indicators 
of the HRRP and the VBP programme overlap, since both programmes are implemented 
in the context of the USA Medicare programme. 
Second, our review includes OBPMs from both in- and outpatient sector, which operate 
differently. Specifically, they are subject to different payment and billing systems, 
which affect the incentive structure. In addition, OBPMs in the outpatient sector tend 
to distribute relatively more money than OBPMs in the inpatient sector. Nonetheless, 
it is useful to use a broader scope by including both sectors.
Third, the effects of the payment models are likely to be influenced by contextual 
factors. The introduction of OBPMs is often part of a larger policy package, such as 
increased registration, public reporting or implementation of feedback systems. 
Effects can also be influenced by the healthcare system of the involved country. 
The fact that models are from different countries leads to challenges in drawing 
conclusions. However, it must be highlighted that nine out of the twelve models in 
this review are from the USA. Although this makes a comparison between these nine 
models easier, the USA is a country with exceptionally high healthcare costs. Positive 
effects on healthcare costs might therefore be easier to achieve than in other countries. 
Consequently, extrapolation of findings from USA-based studies to other healthcare 
systems is hard.
Conclusions 
OBPMs are at the centre of the debate on the future of healthcare reimbursement. 
It is one of the theoretical underpinnings of the movement towards value-based-
We found that larger private providers and providers with initially poor quality scores 
tend to score better than other providers. A possible explanation is that large private 
providers and providers with low baseline quality have more improvement potential. 
Moreover, these findings might be influenced by the ceiling effects found in two 
models (HQID and QOF). In these models, it was relatively easy to achieve a maximum 
score on some indicators. The distance to these maximum scores from the baseline 
(i.e. the achieved improvements) is larger in initially low scoring providers. On the 
other hand, providers with relatively many minority patients or with patients with 
a lower socioeconomic status are known to have poorer quality metrics. Financial 
incentives run the risk of exacerbating these disparities across providers. For example: 
there is evidence that safety net hospitals suffer more from the financial penalties 
introduced by P4P than other hospitals (Shakir, Armstrong, and Wasfy 2018). 
Strengths and limitations 
This review has multiple strengths and limitations. The strengths are: 1) this is the 
most comprehensive review on OBPMs to date, comparing twelve different OBPMs 
from three different countries; 2) this review has been conducted systematically and 
multiple data sources were used; and 3) the reviewed studies have a relatively high 
average level of evidence, since all included quantitative studies adopted a quasi-
experimental design. However, as in previous reviews on payment models (Gillam, 
Siriwardena, and Steel 2012), experimental studies are lacking. This is largely due to the 
nature of the intervention (i.e. payment models), which often precludes experimental 
study designs. In addition, for eight of the twelve models, only up to three studies were 
available. For these models, the results on quality of care or healthcare costs have a 
limited scientific base. 
The use of our definition of OBPMs results in four limitations. First, the required 
minimum 10% dependency on outcomes set by the definition is an arbitrary cut-off 
point; it does not take the total size of the performance related reimbursement into 
account. There is also no evidence for a critical cut-off point in incentive size related 
to effectiveness. Setting the cut-off point at a lower percentage might have resulted 
in the inclusion of more programmes, possibly in more countries. However, the 10% 
threshold seems to allow a reasonably effective distinction between more and less 
outcome based payment models.
Second, in five of the included programmes (AQC, CQUIN, HQID, VBP, and VIP), 
we could not determine with absolute certainty if at least 10% of the total incentive 
payments were always linked to outcome indicators, since these models use separate 
indicator sets in different geographical regions or care settings. Nevertheless, 
excluding payment models of which we know that they match our definition in almost 
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Appendices | Supplementary material
APPENDIX 4.1 SEARCH STRING
(Outcome*[it] OR quality*[it] OR performance*[it] OR value*[it] OR readmission*[it] OR 




(incentiv*[it] OR pay*[it] OR fund[it] OR funding[it] OR funds[it] OR remunerat*[it] OR 
reimburs*[it] OR financ*[it] OR fee[it] OR fees[it] OR purchas*[it] OR buy*[it] OR contract[it] 




(model[tiab] OR models[tiab] system[tiab] OR systems[tiab] scheme[tiab] OR 
schedule*[tiab] OR reform[tiab] OR reforms[tiab] OR program[tiab] OR programme[tiab] 
OR programs[tiab] OR programmes[tiab]OR framework*[tiab] OR contract[tiab] OR 
contracts[tiab] OR contracting[tiab] OR project*[tiab])
APPENDIX 4.2 | Consulted agencies
healthcare which seeks for more quality of care and value against the ‘lowest’ 
possible costs (Porter and Teisberg). We conclude that an increased focus on outcome 
indicators alone is unlikely to result in an increased effectiveness of payment models: 
other design features also influence the effects on quality of care and healthcare costs. 
Specifically, our main findings suggest that OBPMs which combine global payments 
and risk-sharing with explicit bonuses or penalties based on (outcome) indicator 
scores have most potential to contribute to value. Based on our results, these ‘broad’ 
OBPMs seem to be more (cost-)effective than the ‘narrow’ OBPMs, as in the latter 
group evidence of improved quality is less consistent and tends to be short lived, and 
evidence for decreases in healthcare costs is lacking. Despite the limitations of our 
approach and the fact that we still know little about the interaction between costs and 
quality, we feel that we can recommend broad OBPMs. However, given that we could 
only include three broad OBPMs, which have all been implemented more recently than 
the ‘narrow’ OBPMs and all in the USA, more rigorous evaluations of broad OBPMs are 
required to strengthen this conclusion, preferably in a different context than that of 
the USA.
Agency name Country
Agency for Healthcare Research and Quality (AHRQ) USA




Institute for Healthcare Improvement (IHI) USA
Institute for research and information in health economics (IRDES) France
King’s Fund UK
Leapfrog Group USA
National institute for Health and Care Excellence, (NICE) UK
National institute for Health and Medical research (INSERM) France
Nuffield Trust UK
Organisation for Economic Co-operation and Development (OECD) -
Robert Bosch Foundation Germany
Robert Wood Johnson Foundation (RWJF) USA
Swedish Institute: College of Health Sciences Sweden
United States Health Information Knowledgebase (USHIK) USA
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APPENDIX 4.4 | Quality assessment score
Prof. M. Rosenthal Professor of Health Economics and Policy and Associate Dean for Diversity at 
Harvard T.H. Chan School of Public Health, Cambridge, Massachusetts, USA
Prof. F.E. Schut Professor of Health Economics and Health Policy at the Erasmus School of 
Health Policy and Management (iBMG), Erasmus University of Rotterdam, The 
Netherlands
Dr. F. Eijkenaar Assistant Professor at the Erasmus School of Health Policy and Management 
(iBMG), Erasmus University of Rotterdam, The Netherlands
Quantitative studies 




















Afendulis 2014 14 7 1 4 2 0
Alshamsan 2012 14 7 0 4 3 0
Barry 2016 13 7 1 3 2 0
Bhattacharyya 2008 10 5 0 4 1 0
Calikoglu 2012 10 4 0 3 3 0
Campbell 2009 13 6 0 4 3 0
Chatfield 2016 9 4 1 3 1 0
Chien 2010 13 7 0 3 3 0
Chien 2012 13 7 0 3 3 0
Chien 2014 11 5 1 3 2 0
Chung 2010a 13 4 2 4 3 0
Chung 2010b 8 4 0 3 1 0
Crawley 2009 10 6 0 3 1 0
Dalton 2011 15 7 1 4 3 0
Das 2016 12 6 2 3 1 0
Doran 2006 14 8 1 4 1 0
Doran 2008a 13 7 1 4 1 0
Doran 2008b 11 6 1 4 0 0
Doran 2011 15 7 1 4 3 0
Doran 2012 12 5 2 2 3 0
Epstein 2014a 14 8 0 3 3 0
Epstein 2014b 12 7 0 3 2 0
Figueroa 2016 17 9 3 3 2 0
Fleetcroft 2012 12 7 0 4 1 0
Gallagher 2014 15 8 2 4 1 0
Gemmell 2009 16 9 1 4 2 0
Gilman 2015 11 5 1 3 2 0
Gravelle 2010 13 8 1 3 1 0
Greene 2015 11 7 0 3 1 0
Guthrie 2006 10 4 1 4 1 0
Harrison 2014 12 7 1 3 1 0
Jha 2012 12 7 0 3 2 0
Quantitative studies 




















Kahn 2015 10 3 0 4 3 0
Karunaratne 2013 10 6 0 3 1 0
Kasteridis 2016 14 8 1 3 2 0
Kendrick 2015 10 6 0 3 1 0
Kontopantelis 2012 10 5 0 3 2 0
Kontopantelis 2016 10 5 1 3 1 0
Kristensen 2013 10 6 0 2 2 0
Kruse 2012 14 7 2 3 2 0
Lee 2011 9 5 0 3 1 0
Lee 2012 14 6 1 4 3 0
MacBride-Stewart 
2008
11 6 1 3 1 0
McWilliams 2013 13 8 1 3 1 0
Mellor 2016 8 4 0 3 1 0
Millett 2007a 11 7 0 3 1 0
Millett 2007b 12 7 0 3 2 0
Millett 2008 12 6 0 3 3 0
Millett 2009a 11 6 0 3 2 0
Millett 2009b 8 4 0 3 1 0
Nattinger 2016 11 5 1 3 2 0
Nicholas 2011 11 5 0 4 2 0
Ramirez 2016 11 6 0 3 2 0
Ryan 2009 12 5 1 4 2 0
Ryan 2012 11 5 1 3 2 0
Ryan 2014 10 4 1 3 2 0
Ryan 2015 12 7 0 3 2 0
Ryan 2016 12 6 1 3 2 0
Serumaga 2011 12 7 1 3 1 0
Shah 2011 13 5 2 3 3 0
Sharp 2013 13 6 1 4 2 0
Shih 2014 10 6 0 3 1 0
Shlebak 2016 8 5 0 2 1 0
Simpson 2011 8 4 0 3 1 0
Song 2011 13 7 1 3 2 0
Song 2012 11 5 1 3 2 0
Song 2014 11 5 1 3 2 0
Strong 2009 13 5 2 4 2 0
Stuart 2016 13 6 1 3 3 0
Vaghela 2009 12 7 1 2 2 0
Wang 2006 13 6 2 3 2 0
Werner 2011 9 4 0 4 1 0
Whalley 2008 12 6 0 4 2 0
Yang 2016 10 6 0 3 1 0
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scores on individual items 
1 2 3 4 5 6 7 8 9 10
Campbell 2008 yes yes can’t tell can’t tell yes yes yes yes yes highly 
valuable
Chien 2016 no yes can’t tell yes can’t tell yes yes can’t tell no limited
Edwards 2007 yes yes yes yes yes can’t tell yes no yes valuable
Hannon 2012 yes yes can’t tell yes no yes yes can’t tell yes limited
Lester 2013 yes yes can’t tell no no can’t tell yes no yes valuable
Maisey 2008 yes yes can’t tell no can’t tell yes no yes yes limited
McDonald 2009 yes yes can’t tell no can’t tell can’t tell yes no no valuable
Norman 2014 yes yes can’t tell yes can’t tell can’t tell yes no yes limited
Reviews
(CASP method)
scores on individual items 
1 2 3 4 5 6 7 8 9 10
Gillam 2012 no no yes yes can’t tell clearly 
described
can’t tell yes yes no
Mehrotra 2009 yes can’t tell yes yes no clearly 
described
can’t tell can’t tell yes no
Model name Country Effect study 
available?
Alternative Quality Contract (AQC) USA yes
Bridges to Excellence USA no
Chipra USA no
Commissioning for Quality and Innovation (CQUIN) UK yes
Geisinger Health System USA no
General Practitioners Consortiums UK no
Georgia Blues USA no
Health eHearts USA no
Home Health P4P USA no
Hospital Acquired Conditions Reduction Program (HACRP) USA no
Hospital Quality Incentive Demonstration (HQID) USA yes
Hospital Readmissions Reduction Plan (HRRP) USA yes
Hudson Health Plan USA yes
Long Island Health Network P4P USA no
Maryland Hospital Acquired Conditions Program USA yes
Medicare shared savings program (MSSP) USA yes
Minnesota nursing home P4P USA no
New Hampshire Accountable Care Organisations USA no
Norway P4P model Norway no
Oregon Salem USA no
Palo Alto Medical Clinic P4P (PAMC P4P) USA yes
Pharmacist P4P USA no
Pioneer accountable care organisations (Pioneer ACO) USA yes
PROMETHEUS payments USA no
Quality Incentive Program end-stage renal disease USA no
Quality and Outcome Framework UK yes
Value Incentive Program (VIP) Korea yes
Value-Based Purchasing USA yes
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5.1 INTRODUCTION
Achieving optimal care for patients with a chronic neurological condition is 
challenging.(Bloem et al. 2020) Optimal management requires a multidisciplinary 
approach, a complex array of treatment options and a long follow-up. Networks 
of healthcare providers have proven to be useful for improving coordination and 
organization of care.(Willis et al. 2013) Interestingly, healthcare consists of more than 
such formal professional networks, because individual patients also build their own 
informal personalised networks: they choose (or are being allocated to) their own set 
of healthcare providers, leading to a unique network of providers who treat (‘share’) 
the same patient.(Landon et al. 2012) These so called ‘patient-sharing networks’ of 
healthcare providers will typically differ in ‘density’, i.e. in the number of identical 
patients they share.(Pollack et al. 2012)
Denser patient-sharing networks, i.e. networks of providers who share relatively more 
patients with each other, might result in better care provision. Providers in a dense network 
might communicate and cooperate better,(Foy et al. 2010; Barnett et al. 2011) or know 
each other through referrals.(Barnett et al. 2011) This could improve the coordination and 
organization of care for their patients.(Pollack et al. 2012) Increased patient-sharing within 
group practices has been positively associated with patient-reported care coordination.
(Moen and Bynum 2019) Positive effects of dense networks might be expected especially 
among patients with chronic conditions, since these patients likely benefit most from 
integrated, well-organized care delivery.(Bloem et al. 2020) 
In this study, we aimed to study the effects of network density in the context of a chronic 
neurological condition, using Parkinson’s disease (PD) as an illustrative example. 
The care for people with PD is complex, because many different healthcare providers 
are involved, many of whom work in different echelons of healthcare (primary care, 
hospitals, long term care).(Bloem et al. 2010; Radder et al. 2018) Most people with PD 
visit neurologists, physiotherapists, occupational therapists and speech & language 
therapists. Dieticians and psychologists are also frequently involved, and in advanced 
PD the number of involved disciplines can be as high as 18.(Bloem et al. 2010) This 
provides great challenges to the coordination and organization of multidisciplinary 
care. Organising care delivery in professional networks of specifically trained 
healthcare providers at a regional level leads to better collaboration and fewer disease 
complications, (Keus et al. 2014) but there is no evidence that the density of patient-
sharing networks improves care delivery and leads to better outcomes. In this study, 
we therefore assessed the relation between the density of patient-sharing networks 
and health outcomes, healthcare utilization and healthcare costsfor patients with PD. 
Specifically, we aimed to investigate (a) to what extent patient-sharing networks in 
PD vary in density in current daily clinical practice (assuming that large variations are 
ABSTRACT
Background: Optimal care for Parkinson’s disease (PD) requires coordination and 
collaboration between providers within a complex care network. Individual patients have 
personalised networks of their own providers, creating a unique informal network of 
providers who treat (‘share’) the same patient. These ‘patient-sharing networks’ differ in 
density, i.e. the number of identical patients they share. Denser patient-sharing networks 
might reflect better care provision, since providers who share many patients might have 
made efforts to improve their mutual care delivery. We evaluated whether the density of 
these patient-sharing networks affects patient outcomes and costs. 
Methods: We analysed medical claims data from all people with PD in the Netherlands 
between 2012 and 2016. We focused on seven professional disciplines that are commonly 
involved in Parkinson care. We calculated for each patient the density score: the average 
number of patients that each patient’s providers shared. Density scores could range 
from 1·00 (which might reflect poor collaboration) to 83·00 (which might reflect better 
collaboration). This score was also calculated at the hospital level by averaging the scores 
for all patients belonging to a specific hospital. Using logistic and linear regression 
analyses we estimated the relationship between density scores and health outcomes, 
healthcare utilization, and healthcare costs.
Results: The average density score varied considerably (average 6·7, SD 8·2). Adjusted 
for confounders, higher density scores were associated with a lower risk of PD-related 
complications (OR: 0·901; p<0·001) and with lower healthcare costs (coefficients: -0·018, 
p=0·005). Higher density scores were associated with more frequent involvement of 
neurologists (coefficient 0·068), physiotherapists (coefficient 0·052) and occupational 
therapists (coefficient 0·048) (p-values all <0·001). 
Conclusion: Patient sharing networks showed large variations in density, which appears 
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The definition of density
In order to assess how ‘dense’ a patient-sharing network is, we used the model for care 




where np is the number of distinct healthcare providers that patient p saw, m is the total 
number of possible pairs of these healthcare providers, and wp,i is the number of shared 
patients for each pair of healthcare providers. The numerator is the total number of 
instances of patient sharing over the study period among a patient’s providers. The 
denominator is the total number of pairs of healthcare providers for that patient. 
The higher the density score, the more patients the involved providers share. A visual 
example of this method is given in Figure 5.1. More details of this method can be found 




FIGURE 5.1 | Visual example for a situation in which six healthcare providers 
 
(hospital H, speech & language therapist SL, occupational therapist O, and physio-therapists P1, P2 and P3) 
share four patients (blue, red, yellow and green). The density score of the provider network of the blue patient 
= (2+2+3)/(3*(2-1)/2) = 2·33, while density scores are 1·67, 1·67, and 1·00 for the red, green, and yellow patient 
respectively.
generally unwanted); and (b) if denser patient-sharing networks are associated with 
better health outcomes, lower healthcare utilization and lower healthcare costs.
5.2 METHODS
Data
We analysed medical claims data from all people with PD in the Netherlands between 
2012 and 2016. These data were made available through Vektis, a not-for-profit 
organization that collects all claims data for all Dutch healthcare insurance companies.
(Vektis 2020) All Dutch inhabitants are obliged by law to have a private healthcare 
insurance, which is partially paid for by the government. Insurance companies are 
obliged to accept everybody (against the same price), and the compliance among 
Dutch citizens to this health insurance obligations is as high as 99·8% (Zorgwijzer 
2019). The database of Vektis therefore contains the claims data of 17·4 million people.
(CBS 2020) These claims data concern all primary and secondary care, plus the costs 
for nursing home residency. The Vektis data also include the date when a person 
died. We successfully used this same Vektis database in a previous analysis where we 
demonstrated the added value of professional networks of physiotherapists who were 
specifically trained to treat patients with PD.(Ypinga et al. 2018)
Study sample
We included all 48,769 Dutch insured citizens who had at least one diagnostic related 
group code (DRG code) of PD since January 2008. This selection was part of the 
preparation of our database and was performed by Vektis. Data of individual patients 
were included in the analyses from the moment that the first PD DRG appeared for 
that patient. The first PD DRG defines the moment of diagnosis by a neurologist. The 
same approach was used in earlier research on PD care in the Netherlands.(Ypinga et 
al. 2018; Vlaanderen et al. 2019) The included patients were given a unique random 
identifier by Vektis. The key to the identifier was not available to the researchers. 
Similar to previous research on claims data for PD care,(Vlaanderen et al. 2019) we 
included the PD-related claims data of neurologists, specialized PD nurses (both 
included at the hospital level, since some hospitals tend to wrongly claim on just one 
neurologist or specialised nurse while care is provided by many), physiotherapists, 
occupational therapists, speech & language therapists, dieticians, and psychologists. 
These are the healthcare providers that are most frequently involved in PD manage-
ment.(Bloem et al. 2010; Keus et al. 2014; Kalf et al. 2008; Sturkenboom et al. 2008; 
van Asseldonk et al. 2012) Every healthcare provider was given a random identifier in a 




data concern all primary and secondary care, plus the costs for nursing home residency. The Vektis 
data also include the date when a person died. We successfully used this same Vektis database in a 
previous analysis where we demonstrated the added value of professional networks of 
physiotherapists who were specifically trained to treat patients with PD.(Ypinga et al. 2018c) 
Study sample 
We included all 48,769 Dutch insured citizens who had at least one diagnostic related group code 
(DRG code) of PD since January 2008. This selection was part of the preparation of our database and 
was performed by Vektis. Data of individual patients were included in the analyses from the moment 
that the first PD DRG appeared for that patient. The first PD DRG defines the moment of diagnosis by 
a neurologist. The same approach was used in earlier research on PD care in the Netherlands.(Ypinga et 
al. 2018c; Vlaanderen et al. 2019) The included patients were given a unique random identifier by Vektis. The key 
to the identifier was not available to the researchers.  
Similar to previous research on claims data for PD care,(Vlaanderen et al. 2019) we included the PD-related 
claims data of neurologists, specialized PD nurses (both included at the hospital level, since some 
hospitals tend to wrongly claim on just one neurologist or specialised nurse while care is provided by 
many), physiotherapists, occupational therapists, speech & language therapists, dieticians, and 
psychologists. These are the healthcare providers that are most frequently involved in PD 
management.(Bloem et al. 2010b; Keus, Munneke, Graziano, Paltamaa, Pelosin, Domingos, Brühlmann, et al. 2014; Kalf et al. 2008; Sturkenboom et al. 
2008; van Asseldonk et al. 2012) Every healthcare provider was given a random identifier in a similar way as the 
patients.  
The definition of density 
In order to assess how ‘dense’ a patient-sharing network is, we used the model for care density 
defined by Pollack et al(Pollack et al. 2012)  : 
 






where #! is the number of distinct healthcare providers that patient	5 saw, m is the total number of 
possible pairs of these healthcare providers, and w!,# is the number of shared patients for each pair 
of healthcare providers. The numerator is the total number of instances of patient sharing over the 
study period among a patient’s providers. The denominator is the total number of pairs of healthcare 
providers for that patient. The higher the density score, the more patients the involved providers 
share. A visual example of this method is given in Figure 5.1. More details of this method can be 





Figure 5.1. Visual example for a situation in which six healthcare providers  
 
(hospital H, speech & language therapist SL, occupational therapist O, and physiotherapists P1, P2 
and P3) share four patients (blue, red, yellow an  en). The densi y score of the provider network 
of the blue patient = (2+2+3)/(3*(2-1)/2) = 2·33, while density scores are 1·67, 1·67, and 1·00 for the 
red, green, and yellow patient respectively. 
Comparing density scores 
First, the density score per patient was calculated for 36,639 patients. Density scores ranged from 
1·00 (which might reflect poor collaboration) to 83·00 (which might reflect better collaboration). For 
the remaining 12,130 patients it was impossible to calculate a density score because they visited 
either zero, just one or, due to missing values in the dataset, an unknown number of healthcare 
providers (Table 5.1). 
We then calculated the average density score per hospital across their entire PD patient population, 
to see if average density scores varied between hospital populations. We therefore assigned all 
people with PD to the hospital from which they had received most of their hospital care, i.e., from 
which they had the most neurologist and specialized PD nurse claims. We were only able to calculate 
the average scores for 108 out of all 136 Dutch hospitals, since 28 hospitals did not have any people 
with PD assigned to them. These 28 hospitals were probably hospitals which fused shortly after the 
start of our time span with other hospitals, or were large specialised medical clinics which do not 
treat PD. 
To visualize the differences in density scores, we selected the three hospital populations with the 
highest and three other hospital populations with the lowest density score. The average density 
score per hospital population was positively influenced by the number of assigned patients. 
Regarding the lowest density scores, we therefore only considered hospital populations with at least 
369 patients, which was the size of smallest hospital population with the highest density score. We 
visualized the networks of the selected hospital populations by plotting the healthcare providers that 
shared mutual patients with t-distributed Stochastic Neighbour Embedding (t-SNE).(van der Maaten and Hinton 
2008) 
Outcomes, utilization and costs 
Our next main aim was to assess the relation between density scores and health outcomes, 
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the dependent variables were all dichotomous; the associations with utilization and 
costs were performed with linear regression models. In the linear regression analyses 
we log-transformed the dependent variables since the effects on utilization and costs 
were multiplicative rather than additive and the residuals were closer to the normal 
distribution if the dependent variables were log-transformed. For similar reasons, and 
to unify our results and simplify the interpretation, we log-transformed the density 
scores in all regression analyses. 
In all regression analyses, we adjusted for age, sex, the duration of the disease, the 
number of healthcare providers per patient, the average number of patients per 
healthcare provider in the patient’s network, and the follow-up time. Age, sex and 
the duration of the disease might influence the dependent variables, and these were 
therefore added to the regression model as independent variables. For duration of the 
disease, we added an extra variable indicating if a patient had PD-related claims in 2008 
or not. This was done to cope with the limitation that our dataset does not contain data 
prior to 2008, which would otherwise result in underestimation of disease duration. 
The number of healthcare providers per patient and the average number of patients 
per provider in the patient’s network were added in a similar way, since these variables 
appeared to have a correlation with density of -0.093 and 0.254 respectively (p-values 
both < 0.001). 
For all regression models, we excluded patients with either zero, or one or an unknown 
number of healthcare providers. In the logistic regression models on PD-related 
complications, we additionally excluded patients of which we did not have the full 
follow-up time available (five years), since these patients would have had less time 
to develop a complication. This resulted in 13,129 included patients. In the linear 
regression models, we adjusted for follow-up by defining the dependent variables 
as averages per month. Patients with less than six months follow-up were excluded 
to avoid outliers. This resulted in 35,414 included patients for the linear regression 
analyses on healthcare costs. For the linear regression analyses on utilization, only 
patients could be included that had claims from the designated healthcare providers. 
We included 33,703 for neurology utilization, 33,474 for physiotherapist utilization, 
and 14,534 for occupational therapist utilization. For speech and language specialist 
utilization 8,895 patients could be included, and the numbers for dieticians and 
psychologist utilization were 6,490 and 6,437 respectively.
Secondary analysis
Our results might be influenced by the activities of the Dutch nationwide ParkinsonNet 
healthcare network. Covering the entire country, ParkinsonNet is a Dutch not-for-profit 
organization, supporting regional provider networks of medical and allied healthcare 
professionals specialized in the management of patients with PD. The ParkinsonNet 
Comparing density scores
First, the density score per patient was calculated for 36,639 patients. Density scores 
ranged from 1·00 (which might reflect poor collaboration) to 83·00 (which might reflect 
better collaboration). For the remaining 12,130 patients it was impossible to calculate a 
density score because they visited either zero, just one or, due to missing values in the 
dataset, an unknown number of healthcare providers (Table 5.1).
We then calculated the average density score per hospital across their entire PD patient 
population, to see if average density scores varied between hospital populations. We 
therefore assigned all people with PD to the hospital from which they had received 
most of their hospital care, i.e., from which they had the most neurologist and 
specialized PD nurse claims. We were only able to calculate the average scores for 
108 out of all 136 Dutch hospitals, since 28 hospitals did not have any people with PD 
assigned to them. These 28 hospitals were probably hospitals which fused shortly 
after the start of our time span with other hospitals, or were large specialised medical 
clinics which do not treat PD.
To visualize the differences in density scores, we selected the three hospital 
populations with the highest and three other hospital populations with the lowest 
density score. The average density score per hospital population was positively 
influenced by the number of assigned patients. Regarding the lowest density scores, we 
therefore only considered hospital populations with at least 369 patients, which was 
the size of smallest hospital population with the highest density score. We visualized 
the networks of the selected hospital populations by plotting the healthcare providers 
that shared mutual patients with t-distributed Stochastic Neighbour Embedding 
(t-SNE).(van der Maaten and Hinton 2008)
Outcomes, utilization and costs
Our next main aim was to assess the relation between density scores and health 
outcomes, healthcare utilization and healthcare costs. For this purpose, we defined 
the following outcome measures. Health outcomes were defined as the occurrence of 
any one or more of three PD-related complications (i.e. a claimed DRG for pneumonia, 
orthopaedic injury or hospital admission for PD)(Ypinga et al. 2018; Vlaanderen et 
al. 2019) and mortality. Healthcare utilization was defined as the number of DRGs 
(neurologist and specialized PD-nurses) or visits (allied healthcare providers) to the 
included healthcare providers. Healthcare costs were defined as the sum of the prices of 
the claims. We calculated healthcare costs separately with and without the costs of the 
DRGs of PD-related complications. 
Subsequently, we used regression analyses for each outcome. To assess the association 
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TABLE 5.1 | General characteristics of the study sample (n = 48,769)
SD = Standard Deviation; IQR = inter quartile range; * = calculated to date of death or up to December 31st 2016 
(the last day of the dataset); ** = euro-dollar conversion per March 13th 2019
The t-SNE visualization of the variation between hospital populations is shown in 
Figure 5.2. For the top three hospital populations, providers shared more patients with 
the hospital (bigger dots) and also with each other (more clusters, more darker lines).
 
approach stimulates concentration of care among the specifically trained professionals 
(which influences density scores), but also develops guidelines, stimulates collaboration 
and provides education to healthcare providers.(Keus et al. 2014; Nijkrake et al. 2010) 
These efforts have led to improved health outcomes, and decreased healthcare costs.
(Keus et al. 2014)
To assess the relation between the density score and membership of the ParkinsonNet 
network, we identified for all included providers if they were a ParkinsonNet member 
or not. Since the claims of neurologists and specialized PD-nurses in our data set 
were only available at the hospital level, and because membership of ParkinsonNet 
is individual, we excluded the neurology DRGs from this analysis. Subsequently, we 
performed an additional linear regression analysis on the log-transformed density 
scores to identify if there was a correlation between the log-transformed density 
score and the percentage of visits to ParkinsonNet healthcare providers. The variables 
‘number of healthcare providers per patient’ and ‘the average number of patients per 
provider in the patient’s network’ were added as independent variables, since they 
influence the dependent variable (log-transformed density score). After exclusion 
of the hospital claims and exclusion of patients with (then) zero, one or an unknown 
number of healthcare providers, 36,639 patients could be included in this linear 
regression model. 
Ethical Statement
This study was approved by the institutional review board of the Radboud University 
Medical Centre with a waiver of consent for participants in the study (file number 
2019-5106).
Data availability statement
The data that support the findings of this study are available from the corresponding 
author, upon reasonable request. However, the original claims data belong to Vektis. 
Permission of Vektis is required before original claims data can be made available due 
to privacy laws. 
5.3 RESULTS
Variation in density 
The characteristics of the study sample are presented in Table 5.1. The average density 
score varied considerably. At the individual patient level, the average score was 6·7 (SD: 
8·2). At the level of hospital populations, it was 3·9 (SD: 1·8). This difference in average 
scores arose because many hospitals had very few patients assigned (17 hospitals had 
less than 100 patients).  
Average age (in 2012) 71·7 years (SD: 10·1)
Sex 58·9 % men
Time since diagnosis* (in years, median (IQR)) 5·5 (4·5 – 7·7)
Follow-up time (in years, mean (SD))
Number (%) of patients with complete follow-up




Number (%) of providers per patient 








3,0 (2,0 – 5,0)













Number of included Hospitals
Physiotherapists
Occupational therapists









PD-related healthcare costs per year per patient 
   Costs of complications excluded (Mean (SD)) 
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TABLE 5.2 | Adjusted estimates relating log(density score) to health outcomes, healthcare 
utilization and healthcare costs
All values are adjusted for the effects of age, sex, the duration of the disease, the number of healthcare providers 




Higher density scores were associated with more frequent involvement of neuro-
logists, physiotherapists and occupational therapists (coefficients of 0·068, 0·052 
and 0·048 respectively, p-values all <0·001), but to less frequent involvement 
of psychologists (coefficient of -0·032; p-value 0·029). A doubling of the density 
score was associated with an increase 4·8% for neurologist utilization, 3·7% for 
physiotherapist utilization, and 3·4% for occupational therapist utilization. Similarly, 
an exponential increase in density score was associated with decreased psychologist 
utilization of approximately 2·2%. For speech & language therapists and dieticians we 
found no associations. 
Healthcare costs seemed to be negatively associated with density scores (Table 5.2). 
A doubling of the density score was associated with reduced healthcare costs of 
approximately 1·2% (complications excluded) to 2·1% (complications included). 
Compared to the average healthcare costs for PD (Table 5.1), this would equate to an 
annual reduction of $24,06 to $45,22 per patient (over 36,639 patients, this corresponds 
 
FIGURE 5.2 | t-SNE visualization of top three and bottom three hospital populations in terms 
of average density scores
Each dot represents a provider; the colour represents provider type; the size of the dot 
represents the number of shared patients with the hospital (the hospital itself is not 
shown); lines and relative location between the dots represent the number shared 
patients with each other (only when 10+ patients are shared, a line is shown; when 
more patients are shared, the line is darker. 
Regression models on health outcomes, utilization and costs 
Table 5.2 shows that higher density scores were associated with lower incidences of 
PD-related complications (OR: 0·901, p-value <0·001). A doubling of the density score 
was associated with lower odds of complications of approximately 1-2^log(0·901) ≈ 
7·0%. In a similar way, denser patient-sharing networks were associated with a lower 
occurrence of pneumonias and orthopaedic injuries, but not with lower PD-related 
hospitalization.
Health outcomes Odds ratios Confidence
interval (95%)
P-value
Incidence of PD-related complications
Incidence of pneumonia 0·926 0·889 – 0·964 <0·001
Incidence of orthopedic injuries 0·899 0·864 – 0·936 <0·001
Incidence of PD-related hospitalizations 1·023 0·971 – 1·079 0·392
Incidence of all PD-related complications 0·901 0·862 – 0·941 <0·001
Mortality 0·962 0·926 – 1·000 0·052
Healthcare utilization Coefficients Confidence 
interval (95%)
P-value
Log-transformed neurologist utilization 0·068 0·062 – 0·075 <0·001
Log-transformed physiotherapist utilization 0·052 0·038 – 0·065 <0·001
Log-transformed occupational utilization 0·048 0·028 – 0·068 <0·001
Log-transformed speech & language 
therapist utilization
0·024 -0·009 – 0·057 0·156
Log-transformed dietician utilization -0·013 -0·043 – 0·017 0·409
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similar associations between care density and health outcomes: cancer survivors 
with denser networks are hospitalized less often,(Pollack et al. 2014) while diabetes 
patients with denser networks have a lower risk of being readmitted to hospital and 
to experience potentially avoidable complications.(Pollack et al. 2015) The last study 
found no positive associations in the context of congestive health failure and COPD, 
and even found negative associations with some other quality measures. Additionally, 
denser patient-sharing networks have been linked to reduced healthcare costs for 
patients with congestive heart failure,(Pollack et al. 2012) diabetes,(Pollack et al. 2012) 
and cancer.(Pollack et al. 2014)
Our method has several strengths. First, we followed a clear and predefined set 
of analyses. Second, our dataset contained all diagnosed patients in the country, 
which limits the risk of selection bias. However, some selection bias might have 
been introduced because inclusion was based on the PD DRG. Our sample may have 
included cases for whom the initial diagnosis of PD turned out to be incorrect. PD can 
be difficult to diagnose in early disease stages, with reported diagnostic error rates of 
>10%,(Skinner, Scott, and Martin 2016) e.g. because forms of atypical parkinsonism 
can present like PD.(Hijdra, Koudstaal, and Roos 2012) Because our sample matches 
well with the population characteristics of other studies in terms of prevalence,(Hijdra, 
Koudstaal, and Roos 2012) age,(Ypinga et al. 2018; Hijdra, Koudstaal, and Roos 2012) 
division of sex,(Ypinga et al. 2018; Hijdra, Koudstaal, and Roos 2012; Jankovic, Hurtig, 
and Eichler 2019) and healthcare use,(Ypinga et al. 2018) we do not think this has 
greatly affected our findings. And more importantly, a certain rate of misdiagnosis is 
a reality in daily clinical practice, so our findings are pragmatic in the sense that they 
apply to a real-life population of patients with both PD and parkinsonism. Another 
strength is that our study was based on highly standardized claims data. These data are 
a fair representation of the care provided, even though there is not a 100% match: mis-
registrations or non-registrations can occur, as well as errors during the process of data 
registration by a healthcare professional or during the transfer of hospital data to the 
current database. A further strength is that we had a rather long follow-up relative to 
previous studies with a comparable approach. Finally, by using regression models, we 
did not have to divide our study sample into groups of lower or higher density values. 
This way, we avoided loss of data, making the analyses more accurate.
Our study also had some limitations, some of which relate to the generic limitations 
of observational studies of large data sets.(Bloem et al. 2018) For example, for primary 
care providers we were unable to determine if all claims were PD-specific, and their 
inclusion could lead to an overestimation of utilization and costs. Second, it was 
technically impossible to assess the duration of the disease when a patient had received 
the diagnosis before January 1st, 2008, which might have influenced our estimates for 
disease duration. A third limitation is that we faced many (arbitrary) decisions when 
with $0·9 million to $1·7 million). The appendices show the complete regression ana-
lyses on health outcomes (A), healthcare utilization (B), and healthcare costs (C).
Secondary analysis
A high percentage of visits to ParkinsonNet members was associated with higher 
density scores (coefficient of 1·164; p-value <0·001). Patients who exclusively con-
sulted ParkinsonNet professionals had an approximately exp(1,164) ≈ 3·2 times higher 
density score compared to patients who never consulted ParkinsonNet members. The 
linear regression analysis is included as appendix 5.3.
5.4 DISCUSSION
Our aim was to identify whether provider networks for individual people with PD differ 
in density and, if so, whether denser patient-sharing networks would be associated 
with higher value of care. These questions were addressed in a unique cohort of all 
people with PD in the Netherlands followed over a 5-year timeframe. Several findings 
emerged. First, we identified substantial differences in the density scores between 
patient-sharing networks. These differences were found both at the level of the 
individual patient and at the level of hospital populations. Second, our analyses show 
that denser patient-sharing networks are associated with a lower occurrence of PD-
related complications, especially fewer pneumonias and orthopaedic injuries. Third, 
denser patient-sharing networks are associated with more common involvement of 
neurologists, physiotherapists and occupational therapist services, but also with 
somewhat lower utilization of psychologists. Fourth, denser patient sharing networks 
are associated with a small decrease in healthcare costs for PD management. Finally, 
our secondary analysis shows a strong correlation between the density score and the 
percentage of visits to providers associated with ParkinsonNet, a Dutch network of 
specialised healthcare professionals. This suggests that the observed effects might be 
influenced by the efforts of this integrated network approach.
Comparison of our study to previous studies is difficult, since no prior work assessed 
patient-sharing network densities nor their effects in a PD context. Two large studies 
about the density of patient-sharing networks in the US showed no impact on quality 
of care, while healthcare utilization and costs increased.(Barnett et al. 2012; Landon et 
al. 2018) Both studies focused on the densities of general Medicare insured patients, 
rather than on patients with chronic conditions for whom the bests results can be 
expected. When focusing on patients with chronic conditions, the average density 
values that we identified at the individual patient level are comparable with density 
values of patient-sharing networks of patients with diabetes, congestive heart failure, 
COPD and cancer.(Pollack et al. 2012; Pollack et al. 2014; Pollack et al. 2015) This supports 










CHAPTER 5 DENSITY OF PATIENT-SHARING NETWORKS: IMPACT ON THE VALUE OF PARKINSON CARE
80 81
defining our methods. There are other models for assessing care density, for example, 
the model of Landon.(Landon et al. 2012) We preferred the method of Pollack et al. 
since it uses the patient’s perspective, rather than the provider’s perspective.(Pollack 
et al. 2012) Another methodological decision included the assignment of patients 
to a hospital, but not to other providers. For all such decisions, we tried to choose 
methods that had been used in previous research. However, given the limited PD-
specific literature available for this topic, this was not always possible. A methodologic 
limitation is that not all providers in PD are always involved. When a less frequently 
involved provider is included in the patient’s network, its density score will likely 
drop. However, this effect is partially mitigated by the inclusion of the independent 
variable “number of providers per patient”, since less frequently involved providers 
will usually be involved in advanced stage of the disease when the more frequently 
involved providers are already present. Another limitation is that we did not analyze 
the characteristics of patients who were excluded from the analyses. We regarded 
them as data errors, or they might have received the diagnosis shortly before the end 
of the study period or they might have died just after the start of the study period. A 
final limitation is that our analyses did not adjust for correlations within hospital 
populations. However, we expect these correlations to be only small. This was 
corroborated by repeating the analyses using generalized estimating equations, which 
resulted in small estimated correlations between the residuals of patients within a 
hospital and little effect on the estimated coefficients in the models.
Our findings suggest that investing in the density of patient-sharing networks has the 
potential to increase the value of care for individual patients with PD. For individual 
healthcare providers, investing in density can be achieved by increasing the caseload 
of unique patients with PD, which in turn might lead to greater expertise. At the level of 
the patient population, this increased expertise might lead to better value of care and 
less medical practice variation. Such variations in care delivery are frequently reported 
in PD,(Bloem and Stocchi 2012; Willis et al. 2011; Dorsey, Vlaanderen, et al. 2016) 
but these are obviously unwanted as it leads to inequality in access to good care for 
different patients. And more importantly, a higher density was associated with better 
value of care and with better outcomes and lower costs. We therefore recommend 
that density scores be considered as a quality measure for network organizations. At 
the level of societies, density scores might act as a new tool for research on medical 
practice variation, or as an aid for contracting strategies of health care insurance 
companies. Further research might assess if this only applies to PD, or whether such an 
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APPENDIX 5.3 | Parameters of regression on log-transformed healthcare costs (adjusted)
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Without costs for PD-related 
complication costs
With costs for PD-related 
complication costs
Parameter Estim. C.I. P-value Estim. C.I. P-value 
(intercept) 3·319 3·221 - 
3·417
<0·001 3·539 3·443 - 
3·635
<0·001
Log(Density score) -0·018 -0·031 - 
-0·006
0·005 -0·030 -0·043 - 
-0·018
<0·001
Age 0·043 0·042 - 
0·044
<0·001 0·043 0·041 - 
0·044
<0·001
Sex (woman) 0·132 0·109 - 
0·155
<0·001 0·133 0·110 - 
0·155
<0·001
Duration of PD 0·032 0·025 - 
0·039
<0·001 0·036 0·030 - 
0·043
<0·001
PD in 2008 0·458 0·421 - 
0·496
<0·001 0·413 0·377 - 
0·450
<0·001
Number of providers 
per patient
0·015 0·010 - 
0·020
<0·001 0·015 0·010 - 
0·020
<0·001
Number of patients 
per provider
-0·075 -0·087 - 
-0·062





Parameter estimates 95% CI P-value
(intercept) 0·648 0·620-0·675 <0·001
% ParkinsonNet provider visits 1·164 1·145 – 1·184 <0·001
Number of providers per patient 0·005 0·002-0·009 0·004
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6.1 THE SHORTCOMINGS OF CURRENT CARE
Current care models do not meet the needs of people with Parkinson disease (PD).
(Bloem and Stocchi 2012; Willis et al. 2011; Achey et al. 2014) Many have limited access 
to proper care and that care, when delivered, is institution-based rather than patient-
centered (Table 6.1). In this viewpoint, we examine the shortcomings in current care, 
the need for home-based care, the emerging models, and the barriers to overcome. 
While written from the perspective of the United States and Europe, the piece will 
hopefully have broader applications. 
 
TABLE 6.1 | How different care models meet the needs of people with Parkinson disease
In 2001, the Institute of Medicine (now the Health and Medicine Division of the 
National Academy of Sciences, Engineering, and Medicine), a U.S. non-profit that 
provides independent, objective analysis, issued its landmark report Crossing the 
Quality Chasm. The report opens, “The American health care delivery system is in need 
of fundamental change.” It further states, “Quality problems are everywhere, affecting 
many patients. Between the health care we have and the care we could have lives not 
just a gap, but a chasm.”(Institute of Medicine (U.S.). Committee on Quality of Health 
Care in America. 2001) The report lists six aims to cross this chasm, proposing that 
health care should be safe, effective, patient-centered, timely, efficient, and equitable.
However, current care for PD, in the U.S., Europe, and likely the majority of the world, 
frequently does not meet these six aims. First, Parkinson disease care is often not 
safe. People with PD who are hospitalized are often subjected to delayed treatment, 
contra-indicated medications, prolonged immobility, lengthy stays, and high 
ABSTRACT
In many ways, the care of people with Parkinson disease is poorly designed. Despite 
the documented benefits of receiving care from clinicians with Parkinson disease 
expertise, many (if not most) do not. Moreover, current care models frequently require 
older individuals with impaired mobility, cognition, and driving ability to be driven by 
overburden caregivers to large, complex urban medical centers.
Moving care to the patient’s home would make Parkinson disease care more patient-
centered. Demographic factors, including aging populations, and social factors, such 
as the splintering of the extended family, will increase the need for home-based care. 
Technological advances, especially the ability to assess and deliver care remotely, will 
enable the transition of care back to the home. However, despite its promise, this next 
generation of home-based care will have to overcome barriers, including outdated 
insurance models and a technological divide. Once addressed, home-based care will 
increase access to high quality care for the growing number of people with Parkinson 
disease. 
Feature Individuals with Parkinson 
disease
Current care models Home-based care
Location Primarily suburban and rural 
areas (Kent 2015)
Primarily urban centers Where the individual is 
located
Driving Impaired ability (Santos-Garcia 
and de la Fuente-Fernandez 
2015; Crizzle, Classen, and Uc 
2012)
Usually requires driving Little or no driving 
required (Qiang and 
Marras 2015)
Mobility Limited(Parkinson 2002) Generally required to 
access care
Not required to access 
care
Cognition Frequently impaired
(Aarsland et al. 2009)
Often demanding to 
navigate
Less demanding to 
receive
Disease course Progressive (Parkinson 2002) Least accessible for those 
with the most advanced 
disease
Accessible to those 
with greatest need 
(Dorsey et al. 2010)
Caregivers Burdened (Martinez-Martin et 
al. 2007)
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requirements – often lifelong ones – for follow-up care for individuals with more 
advanced disease.
6.2 NEED FOR HOME-BASED CARE
To improve PD care, more of it must be delivered at home. Home care is not new. In 
the early part of the 20th century, the house call was a dominant means of providing 
care, with 40% of physician-patient encounters in 1930 occurring in the home.
(Meyer and Gibbons 1997) However, advances in transportation and diagnostics 
that had to be delivered in medical centers (e.g., x-ray, EKG) contributed to the house 
call’s decline. Early in the 21st century, house calls are returning. They are available 
through home-based chronic care models,(Landers 2010) on-demand house calls by 
physicians for episodic care,(Jolly 2015) and a “hospital at home” model.(Cryer et al. 
2012) The latter model provides hospital-level care, including physician and nurse 
visits and intravenous medications, for acute conditions like pneumonia directly 
in the home. These models can generate equal or better clinical outcomes, improve 
patient satisfaction, and lower costs, (Cryer et al. 2012) yet few have been applied to 
PD. In addition to in-person care at home, the next generation house call, enabled by 
advances in telecommunications, is also emerging.(Dorsey et al. 2013; Achey et al. 
2014) Through video visits, these virtual house calls enable frequent consultations 
and provide specialty care to patients independent of geography.
The demand for in-home care is likely to grow due to demographic, social, and 
technological factors. Both the absolute number and proportion of older people with 
PD will increase. Due to aging populations, the prevalence of PD in the world’s most 
populous nations will rise to over 8.7 million patients, twice as much as it was in 2005.
(Dorsey et al. 2007) Similarly, rising life expectancies (four years in the U.S. and six 
years globally in the last two decades)("Health Care's Big Spenders: The Characteristics 
Behind the Curve" 2016) along with new therapies for advanced PD(Olanow et al. 2014) 
may increase the survival of people with the condition, leading to more people with 
advanced disease.
Social shifts are also driving home care. The splintering of the extended family, the 
increased mobility of the nuclear family, and the strong desire of older individuals to 
remain in their own homes(Levitz) lead to geographically separated children caring 
for aging parents. These children will increasingly demand technology solutions 
that enable them to care for their parents, monitor their health, and connect to their 
parents’ clinicians conveniently. In addition, more older individuals are discovering 
the internet, tablets, and smartphones for themselves.(Perrin and Duggan June 26, 
2015).
mortality.(Gerlach, Winogrodzka, and Weber 2011; Aminoff et al. 2011) Second, while 
some comprehensive and distributed PD care models (Achey et al. 2014; Miyasaki 
et al. 2012) are quite effective, few patients receive such care, and many PD-related 
hospitalizations are likely preventable.(Willis et al. 2012) Third and fourth, providing 
patient-centered care that is timely has been studied little. (van der Eijk, Faber, Al 
Shamma, et al. 2011) Despite the limited evidence, focus groups and surveys suggest 
that people with PD want more personalized information from multiple disciplines 
that is delivered remotely in a timely manner.(van der Eijk, Faber, Al Shamma, et al. 
2011; van der Eijk, Faber, et al. 2015) Fifth, PD care is very inefficient. Patients and 
their caregivers spend hours travelling and waiting in the clinic for routine follow-up 
appointments.(Dorsey et al. 2013) Outside the clinic, nearly 25% of Americans over 65 
with PD reside in expensive nursing homes that cost more than $200 per day(Safarpour 
et al. 2015) – money than could be devoted to preventing the need for institutional care 
for many. 
Finally, perhaps most concerning is the inequity of current PD care. A primary 
determinant of care received remains where you live. In the U.S., 42% of people with 
PD over 65 and up to 100% of individuals in some rural areas do not see a neurologist 
soon after diagnosis.(Willis et al. 2011) In Europe, the first right expressed in the 
European Parkinson’s Disease Association Charter is care from a physician with a 
special interest in PD,('The European Parkinson’s disease Standards of Care Consensus 
Statement' 2011) yet 44% of Europeans do not see a PD specialist in the first two years 
after diagnosis.(Bloem and Stocchi 2012) Beyond neurological care, access to specialist 
nurses, occupational therapists, and counselors is often more limited.(Stocchi and 
Bloem 2013) In less wealthy countries, the situation is even worse. China only has 
approximately 50 movement disorder specialists to care for over two million people 
with PD.(Dorsey and Willis 2013) In Bolivia, a door to door epidemiology study found 
that none of the persons identified with PD had ever seen a physician, much less 
received treatment.(Nicoletti et al. 2003) 
New, comprehensive PD care models are emerging that seek to deliver care that 
is aligned with the aims articulated by the Institute of Medicine. (Achey et al. 2014; 
van der Marck, Bloem, et al. 2013) For example, ParkinsonNet, a comprehensive, 
multi-disciplinary care model in the Netherlands, can enhance care, improve health, 
and lower costs.(Achey, Aldred, Aljehani, Bloem, Biglan, Chan, Cubo, Dorsey, Goetz, 
Guttman, Hassan, Khandhar, Mari, Spindler, Tanner, van den Haak, Walker, and 
Wilkinson 2014; van der Marck, Bloem, et al. 2013) Still, these models are resource 
intensive and demanding of patients and their caregivers. For example, integrated 
multi-disciplinary care models require individuals with limited mobility and driving 
ability to visit physical therapists and speech therapists three times per week for 
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Finally, multidisciplinary care both in-person and remotely can be delivered into 
the home. The combination of in-person consultations in the home (e.g., to develop 
personal relationships or to conduct detailed examinations) and remote consultations 
in the home (e.g., to provide ongoing care) could meet the needs of patients.(Qiang 
and Marras 2015) Such a combination of in-person and virtual house calls can reveal 
information that is not easily observed in clinic, where patients often perform very 
differently compared to their usual behavior at home. These house calls can also 
provide valuable insights into a patient’s domestic circumstances (e.g., safety of 
physical environment, level of social support). Specialized Parkinson’s nurses, who 
have a broad perspective and can act as liaison to other healthcare professionals within 
the team, have already begun offering house calls.(Jolly 2015) In an ideal situation, 
such Parkinson’s nurses could leave the clinic as agents of integrated regional 
networks of professionals specialized in PD. House calls are also important for other 
PD professionals, including physiotherapists (e.g., to help patients learn to transfer 
from their own beds) and occupational therapists (e.g., to remove domestic hazards). 
Current professional guidelines, for example, recommend that certain assessments 
(e.g., transfers) are best done at home. (Keus et al. 2014) Finally, some remote care could 
be delivered asynchronously with information flowing from patients to clinicians and 
advice being delivered from clinicians to patients or other clinicians.(Cubo ; Wilson 
and Maeder 2015) 
6.4 OVERCOMING BARRIERS
Several barriers, including reimbursement, access to technology, and limited evidence, 
can slow the migration of care to the home. Currently, major insurers, including 
Medicare (the universal health insurer for older Americans), incent institution-based 
care by paying more for care rendered in institutions than in the home. Organizations 
that have integrated delivery and financing of health care can benefit from cost savings 
from home-based care and thus are likely to be early adopters of this patient-centered 
model. In the U.S., the Department of Veterans Affairs(Darkins et al. 2008) and Medicare 
Advantage programs(Tompkins C 2013) have implemented home-based care models. 
Kaiser Permanente, a large integrated health system in the U.S., uses internet, mobile, 
and, more recently, video technology to improve outcomes and increase convenience 
for its patients.(Pearl 2014; Vlaanderen et al. 2016) In the Netherlands, ParkinsonNet 
is developing an integrated reimbursement system to assist their network approach 
of care delivery, which includes many telehealth solutions as video consultations and 
online platforms for patients. Countries with single payer health systems, like Canada, 
Norway, or Luxemburg, are also poised to realize the advantages of home-based care 
for PD. Likewise, across Europe, consumer choice and flexibility have become a major 
goal of modern home-based care systems.(Colombo and Organisation for Economic 
Co-operation and Development. 2011) However, funding for these systems remains a 
Lastly, technological advances are enabling people with PD and other chronic 
conditions(Darkins et al. 2008) to access specialists in satellite clinics or in their 
homes.(Achey et al. 2014) Preliminary evidence suggests that web-based video 
conferencing may offer similar clinical benefits to that of in-person care while saving 
patients and caregivers 100 miles of travel and 3 hours of time per visit.(Dorsey et al. 
2013) Multidisciplinary care, including speech therapy,(Constantinescu et al. 2011) 
mental health care, and “tele-rehabilitation”(Bloem, de Vries, and Ebersbach 2015) can 
also be delivered remotely. 
6.3 EMERGING HOME-BASED CARE MODELS
Emerging care models will combine remote monitoring, self-monitoring, and 
multi-disciplinary care to enable the provision of patient-centered care at home 
and decrease the need for in-clinic assessments. Remote monitoring from devices, 
such as wearable sensors,(Ferreira et al. 2015) smart beds, wall-mounted cameras, 
smart glasses, and even utensils, can monitor a patient’s symptoms and function 
objectively in their environment, facilitating the delivery of highly personalized care.
(Espay et al. 2016; Maetzler et al. 2013) These devices increasingly form the “Internet of 
Things,”(Pasluosta et al. 2015) a network of objects that can collect and exchange data, 
and can measure relevant outcomes (e.g., physical activity, sleep, falls) that are hard to 
assess using traditional questionnaires or personal interviews. 
Issues such as feasibility (can patients manage these new devices?), compliance (can 
patients handle prolonged use of wearable sensors?), and validity (do the devices 
capture clinically relevant information that inform care?) remain to be addressed, 
but the initial experience is positive, provided that patients are fully informed and 
engaged from the outset.(Ferreira et al. 2015) Wearable devices will also shift current 
snapshot measurements in the clinic into a more constant flow of measurements in 
the comfort of the patient’s own surroundings, allowing for more ecologically valid 
observations. 
In addition, the increasing ubiquity of smartphones is enabling self-management by 
patients through self-monitoring apps.(Arora et al. 2015) These apps allow patients to 
record symptoms and signs, track progression, and identify warning signals that may 
necessitate a clinical follow-up. When integrated with the hospital-based electronic 
health record, these data will provide feedback to the clinician to guide treatment 
decisions and improve health outcomes. When combined with online education, 
such as a web-based, informative, and interactive television program (e.g., www.
ParkinsonTV.nl) or social media-based community building,(Achey et al. 2014) remote 
monitoring tools can increase the ability of people with PD “to adapt and self-manage,” 
a new definition of health.(Huber et al. 2011) 
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challenge because hospitals lose income in a “fee-for-service” model by facilitating 
care outside the hospital.
The digital divide,(Norris 2001) the differential access to internet and telecommu-
nication technologies based on economic and social factors, prevents the use of 
technology to receive care at home. People who are older and have more chronic 
conditions are less likely to use the internet,(Smith 2014; Fox and Purcell 2010) and 
the digital divide has hampered efforts to use technology to deliver PD care at home.
(Dorsey, Achey, et al. 2016) The divide can be overcome by delivering in-person home 
care to people with PD,(Hack et al. 2015) providing remote care via satellite clinics close 
to one’s home as is done in Canada,(Achey et al. 2014; Qiang and Marras 2015) engaging 
children in the care of their parents, and increasing access to telecommunication 
technologies. The digital divide is narrowing and the increasing ubiquity of 
smartphones, which are projected to be in the hands of 90% of individuals over age 
6 by 2020,(Dorsey, Vlaanderen, et al. 2016) provides a promising avenue to increase 
access to care, especially in resource limited countries like China and India.(Tian et al. 
2015) 
Despite its promise, evidence for these new, home-based care programs is needed. 
Some of that evidence is being gathered currently,(Dorsey, Achey, et al. 2016) and 
some is being generated in other chronic conditions.(Power and Ashby 2014; Landers 
2010) Preliminary interest in these models for PD is robust. For example, over 11,000 
individuals from 80 countries and all 50 U.S. states visited a recruitment website for 
a randomized controlled trial of virtual house calls for PD.(Dorsey, Achey, et al. 2016) 
Notwithstanding the barriers, “[it] seems inevitable that health care is going home.” 
(Landers 2010) Ushering in the next generation of home care will require collective 
efforts from patients, families, clinicians, advocates, philanthropists, insurers, 
technology firms, and policy makers. Unless these models gain more visi-bility, these 
stakeholders will remain ignorant of opportunities to develop, fund, evaluate, and 
advocate for models to improve care. To bridge the chasm identified by the Institute 
of Medicine, we need to be more critical of our current care models, more willing to 
experiment with disruptive ones, and more prepared to refine them. The more clearly 
we envision and adopt these future models, the sooner the growing number of people 














In this chapter, I discuss the main findings of this thesis and combine them to 
construct general conclusions. I start with an overview of the findings of the five 
individual chapters (paragraph 7.1), and then discuss the interpretations of these 
findings and how they relate to each other (paragraph 7.2). I then point out the strengths 
and limitations of our work (paragraph 7.3) before formulating our conclusions and 
presenting an outlook to the future (paragraph 7.4).
 
7.1  OVERVIEW OF THE MAIN FINDINGS 
Parkinson’s disease (PD) is a progressive, disabling chronic condition. Its management 
does not only require treatment by knowledgeable professionals, but also seamless and 
sustainable care provision. Seamless care is understood to be “care which is consistent 
and coherent, marked by an orderly, logically and aesthetically consistent relation of parts, 
without discontinuities or disparities, uniform in quality and combined in an inconspicuous 
way” (Hammond 2010). Sustainable care is defined as “care that can be maintained 
through time, and that does not drain ending resources, most notably financial boundaries” 
(Jeurissen, Maarse, and Tanke 2018). However, in my introduction chapter (Chapter 1), 
I stated that care for people with PD is often neither seamless nor sustainable. In the 
work presented in this dissertation, I aimed to answer the critical and vexing question 
how to best achieve seamless and sustainable care for people with PD. 
I first reconstructed, from a national administrative medical claims database, a 
sex-specific patient journey for Dutch people with PD during the first 5 years after 
diagnosis (Chapter 2). I included claims data of 13,518 men and 8,775 women with 
newly diagnosed PD. The reconstruction revealed quantitative information about 
healthcare utilization and the occurrence of clinical milestones over time. It also 
revealed profound sex differences: after diagnosis, women visited on average their 
general practitioner 10 days and physiotherapist 89 days sooner than did men. I found 
little difference in neurologist utilization. Approximately two years after diagnosis, 
the first PD-related complication occurred (women: 1.8 years; men: 2.3 years). After five 
years, 37.9% of the women had visited an occupational therapist and 18.5% a speech & 
language therapist at least once. The corresponding figures for men were 33.1% and 
23.7%. Moreover, 72.9% of women and 68.7% of men had experienced at least one 
PD-related complication, such as pneumonias, orthopaedic injuries and unexpected 
hospital admissions; 27.5% of women and 22.5% of men were admitted to a nursing 
home. Within five years after diagnosis, 14.6% of women and 18.3% of men had died. 
The identified sex differences contribute to the debate about phenotypical differences 
in PD between men and women. Insight into the sex differences might also lead to 
better patient-centred care.











number of mutual people with PD treated by the network members. I assessed whether 
denser patient-sharing networks can be linked to better health outcomes, lower 
healthcare utilization and lower healthcare costs (Chapter 5). To quantify density, 
the density model of Pollack et al was used (Pollack et al. 2012), which calculates a 
density score: the more mutual patients are served by a patient-sharing network, the 
higher the network’s density score. density scores differed on the patient level, but 
also on the level of hospital populations. The average density score per patient was 
6.7 with a standard deviation of 8.2. The top three hospital populations had average 
density scores of, respectively, 8.8, 8.3, and 8.0; the bottom three had, respectively, 
2.1, 2.0, and 1.6. Adjusted for confounders, denser networks were found associated 
with lower occurrence of PD-related complications (OR: 0.901; p<0.001), especially 
pneumonias and orthopaedic injuries, but not associated with lower mortality (OR: 
0.962; p=0.052). Higher density scores were associated with higher utilization of 
neurologists, physiotherapists and occupational therapists (coefficients: 0.068, 0.052 
and 0.048, respectively; p-values all <0.001) and lower utilization of psychologist 
(coefficient: -0.032, p=0.029) and lower healthcare costs (coefficients: -0.018, p=0.005 
and -0.030, p<0.001 for with and without costs for complications, respectively). A 
secondary analysis showed that a strong correlation between the density score and 
the percentage of visits to providers who are members of ParkinsonNet (a Dutch not-
for-profit organization aiming to improve quality of care for people with PDs; see also 
Table 1.2). This suggests that the effects might in part be caused or influenced by the 
efforts of ParkinsonNet. 
In Chapter 6, I discussed how we could improve the care for people with PD by moving 
it to the patient’s home. Care of people with PD is poorly designed. For one thing, 
despite the documented benefits of receiving care from clinicians with PD expertise, 
many people with PD do not receive this expert care. Moreover, current care models 
frequently require older individuals with impaired mobility, cognition, and driving 
ability to be driven by overburdened informal caregivers to large, complex urban 
medical centres. Moving care to the patient’s home would make PD care more patient-
centred. Demographic factors, including aging of the populations and other social 
factors, such as the splintering of the extended family unit, will increase the need for 
home-based care. Technological advances, especially the ability to remotely assess 
and deliver care, will enable the transition of care back to the home. However, despite 
its promise, this next generation of home-based care will have to overcome barriers, 
including outdated insurance models and a technological divide. Once addressed, 
home-based care will increase access to high-quality care for the growing number of 
people with PD.
To identify seams in healthcare from the perspective of people with PD, the Voice of the 
Customer approach was applied: a methodology originally developed in industry to 
probe for the clients’ needs (Chapter 3). The participants reported unmet needs mainly 
concerning the social, emotional or domestic domain, rather than the bio-medical 
aspects of the disease. Their top unmet needs were: (1) more self management; (2) 
better interdisciplinary collaboration between different healthcare providers; (3) more 
time to discuss the future and possible scenarios; and (4) one healthcare provider 
acting as case manager, either to solve problems directly or to direct a person with PD 
to the healthcare provider best equipped to address the problem at hand. 
Outcome-based payment models (OBPMs) might contribute to seamless and 
sustainable care for people with PD by aligning incentives with quality of care, 
rather than with volume of care. Regrettably, no specific OBPM has been designed, 
implemented and evaluated for PD care. I therefore reviewed the effects of OBPMs in 
general healthcare on quality of care and healthcare costs (Chapter 4). Our review 
provided an analysis of the characteristics and effectiveness of OBPMs, enabling to 
identify models that lead to favourable effects. 88 studies could be included, describing 
12 OBPMs. Based on differences in design features, two groups were distinguished: 
narrow OBPMs, which only contain financial incentives for objectively measured 
quality performance; and broad OBPMs, which combine global budgets and risk 
sharing for multidisciplinary provider groups with financial incentives for quality. 
Five out of nine narrow OBPMs showed positive effects on quality; the others had 
mixed (2) or negative (2) effects. The effects of narrow OBPMs on healthcare utilization 
or costs were, however, either unfavourable (3) or unknown (6). All broad OBPMs (3) 
showed positive effects on quality of care, while reducing healthcare cost growth. 
Although only three thoroughly evaluated, broad OBPMs could be included in this 
review, their effects on both quality of care and healthcare utilization/costs are more 
favourable as compared to the narrow OBPMs. Moreover, the effects of the broad 
OBPMs improved over time, whereas the effects of narrow OBPMs tended to be more 
short-lived. I also found that in both groups of OBPMs the process indicators showed 
larger improvements than did the outcome indicators. Other findings were: (1) larger 
private providers and providers with initially poor quality scores tended to score better 
than other providers; (2) high-need patients do not seem to benefit more from OBPMs 
than other patients; (3) broad OBPMs had little effect on non-incentivized indicators, 
while there are signs that non-incentivized indicators may deteriorate in the narrow 
OBPMs; (4) narrow OBPMs do not seem to decrease social or ethnic disparities; and (5) 
narrow OBPMs do not seem to lead to gaming on a large scale.
Every person with PD receives care from multiple healthcare providers, who form 
what is known as a ‘patient-sharing network’. These networks differ in density: the 











a personal case manager who is readily accessible for answering simple questions 
(Chapter 3), or a few providers who share the responsibility for navigating people with 
PD to the appropriate healthcare provider (van Halteren et al. 2020). 
To identify seams in care, we need to include the perspective of the individual patient 
(Chapter 3). This is often achieved through open or semi-structured interviews, 
focus group interviews or questionnaires. These are methods that tend to focus 
on the biomedical domain or the professional-patient relation. I introduced a new 
interview method to assess unmet patient needs, named the Voice of the Customer 
method (Chapter 3). This method places the interviewee in the expert role while being 
in his or her own environment. This creates an atmosphere in which the interviewee 
feels safe to share his or her deepest feelings. The social, emotional and domestic 
domains might be more accessible by using such method (Chapter 3). When aiming 
for a complete inclusion of seams in care from the patient’s perspective, the Voice of 
the Customer method might be a welcome contribution to further research, as we 
continue our quest to improve the quality of care for people living with PD. 
How can we make care delivery for PD more seamless and sustainable?
Combining the results of the individual chapters brings us to three main suggestions 
to address the identified seams. First, the way in which healthcare providers are 
organised and have divided tasks needs to be rethought. When the disease progresses, 
complications related to PD are likely to occur, and progressively more different 
healthcare providers may get involved (Chapter 2), necessitating multidisciplinary 
network approaches. The patient, however, may have difficulty to oversee the situation 
when the number of involved healthcare providers is increasing. When this moment 
arrives (but perhaps even earlier in the disease process), it would be wise to appoint 
one of the healthcare providers as the personal case manager (Chapter 3), or organise 
case management among few providers with shared responsibilities in different 
domains of care (van Halteren et al. 2020). 
Theoretically, any member of the multidisciplinary team could take on this task of 
personal case manager, as long as it is clear who is now responsible for this specific task, 
and of course, provided that sufficient time is available to fulfil these responsibilities. 
Having said that, I do think that specialist Parkinson’s nurses might be the most 
suited for this task. In the Netherlands, they already play a central role in care delivery, 
especially the care delivered in the hospital (Bloem et al. 2010). If a hospital employs 
a specialist Parkinson’s nurse, almost all patients are seen by this nurse several times 
a year (Bloem et al. 2010). Moreover, compared to the consultant neurologist, they are 
usually more readily accessible for people with PD, for example by phone or email. 
Challenges might arise in the social and domestic domains, where these nurses are 
normally less involved, which are perhaps not necessarily the responsibility of the 
7.2  INTERPRETATION
In this paragraph, I provide interpretative answers and discuss possible approaches on 
how we can best achieve seamless and sustainable care for people with PD.
What are the current seams in the care for people with PD and how can we identify them? 
Care for people with PDs in the Netherlands (and in many other countries in the world) 
is currently not seamless. Earlier work reported delays in the diagnostic process or the 
diagnosis delivery (Bloem and Stocchi 2012), difficulties in finding allied healthcare 
professionals or specialized nurses (Stocchi and Bloem 2013), limited information 
provision, and a lack of multidisciplinary collaboration (Bloem and Stocchi 2015; van 
der Eijk, Faber, Al Shammaa, et al. 2011; Buetow et al. 2008). My present findings align 
with these studies and add some further important ‘seams’, such as the great variation 
in the care that different people with PD receive. This suggests that not all people 
with PD receive the support from healthcare providers that they need and deserve. A 
remarkable finding is that women receive care earlier after their diagnosis than men 
(Chapter 2), even though PD progresses at an equal or even faster rate in men. I also 
found considerable variation in the density of provider networks. This variation in 
density can affect the quality of care and health outcomes (Chapter 5). Additionally, 
there is a substantial amount of variation in healthcare use across people with PD as 
well (Chapters 2 and 5). PD is more common among men than women, by a ratio of 
roughly 60%:40% (as was confirmed in Chapters 2 and 5). However, the total healthcare 
costs per year for PD are equally divided over the sexes (National Institute of Public 
Health and the Environment 2019c). For residential care, the total costs for women 
are significantly higher than for men (National Institute of Public Health and the 
Environment 2019c). This implies that women face higher per capita costs than men. 
Despite some reasons why care delivery might slightly differ between men and women 
(Göttgens et al. 2020), they are likely to be treated according to the same guidelines. 
Therefore, the afore mentioned variations might be signs that women either receive 
unnecessary care, or that their care is delivered too late or in an inadequate fashion, 
leading to disease complications that are both costly and perhaps partially avoidable.
The seams identified above all concern organisational aspects, rather than bio-medical 
aspects: in Chapter 3, respondents had not encountered problems with access to care, 
either financially or otherwise, or seams regarding medication and therapies. The 
most urgent seams reported by the people with PD concerned one’s social, emotional 
or domestic domain. The respondents wished for more self management; more 
emotional support, and more time to discuss future scenarios. Therefore, although 
healthcare providers do very well in the medical aspect of treating PD, they perhaps 
do not pay enough attention to how people with PD experience this care. Importantly, 
they also dearly missed a single point of access, i.e. one healthcare provider acting as 











meet the needs of people with PD, while also improving their clinical outcomes, daily 
functioning and quality of life, and without increasing social and healthcare costs 
(Qiang and Marras 2015). It might also offer people with PD a greater span of control 
over their own health. Being more skilled in self-management was one of the main 
identified needs from Chapter 3, in line with previous work as well (Bloem and Stocchi 
2015). Digital or in-person home visits also help healthcare providers to obtain a 
better impression of how their patients are functioning at home, rather than in the 
clinic where many people with PD perform paradoxically rather well. Freezing of gait, 
for example, is notoriously difficult to elicit during in-person visits to the hospital, 
even among people who are severely debilitated by very regular episodes of marked 
freezing at home. People with PD then have the opportunity to show their healthcare 
providers what problems they experience in their daily lives, and providers can more 
easily suggest individually tailored solutions. 
How should we pay for care for people with PD in order to be more seamless and 
sustainable? 
Traditional fee-for-service payment models have important shortcomings. They 
incentivise volume, thus increasing healthcare costs, while lacking an incentive for 
improving quality of care (Orszag and Ellis 2007; Tai, Kalanithi, and Milstein 2014; 
Jeurissen, Maarse, and Tanke 2018). As shown in Chapter 4, outcome-based payment 
models (OBPMs) might be a good alternative to counter these shortcomings. OBPMs 
are payment models that align financial incentives with outcomes and quality of care 
(Chapter 4). An OBPM for PD was not yet available, but PD shares many features with 
other chronic diseases that have been addressed successfully using these models 
(Chapter 4). As is the case for many other chronic conditions, optimal management 
of PD requires a multidisciplinary team approach (Chapters 2, 3, 5 and 6). However, 
this multidisciplinary care approach is often poorly organised (Chapter 6) with great 
variation in care delivery (Chapter 2), and does not meet the expectations of people 
with PD (Chapter 3).
Of the two identified types of OBPMs in Chapter 4, ‘broad’ OBPMs, which combine 
global budgets and risk sharing with financial incentives for quality, had the most 
promising results. Unlike the ‘narrow’ OBPMs, which contain financial incentives 
for quality measures alone, broad OBPMs have shown the ability to save costs over 
time (Eijkenaar and Schut 2015; Song et al. 2011; Song et al. 2012; Song et al. 2014; 
McWilliams, Landon, and Chernew 2013; McCarthy 2015) (Chapter 4). Furthermore, 
broad OBPMs seem to be less prone to ceiling effects (Eijkenaar and Schut 2015; Song et 
al. 2011; Song et al. 2012; Song et al. 2014) (Chapter 4). Another disadvantage of narrow 
OBPMs is that non-incentivised indicators may deteriorate (Calikoglu, Murray, and 
Feeney 2012; Doran, Fullwood, et al. 2008; Campbell et al. 2009) (Chapter 4). This is 
much less seen in broad OBPMs (Chien et al. 2014; McWilliams, Landon, and Chernew 
hospital-based medical team, but which are presumably more appropriate areas 
to be addressed by general practitioners or other community-based professionals. 
Alternatively, home visits by Parkinson nurse specialists to discuss any problems in 
these domains could be helpful. Ideally, these specialist nurses would leave the clinic 
as an agent of the integrated regional network of healthcare providers specialized in 
PD (Chapter 6). They should not only arrange care for their patients, but also help them 
finding their way in the world of long-term care and welfare, and provide emotional 
support. Such case managers have been successfully and sustainably implemented 
in the care for people with other neurodegenerative disorders (MacNeil Vroomen et 
al. 2016; Alzheimer Nederland 2020), but there is still relatively little experience with 
this in the field of PD. Interestingly, two recent studies have examined the value of 
home visits, in one study performed by just the Parkinson nurse (Eggers et al. 2018), 
in another study by the nurse combined with other members of the multidisciplinary 
team (Fleisher et al. 2018). Currently efforts are made to examine if such interventions 
are cost-effective (Radder et al. 2020).
Second, technological innovations such as video visits and self-monitoring apps can 
help to mend some seams in PD care, at least in part (Mancini et al. 2020). Remote 
monitoring from smartphones and devices such as wearable sensors, smart beds, 
wall-mounted cameras, smart glasses, and digitised utensils may help to move clinical 
measurements back into the patient’s home. These innovations hold promise of 
making the retrieved values more valid (Chapter 6). However, the digital divide (Norris 
2001), with differential access to internet and telecommunication technologies, 
may prevent the use of technology to receive care at home for a sizeable proportion 
of people with PD in the world (Smith 2014; Fox and Purcell 2010; Dorsey, Achey, et 
al. 2016). This divide can be overcome by delivering in-person home care (Hack et al. 
2015), providing remote care via satellite clinics close to one’s home (Achey et al. 2014; 
Qiang and Marras 2015), engaging children in the care of their parents, and improving 
access to telecommunication technologies (Chapter 6).
Finally, there is a need for new, home-based care programs. Currently, much of the 
care for people with PD is delivered at the hospital, and many treatment decisions are 
made based on the relatively brief consultations there. This creates difficulties for 
people with PD living far away from their hospital (Chapter 6). Additionally, it may 
be hard for healthcare providers to capture a patient’s home situation during these 
brief consultations (Bloem et al. 2020). To overcome this, care needs to be delivered 
more closely to, or ideally within, the patient’s own home (Chapter 6). One way is 
to intermittently use both virtual house calls and in-person consultations, where 
the relative proportion of these two types of consultations should be dictated by the 
individual preferences and clinical needs of each person living with PD (Mancini et 
al. 2020). This individually tailored approach would be an attractive way to optimally 











FIGURE 7.1 | the suggested outcome-based payment model for PD
However, our methods of studying non-PD-specific OBPMs contain limitations which 
make it still uncertain if such an OBPM will be a success. First, comparing different 
outcome measures, used in different OBPMs, is not ideal. Some outcome indicators 
may have more improvement potential than others, and the availability of clear 
guidelines can increase this potential. Second, our review included OBPMs from both 
the inpatient and the outpatient sectors, which operate differently and can be subject 
to different payment and billing systems. Third, the effects of the payment models are 
likely to be influenced by contextual factors, and most models in this review stem from 
the USA. Extrapolation of these findings from USA-based studies to other healthcare 
systems (and to PD: a different disease) is hard. Fourth and finally, our suggested 
model is disease-specific which aids to the conciseness of the pilot. However, this 
counts as a feature of narrow OBPMs and might affect few patients per provider. We 
hope this pilot might be extended to other chronic diseases or can be incorporated 
in other broad OBPM initiatives. Together with robust risk-mitigating measures, this 
should diminish the incentives for gaming that accompany small numbers of patients 
per provider. 
The aim for higher density might have disadvantages as well. A higher density might 
lead to concentration of care. This limits the number of providers that a person with 
PD can choose from, thus obstructing their ability to freely choose a desired provider. 
However, having a dense specialised network could still coincide with the ability of 
patients to choose a different provider who operates largely in isolation outside the 
network, provided that the patient receives clear upfront information about the 
expertise that each provider can offer, and about the outcomes that are likely to occur 
when being treated by either an expert in a network or an isolated provider outside 
2013) possibly due to the additional incentives for cost containment in broad OBPMs 
(i.e. global budgets and risk sharing). These incentives create an extra incentive to 
minimize avoidable healthcare use due to sub optimal care (Chapter 4). Broad OBPMs 
also seem to be better applicable in PD due to the nature of the provided care. In 
general, people with PD receive care from a hospital combined with care from multiple 
primary care providers. (Chapters 2 and 5). The global budgets of OBPMs can target 
the complete chain of delivered care, whereas narrow OBPMs typically target specific 
institutions. 
I would therefore welcome the development and subsequent rigorous evaluation 
of an experimental broad OBPM that links financial incentives to quality indicators 
relevant for PD. As a pilot we would suggest a model as shown in Figure 7.1. This models 
is based on features of broad OMPMs (global budgets, different providers, shared risks; 
see Chapter 4), while being disease-specific (a feature of narrow OBPMs; Chapter 4). 
Depending on the existing healthcare system, target populations could be all people 
with PD of a specific geographical area, or all insured people with PD of a particular 
insurance company. The first option seems more applicable in a single payer system; 
the second in a multiple payer system. Benefits from shared risks should be dependent 
on quality requirements. These requirements should include outcome indicators of 
PD-specific complications that are common, debilitating and costly, such as aspiration 
pneumonias and fractures of the hip or elsewhere due to falls, or avoidable PD-related 
hospitalisations. Risk mitigating measures for providers are essential to ensure reliable 
data and prevent providers from ‘gaming’ the model: selective inclusion or manipulation 
of the data in order to maximise financial gains. The incentives should be combined 
with a global budget for PD care, with shared risks for providers and healthcare payers. A 
shown in Chapter 4, this also improves the sustainability of these models. The budgets 
might be attributed to healthcare organisations or geographical regions. 
Further selective attribution of these budgets would concentrate the care for people 
with PD among fewer providers. This might not only be a stimulus for more efficient 
care delivery, but also should be used to increase the density of care; this is a measure 
of the number of mutual patients that the different providers share (Pollack et al. 2012). 
Dense providers might communicate and cooperate better (Foy et al. 2010; Barnett et 
al. 2011), or know each other better via referrals (Barnett et al. 2011). This might lead to 
better coordination and organization of care for their patients (Pollack et al. 2012). As 
we have seen, care for people with PD becomes more seamless and more sustainable 
if there is a high density between the different providers of care (Chapter 5). Density 
itself could therefore act as a quality indicator for the payment model, comparable 




global budget for PD





PD budget for target population
healthcare payer(s)
dense providers











A second limitation is that our review of OBPMs (Chapter 4) is not PD-specific. All 
included models covered a range of chronic conditions or entire healthcare sectors, 
such as primary care. None of these OBPMs is disease-specific, let alone PD-specific. 
Drawing conclusions about the effects of these payment models on quality of care and 
healthcare costs for PD might therefore be a little far-fetched. However, the results of 
these models showed especially improvements in managing chronic conditions. I do 
not have reasons to think PD might be an exception to this, due to its chronic character 
and the availability of clear outcome measures.
Finally, the activities of the Dutch ParkinsonNet might have influenced the 
generalisability of our findings in Chapter 3 and 5. ParkinsonNet is a Dutch network 
of over 3,600 specifically trained healthcare providers who strive to improve multi-
disciplinary collaboration, increase PD-specific knowledge, and stimulate patient-
centeredness. The interviewed people with PD in Chapter 3 were all from the area of 
Nijmegen, the Netherlands, a region in which ParkinsonNet deploys relatively many 
activities and experiments. Therefore, it might be possible that the identified needs 
are not equal to those in regions of the Netherlands where ParkinsonNet is less active, 
or in other countries where such a professional network approach is not operational 
at all. As already stated in Chapter 5, ParkinsonNet actively influences the density of 
provider networks for people with PD, while its other activities (providing education, 
developing guidelines) influence quality of care too. Additionally, as stated in Chapter 
6, many countries lack organizations attempting to improve the care for people with 
PD.
7.4  CONCLUSIONS AND FUTURE OUTLOOK
I draw the following conclusions and suggestions (Box 7.1). First, PD requires a 
multidisciplinary treatment approach by professionals working in different echelons 
of healthcare, which provides great challenges to the current organisation of care. We 
should aim for care that is more seamless and sustainable. 
Second, women with PD receive more and earlier healthcare across almost all 
disciplines. I expect that this might be due to a doctor delay, a patient delay, or both 
in the diagnostic process in women. Maybe care could become more seamless if 
healthcare providers would be more alert with respect to the early signs of PD in women. 
I would therefore encourage more research on differences in health care utilisation 
between men and women living with PD. There is ample literature about differences in 
disease presentation or progression between the sexes. What is missing is research on 
possible sex-specific delays on behalf of doctors or patients in the management of PD. 
I believe that more knowledge in this area will lead to care that is better tailored to the 
individual patient, thereby making it more seamless and sustainable. 
the network. Freedom of choice is important, but should be based on transparent 
information about the offerings of each provider. Having more dense networks 
might also increase the distances that people with PD may need to travel in case they 
require an in-person assessment. At the same time, as I discussed earlier, the need for 
such in-person visits for chronic follow-ups may diminish as the opportunities for 
telemedicine services continue to improve. Also, the willingness of people with PD 
to travel longer distances will likely depend on the received urgency of the problem 
at hand; many patients are typically to travel longer distances to receive the best 
possible care for important and vexing clinical issues. And finally, higher density and 
concentration of care can cause increased market power for the involved healthcare 
providers, leading to higher prices. Further research should assess if this is the case for 
PD, and if density has the same effects on the treatment of other chronic conditions.
7.3  STRENGTHS AND LIMITATIONS
My methods had several strengths and limitations. The methodological limitations 
of each research project have been addressed in the designated chapters. However, 
several additional strengths and limitations need to be mentioned regarding the 
interpretation of our findings in relation to the research questions.
Strengths
One important strength is that our research applied a mix of research methodologies. 
Chapters 2 and 4 consist of quantitative database analyses of data of large samples of 
people with PD (22,293 in Chapter 2 and 50,508 in Chapter 4). These samples constitute 
de facto the whole patient population of the Netherlands. The analyses were driven by 
a predefined set of analyses, rather than an exploratory approach. The two empirical 
studies are supplemented with a qualitative study and a provocative viewpoint. 
Additionally, the findings of Chapter 4 are from a comprehensive systematic review 
consisting of 12 different OBPMs, retrieved from four different data sources.
Limitations
Several limitations need to be mentioned. An important limitation concerns the 
assessment of the current state of the PD care by reconstructing the gender-specific 
patient journey (Chapter 2). Although the conclusions of this study are based on 
a large sample, the sample consisted only of people with PD who were in their first 
five years of their disease. The state of care for people with PD with a longer disease 
duration could therefore not be assessed. This is an important limitation, since PD is 
a progressive disease, and people with PD over time require more, and more complex, 
care from an increasing number of professional disciplines (Oliver et al. 2019; Fleisher 
et al. 2019; Spindler et al. 2019). A similar approach for people with PD with longer 
disease duration would require a database that can go further back in time than ours. 












If all of the above-mentioned suggestions are implemented, I have good hope that 
the care for people with PD will contain fewer and smaller seams than it has now, 
and that it will be more sustainable. I hope that future efforts of healthcare providers, 
policymakers, patient organizations, healthcare insurers, and – last but not least– 
people with PD and their caregivers will further contribute to the introduction of 
seamless and sustainable care for people with PD. Fortunately, I see great interest in 
developing and researching innovative care models. I also think that PD does not stand 
on itself. A better, more seamless and more sustainable care delivery for PD can serve 
as a blueprint for other chronic conditions, such as diabetes, COPD, or any chronic 
condition requiring a highly multidisciplinary approach.
Third, many seams in our current care were identified. During interviews, the people 
with PD expressed a desire for more self management, better interdisciplinary colla-
boration between healthcare providers, more emphasis on prediction of disease 
development, and having access to a personal case manager. I believe that healthcare 
providers or organisations involved in PD should organize the care delivery in such 
way that such a dedicated care management professional can be created. Specialised 
PD nurses might be well suited to assume this role, but they might need to extend their 
focus to the social domain. Alternatively, rather than having a single case manager, 
it might be necessary to organise case management, whereby the responsibilities 
could be divided among for example a Parkinson nurse who would cover the medical 
domain in the hospital, and a general practitioner or a community nurse who covers 
the social and domestic domain. Regardless of the solution, introducing an optimal 
form of care management almost inevitably implies that care for people with PD 
should be moved more closely to the patient’s home by introducing home-based care 
models. Technological innovations and self-monitoring apps can assist this important 
development. 
Fourth, I think that the development or adoption of a broad OBPM might contribute to 
seamless care for people with PD. The current fee-for-service systems have important 
limitations regarding quality of care and healthcare costs. Broad OBPMs have proven 
to improve these limitations in other chronic conditions. I would recommend the 
development of a payment model that links financial incentives to quality indicators 
that are relevant for PD. These incentives should be combined with a global budget for 
PD care, with shared risks for providers and insurers. 
Finally, I conclude that differences in density between individual provider networks for 
PD exist. Denser networks are associated with a lower risk of PD-related complications, 
higher healthcare utilization (of neurologists, physiotherapists and occupational 
therapists), and lower total healthcare costs for people with PD. Increasing density 
therefore has the potential to increase the value of care for individual people with 
PD. Selective purchasing methods aiming for higher density, could concentrate care 
among fewer providers. I suggest incorporating density as a quality indicator in an 
OBPM for PD. 
Box 7.1: Suggestions for future research for seamless and sustainable care 
for people with PD
1  Examine the effects of possible sex-specific doctor’ or patient’ delays in PD to 
explain the ‘earlier’ use of multiple health services in women with PD.
2  Start a pilot in which specialized PD nurses act as a personal case manager for 
people with PD. Alternatively, perform experiments where case management for 
people with PD is ascertained, by dividing responsibilities across different domains.
3  Stimulate the use of technological innovations such as video consultations, 
wearable sensor technologies and self-monitoring apps, to further support the 
introduction of home-based care.
4  Design innovative care models that deliver care for people with PD more at home, 
with remote support by dedicated professional teams working either nearby in the 
community, a regional hospital or a remote university-based centre of expertise.
5  Develop an OBPM for PD care with density as an incorporated quality indicator, and 
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general practitioner 10 days and the physiotherapist 89 days sooner than men. We 
found little difference in this regard for neurologist utilization. Approximately two 
years after diagnosis, the first PD-related complication occurred (women: 1.8 years; 
men: 2.3 years). Within five years, 37.9% of the women had at least once visited an 
occupational therapist and 18.5% a speech & language therapist. The corresponding 
figures for men were 33.1% and 23.7%. Furthermore, 72.9% of women and 68.7% of 
men had experienced at least one PD-related complication; 27.5% of women and 22.5% 
of men had been admitted to a nursing home. Within five years after diagnosis, 14.6% 
of women and 18.3% of men had died. These sex differences might be due to a doctor 
or patient delay in the diagnostic process in women, rather than to a more aggressive 
disease progression in women. 
Chapter 3
In Chapter 3 we identified the core needs of people with PD using the Voice of the 
Customer (VoC) approach: this is a novel methodology originally developed in the 
field of industry to probe the clients’ needs. A group of 12 interviewers carried out in-
depth interviews with people with PD (n=20), relatives (n=12) and healthcare providers 
(n=11). The interviewers identified ten frequently mentioned needs and combined 
the most informative quotations into a comprehensive video, which was shown 
to the interviewees in a consensus meeting. During that meeting, the interviewees 
prioritized the ten identified needs by allocating a maximum of three points to each 
of the different needs. They could allocate all three points to one need or divide these 
between two or three needs. The total number of points represented the importance of 
the topic. 
The VoC approach revealed that the most urgent patient needs concerned the social, 
emotional or domestic domain, rather than the bio-medical aspects of the disease. 
The top unmet needs were: (1) more self management; (2) better interdisciplinary 
collaboration between different healthcare providers; (3) more time to discuss 
the future and possible scenarios; and (4) a healthcare provider acting as personal 
case manager, either to solve problems directly or to direct people with PD to the 
professional best equipped to address the problem at hand. These results may serve to 
optimize the care for people with PD.
Chapter 4
Chapter 4 describes a review on the effects of outcome-based payment models 
(OBPMs) on quality of care and healthcare costs. We first developed a definition for 
OBPMs: a payment model in healthcare in which the performance-related incentive 
payments for the healthcare providers depend for at least 10% on outcomes of the 
provided care, and which is designed to stimulate favourable effects in terms of quality 
of care or healthcare costs. Next, we searched four data sources to identify the models: 
Summary 
Chapter 1
Parkinson’s disease (PD), is a chronic progressive neurodegenerative disorder, 
characterized by a wide range of symptoms. Many different healthcare providers are 
involved in the treatment of people with PD, at substantial costs. To achieve optimal 
outcomes, care for people with PD needs to be seamless and sustainable. In this 
thesis we used the following definitions: seamless care is care which is consistent 
and coherent, marked by an orderly, logically and aesthetically consistent relation of 
parts, without discontinuities or disparities, uniform in quality and combined in an 
inconspicuous way. Sustainable care is care which can be sustained through time, and 
that is efficient and does not unnecessary drain finite resources.
Despite efforts, the current care for people with PD is often far from seamless and 
sustainable. First, the care people with PD receive is quite variable, which implies that 
care is not ‘consistent’, ‘coherent’ or ‘uniform in quality’. Second, people with PD do 
not regard their care as ‘marked by an orderly, logically and aesthetically consistent 
relation of parts’. Third, financial issues in healthcare systems stand in the way of 
seamless and sustainable care delivery. And finally, care for people with PD is delivered 
by scattered healthcare providers, complicating multidisciplinary collaboration, and 
as a result, healthcare providers treat few people with PD, and do not become experts. 
The aim of this thesis is to study potential measures to achieve seamless and 
sustainable care for people with PD. This results in the following research questions: 
How does the current patient journey of people with PD look like? What are the current 
seams in the care for people with PD? Can outcome-based payment models contribute 
to seamless and sustainable care for people with PD? Will care for people with PD be 
more seamless and sustainable if providers share more patients?
Chapter 2
In Chapter 2 we used the Dutch national medical claims database to reconstructed the 
sex-specific patient journey for PD during the first five years after diagnosis. In a time-
to-event analysis using claims data of all persons diagnosed with PD between 2012 
and 2016 in the Netherlands, we identified the moments in time when these persons 
received care from neurologists, allied healthcare therapists and general practitioners. 
Similarly, we identified the time points at which relevant clinical milestones were 
reached: the occurrence of PD-related complications (e.g. pneumonia, orthopaedic 
injury, and PD-related hospitalization), nursing home admission, and mortality. 
The analysis included claims data of 13,518 men and 8,775 women with newly 
diagnosed PD. It appeared that after diagnosis, women visited on average their 
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psychologists. We therefore propose to use density scores as a quality indicator for 
provider networks.
Chapter 6
In Chapter 6, we discussed how we could improve the care for people with PD by 
moving it to the patient’s home. Care of individuals with PD is often poorly designed: 
individuals with PD who are hospitalized often experience delayed treatment, contra-
indicated medications, prolonged immobility, lengthy stays, and high mortality. 
Despite the documented benefits of receiving care from clinicians with PD expertise, 
many people with PD do not receive such expert care. Moreover, current care models 
frequently require older individuals with impaired mobility, cognition, and driving 
ability to be driven by overburdened informal caregivers to large, complex urban 
medical centers.
Moving care to the patient’s home would make PD care more patient-centered. 
Demographic factors, including aging of the populations, and social factors such as 
the splintering of the extended family, will increase the need for home-based care. 
Technological advances, especially the ability to assess and deliver care remotely, will 
enable the transition of care back to the home situation. However, despite its promise, 
this next generation of home-based care will have to overcome barriers, including 
outdated insurance models and a technological divide. Once addressed, home-based 
care will increase access to high-quality care for the growing number of individuals 
with PD.
Chapter 7
In Chapter 7 we interpreted our findings and formed our conclusions. We started with 
an overview of the main findings. First, the reconstruction of the Parkinson patient’s 
journey during the first five years after diagnosis revealed profound sex differences: 
women visit most of the included healthcare providers sooner after diagnosis and 
more frequently than do men (Chapter 2). Second, patients’ top unmet needs were: 
1) more self management; 2) better interdisciplinary collaboration between different 
healthcare providers; 3) more time to discuss the future and possible scenarios; and 4) 
a healthcare provider who can act as a personal case manager (Chapter 3). Third, broad 
OBPMs seem to have the most promising effects on quality of care and healthcare 
costs (Chapter 4). Fourth, denser networks are associated with lower occurrence of 
PD-related complications, higher utilization, but lower costs (Chapter 5). Finally, care 
needs to be offered closer to the patient’s home (Chapter 6).
Our interpretations are the following. Care for people with PD in the Netherlands is 
currently neither seamless nor sustainable. The seams we identified all concern 
organisational aspects, rather than bio-medical aspects. The identified seam of 
1) scientific literature databases; 2) websites of relevant governmental and scientific 
agencies; 3) the reference lists of included articles; 4) experts in the field. We selected 
only studies that examined the impact of the payment model on quality and/or costs. 
A narrative evidence synthesis was used to link specific design features to effects on 
quality of care or healthcare costs.
We included 88 articles, describing 12 OBPMs. None of them specifically focused on PD; 
though all models targeted populations with chronic conditions. Based on differences 
in design features, we could distinguish two groups of OBPMs: narrow OBPMs, 
which contain only explicit financial incentives for objectively measured quality 
performance; and broad OBPMs, which combine global budgets and risk sharing for 
multidisciplinary provider groups with explicit financial incentives for quality. Most 
(5 out of 9) narrow OBPMs showed positive effects on quality; the others had mixed (2) 
or negative (2) effects. The effects of narrow OBPMs on healthcare utilization or costs, 
however, were unfavourable (3) or unknown (6). The three broad OBPMs showed all 
positive effects on quality of care, while reducing healthcare cost growth. Although 
only three broad OBPMs could be included in this review, these were the ones that had 
the most favourable effects on both quality of care and healthcare utilization/costs. 
Chapter 5
In chapter 5, we noted that people with PD create so called ‘patient-sharing networks’ 
of healthcare providers by choosing their own healthcare providers. These networks 
differ in ‘density’: the number of patients the providers share. Our objective was 
to identify whether denser healthcare provider networks could be linked to better 
patient outcomes, lower healthcare utilization and lower healthcare costs in PD. We 
used claims data of all people with PD in the Netherlands between 2012 and 2016. We 
included all claims of those healthcare providers most frequently involved in care for 
people with PD. To assess the density of healthcare provider networks, we used the 
average number of patients that healthcare providers share as a proxy for the density of 
their collaboration (density score). We calculated the average density score per person 
with PD and per hospital population. We visualized collaboration graphs of the top and 
bottom three hospitals using t-distributed Stochastic Neighbour Embedding (t-SNE). 
Using logistic and linear regression analyses, we estimated the relationship between 
density and health outcomes, healthcare utilization, and healthcare costs. 
The average density score varied considerably on the patient level (average 6.7, SD 
8.2), as well as on the level of hospital populations (average 3.9, SD 8.2). Adjusted for 
confounders, higher density scores were associated with a lower risk of PD-related 
complications and with lower healthcare costs, but not with mortality. Higher 
density scores were associated with more frequent involvement of neurologists, 
physiotherapists and occupational therapists, but less frequent involvement of 
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unexplained sex-differences in healthcare use might be due to doctor’s or patient delay 
in the diagnostic process in women. The most urgent seams reported by people with 
PD themselves concern the social, emotional or domestic domain. To identify seams 
in care, the perspective of the individual people with PD needs to be included, and the 
Voice of the Customer method might be an aid to this.
We offered some suggestions on how to address these seams. First, the way in which 
providers are organised and have divided tasks needs to be rethought. We argue that 
specialist Parkinson’s nurses are best suited to act as a personal case manager. Second, 
video visits and self-monitoring apps can help to overcome some seams in PD care. 
Third, we would welcome the development of home-based care programs for PD, 
rather than the more hospital-based models of current care.
Concerning the payment model for PD care, we suggest an experimental broad OBPM 
that links financial incentives to quality indicators relevant for PD. ‘Density’ could 
therefore act as a quality indicator in this new model, whereby high density has 
favourable effects on quality of care and healthcare costs. 
Summarizing the strengths and limitations of the research, we propose that applying 
a mix of research methodologies is a major strength. Other strengths are the large 
samples of our analyses and the comprehensiveness of our systematic review. One 
limitation is the lack of long-term effects; i.e., beyond five years after diagnosis. 
A second limitation is that our review on OBPMs is not PD-specific. And finally, the 
activities of ParkinsonNet might have influenced the generalisability of our findings 
in several chapters.
In our future outlook we advocate for more research on sex-specific doctor’ or patient’ 
delays in PD to explain the ‘earlier’ use of multiple health services in women with PD. 
We would recommend a pilot in which specialist PD nurses act as a personal case 
manager for people with PD, to confirm whether this can make care for people with 
PD more seamless. We would like to enhance the use of technological innovations 
such as self-monitoring apps. We suggest innovative care models that deliver care 
for people with PD closer at home. And finally, we advocate for the development of an 
OBPM for PD care with density as incorporated quality indicator. We encourage a pilot 
to study the effects of this model on quality of care and healthcare costs. A better, more 
seamless and more sustainable care delivery for PD can serve as a blueprint example 
for other chronic conditions.
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geïdentificeerd waarop relevante klinische mijlpalen werden bereikt: het optreden 
van ZvP-gerelateerde complicaties (bijv. Longontsteking, orthopedisch letsel en ZvP-
gerelateerde ziekenhuisopname), verpleeghuisopnames en mortaliteit.
De analyse omvatte declaratiegegevens van 13.518 mannen en 8.775 vrouwen met nieuw 
gediagnosticeerde ZvP. Het bleek dat vrouwen na de diagnose hun huisarts gemiddeld 
10 dagen eerder bezochten dan mannen en hun fysiotherapeut gemiddeld 89 dagen 
eerder. We vonden in dit opzicht weinig verschil voor het bezoek aan neurologen. 
Ongeveer twee jaar na de diagnose trad de eerste ZVP-gerelateerde complicatie op (bij 
vrouwen: na 1,8 jaar; bij mannen: na 2,3 jaar). Binnen vijf jaar had 37,9% van de vrouwen 
minstens één keer een ergotherapeut en 18,5% minstens één keer een logopedist 
bezocht. De overeenkomstige cijfers voor mannen waren 33,1% en 23,7%. Bovendien 
had 72,9% van de vrouwen en 68,7% van de mannen ten minste één ZvP-gerelateerde 
complicatie ervaren. 27,5% van de vrouwen en 22,5% van de mannen waren na vijf jaar 
opgenomen in een verpleeghuis. Binnen vijf jaar na de diagnose waren 14,6% van de 
vrouwen en 18,3% van de mannen overleden. Deze sekseverschillen lijken eerder te 
wijten zijn aan een doctor of patient delay in het diagnostische proces bij vrouwen, 
dan aan een agressievere ziekteprogressie bij vrouwen.
Hoofdstuk 3
In Hoofdstuk 3 hebben we de kernbehoeften van mensen met de ZvP geïdentificeerd 
met behulp van de Voice of the Customer (VoC) benadering: een nieuwe metho-
dologie die oorspronkelijk in de industrie is ontwikkeld om de behoeften van 
klanten te onderzoeken. Een groep van 12 interviewers voerde diepte-interviews 
uit met mensen met de ZvP (n = 20), familieleden (n = 12) en zorgverleners (n = 11). 
De interviewers identificeerden 10 vaak genoemde behoeften en combineerden 
de meest informatieve citaten tot een uitgebreide videoboodschap, die tijdens een 
consensusvergadering aan de geïnterviewden werd getoond. Tijdens die bijeenkomst 
hebben de geïnterviewden prioriteit toegekend aan de tien geïdentificeerde 
behoeften door elk drie punten toe te wijzen aan een van de verschillende behoeften. 
Ze zouden alle drie de punten aan één behoefte kunnen toewijzen of deze over twee of 
drie behoeften kunnen verdelen. Het totale aantal punten representeerde zodoende 
het belang van het onderwerp.
Uit de VoC-benadering kwam naar voren dat de meest urgente behoeften van de 
patiënt betrekking hadden op het sociale, emotionele of huiselijke domein, en niet op 
de biomedische aspecten van de ziekte. De belangrijkste onvervulde behoeften waren: 
(1) meer eigen regie; (2) betere samenwerking tussen verschillende zorgaanbieders; 
(3) meer tijd om mogelijke toekomstscenario's te bespreken; en (4) een zorgverlener 
die optreedt als persoonlijke aanspreekpunt, hetzij om problemen rechtstreeks op te 
lossen, hetzij om mensen met de ZvP door te verwijzen naar de professional die het 
Samenvatting
Hoofdstuk 1
De ziekte van Parkinson (ZvP), is een chronische progressieve neurodegeneratieve 
aandoening, gekenmerkt door een breed scala aan symptomen. Bij de behandeling 
van mensen met de ZvP zijn veel verschillende zorgaanbieders betrokken, en daar 
gaan aanzienlijke zorgkosten mee gepaard. Om optimale resultaten te bereiken, 
moet de zorg voor mensen met ZVP naadloos en betaalbaar zijn. In dit proefschrift 
hebben we de volgende definities gehanteerd: naadloze zorg is zorg die consistent en 
coherent is, gekenmerkt door een ordelijke, logisch en esthetisch consistente relatie 
van onderdelen, zonder discontinuïteiten of ongelijkheden, uniform in kwaliteit en 
gecombineerd op een natuurlijke manier. Betaalbare zorg is zorg waarbij de kwaliteit 
die door de tijd heen gehandhaafd kan blijven; die efficiënt is, en die niet onnodig 
(financiële) bronnen of mankracht uitput.
Ondanks inspanningen is de huidige zorg voor mensen met de ZvP vaak verre van 
naadloos en betaalbaar. Ten eerste is de zorg die mensen met de ZvP ontvangen nogal 
variabel, wat impliceert dat de zorg niet ‘consistent’, ‘coherent’ of ‘uniform van kwaliteit’ 
is. Ten tweede beschouwen mensen met de ZvP hun zorg niet als ‘gekenmerkt door een 
ordelijke, logisch en esthetisch consistente relatie van onderdelen’. Ten derde staan 
financiële problemen in de gezondheidszorg een naadloze en betaalbare zorgverlening 
in de weg. En tot slot wordt de zorg voor mensen met de ZvP geleverd door zeer veel 
individuele zorgaanbieders. Dit bemoeilijkt de multidisciplinaire samenwerking, en 
belemmert expertise vorming omdat een individuele zorgaanbieder weinig mensen 
met de ZvP behandelt.
Het doel van dit proefschrift is om mogelijke maatregelen te bestuderen die naad-
loze en betaalbare zorg voor mensen met de ZvP dichterbij brengt. Dit levert de 
volgende onderzoeksvragen op: Hoe ziet de huidige patiëntenreis van mensen met 
de ZvP eruit? Wat zijn de huidige naden in de zorg voor mensen met de ZvP? Kunnen 
uitkomstbekostiningsmodellen (UBM’s) bijdragen aan naadloze en betaalbare zorg 
voor mensen met de ZvP? Zal de zorg voor mensen met de ZvP naadlozer en beter 
betaalbaar zijn als zorgverleners meer gemeenschappelijke patiënten hebben?
Hoofdstuk 2
In Hoofdstuk 2 hebben we gebruik gemaakt van een landelijke database van zorg-
verzekeraars om de sekse-specifieke patiëntreis voor de ZvP gedurende de eerste 
vijf jaar na de diagnose te reconstrueren. Met een time-to-event analyse op de 
declaratiegegevens van alle mensen in Nederland bij wie de ZvP tussen 2012 en 2016 
is vastgesteld, hebben we de momenten in kaart gebracht waarop deze personen zorg 





Om de dichtheid van netwerken van zorgaanbieders te beoordelen, hebben we het 
gemiddelde aantal patiënten dat zorgaanbieders delen, gebruikt als een maatstaf voor 
de dichtheid van hun samenwerking (dichtheidsscore). We berekenden de gemiddelde 
dichtheidsscore per patiënt en per ziekenhuispopulatie. We visualiseerden deze 
dichtheidsscores van de hoogst scorende en de laagst scorende drie ziekenhuizen met 
behulp van t-gedistribueerde Stochastic Neighbor Embedding (t-SNE). Met behulp 
van logistieke en lineaire regressieanalyses hebben we de relatie geschat tussen 
dichtheidsscores enerzijds en de gezondheidsresultaten, zorggebruik en zorgkosten 
anderzijds.
De gemiddelde dichtheidsscore varieerde aanzienlijk op patiëntniveau (gemiddeld 
6,7; SD 8,2), maar ook op het niveau van ziekenhuispopulaties (gemiddeld 3,9; SD 
8,2). Gecorrigeerd voor confounders waren hogere dichtheidsscores geassocieerd 
met een lager risico op ZvP-gerelateerde complicaties en met lagere zorgkosten, maar 
niet met een lagere mortaliteit. Hogere dichtheidsscores werden geassocieerd met 
frequente betrokkenheid van neurologen, fysiotherapeuten en ergotherapeuten, maar 
met minder frequente betrokkenheid van psychologen. We stellen daarom voor om 
dichtheidsscores te gebruiken als kwaliteitsindicator voor zorgnetwerken.
Hoofdstuk 6
In Hoofdstuk 6 bespraken we hoe we de zorg voor mensen met de ZvP kunnen verbeteren 
door de zorg zo veel mogelijk bij de patiënt thuis te leveren. De zorg voor men- 
sen met de ZvP is vaak slecht opgezet: mensen met de ZvP die in het ziekenhuis 
worden opgenomen, komen vaak in aanraking met ertraagde behandelingen, 
gecontra-indiceerde medicatie, langdurige immobiliteit, langdurige opnames en 
hoge mortaliteit. Ondanks de voordelen van het ontvangen van zorg door clinici met 
ZvP-expertise, ontvangen veel mensen met de ZvP dergelijke deskundige zorg niet. 
Bovendien vereisen de huidige zorgsystemen vaak dat oudere personen met beperkte 
mobiliteit, cognitie of rijvaardigheid door overbelaste mantelzorgers naar grote, 
complexe stedelijke medische centra worden gebracht.
Door de zorg naar het huis van de patiënt te verplaatsen, zou de Parkinsonzorg 
patiëntgerichter kunnen worden. Demografische factoren, waaronder vergrijzing 
van de bevolking, en sociale factoren zoals de verwatering van familiebanden, 
zullen de behoefte aan thuiszorg doen toenemen. Technologische vooruitgang, met 
name het vermogen om zorg op afstand te verlenen, zal de overgang van zorg naar de 
thuissituatie mogelijk maken. Ondanks bovenstaande zullen er barrières overwonnen 
moeten worden, waaronder verouderde verzekeringsmodellen en beperkte digitale 
vaardigheden van sommige patiënten. Eenmaal aangepakt, zal zorg thuis de toegang 
tot kwalitatief hoogwaardige zorg voor het groeiende aantal mensen met de ZvP 
vergroten.
best is toegerust om het probleem aan te pakken. Deze resultaten kunnen dienen om 
de zorg voor mensen met de ZvP te optimaliseren.
Hoofdstuk 4
Hoofdstuk 4 beschrijft een overzicht van de effecten van uitkomstbekostigingsmodellen 
(UBM's) op de kwaliteit van zorg en de zorgkosten. We ontwikkelden eerst een 
definitie voor UBM's: een bekostigingsmodel in de zorg waarbij kwaliteitsprikkels 
voor zorgaanbieders voor minimaal 10% afhankelijk zijn van de uitkomsten van de 
geleverde zorg, en dat gericht is op het stimuleren van gunstige kwaliteitseffecten 
van zorg of zorgkosten. Vervolgens hebben we vier databronnen doorzocht om deze 
modellen te identificeren: 1) wetenschappelijke literatuurdatabases; 2) websites van 
relevante overheids- en wetenschappelijke instanties; 3) de referentielijsten van 
opgenomen artikelen; 4) consultatie van experts. We selecteerden onderzoeken die de 
impact van het betalingsmodel op kwaliteit en/of kosten onderzochten. Een narratieve 
evidence-synthese werd gebruikt om specifieke ontwerpkenmerken van de modellen 
te koppelen aan de gevonden effecten op de kwaliteit van zorg en de zorgkosten.
We hebben 88 artikelen geïncludeerd die 12 UBM's beschrijven. Geen van de modellen 
was specifiek gericht op de ZvP; hoewel alle modellen gericht waren op chronische 
aandoeningen. Op basis van verschillen in ontwerpkenmerken konden we twee 
groepen UBM's onderscheiden: smalle UBM's, die alleen expliciete financiële prikkels 
bevatten voor objectief gemeten kwaliteitsindictoren; en brede UBM's, die globale 
budgetten en risicodeling voor multidisciplinaire zorgaanbieders combineren met 
expliciete financiële prikkels voor kwaliteit. De meeste (5 van de 9) smalle UBM's 
vertoonden positieve effecten op de kwaliteit; de anderen hadden gemengde (2) 
of negatieve (2) effecten. De effecten van smalle UBM's op het zorggebruik of de 
zorgkosten waren echter ongunstig (3) of onbekend (6). De drie brede UBM's lieten 
allen positieve effecten zien op de kwaliteit van zorg, terwijl de groei van de zorgkosten 
afnam. Hoewel in dit review slechts drie brede UBM's konden worden geïncludeerd, 
hadden deze de meest gunstige effecten op zowel kwaliteit van zorg als op het 
zorggebruik en de zorgkosten.
Hoofdstuk 5
In hoofdstuk 5 bestudeerden we de zogenoemde ‘patient-sharing networks’ van 
zorgaanbieders die mensen met de ZvP creëren door hun zorggebruik. Deze net-
werken verschillen in ‘dichtheid’: het aantal gemeenschappelijke patiënten dat de 
zorgverleners hebben. Ons doel was om vast te stellen of dichtere netwerken kunnen 
worden gekoppeld aan betere zorguitkomsten, lager zorggebruik en lagere zorgkosten 
voor de ZVP. We hebben gebruik gemaakt van declaratiegegevens van alle mensen met 
de ZvP in Nederland tussen 2012 en 2016. We hebben alle declaraties meegenomen 
van de zorgaanbieders die het meest betrokken zijn bij zorg voor mensen met de ZvP. 
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De sterkes en zwaktes van ons onderzoek in ogenschouw nemend, stellen we dat 
het toepassen van een mix van onderzoeksmethodologieën een grote kracht van 
dit proefschrift is. Andere sterke punten zijn de grote steekproefgroottes van onze 
analyses en de volledigheid van ons systematic review. Een beperking is het ontbreken 
van langetermijneffecten; d.w.z. langer dan vijf jaar na de diagnose. Een tweede 
beperking is dat onze beoordeling van UBM's niet ZvP-specifiek is. En tot slot hebben 
de activiteiten van ParkinsonNet mogelijk invloed gehad op de generaliseerbaarheid 
van onze bevindingen.
In onze toekomstvisie pleiten we voor meer onderzoek naar seksespecifieke doctor 
of patient delays om het ‘eerdere’ zorggebruik bij vrouwen met de ZvP te verklaren. 
We zouden graag een pilot zien waarin gespecialiseerde Parkinsonverpleegkundigen 
optreden als persoonlijke casemanagers voor mensen met de ZvP om te onderzoeken 
of dit de zorg voor mensen met de ZvP verbetert. We willen het gebruik van 
technologische innovaties zoals zelfcontrole-apps stimuleren. We zouden 
innovatieve zorgmodellen die zorg dichter bij huis brengen toejuichen. En tot slot 
pleiten we voor de ontwikkeling van een brede UBM voor ZVP-zorg met de dichtheid 
van zorgnetwerken als kwaliteitsindicator. We pleiten ook voor een pilot om de 
effecten van dit model op de kwaliteit van zorg en de zorgkosten te onderzoeken. Een 
betere, meer naadloze en betaalbarere zorgverlening voor mensen met de ZvP kan als 
blauwdrukvoorbeeld dienen voor andere chronische aandoeningen.
Hoofdstuk 7
In Hoofdstuk 7 presenteren we de interpretatie van onze bevindingen en de conclusies 
die wij daaruit trekken. We zijn begonnen met een overzicht van de belangrijkste 
bevindingen. Ten eerste bracht de reconstructie van de reis van mensen met de ZvP 
gedurende de eerste vijf jaar na de diagnose grote sekseverschillen aan het licht: 
vrouwen bezoeken de meeste zorgverleners eerder en vaker dan mannen (Hoofdstuk 
2). Ten tweede waren de belangrijkste onvervulde behoeften van mensen met de ZvP: 
1) meer eigen regie; 2) betere samenwerking tussen verschillende zorgaanbieders; 3) 
meer gelegenheid om toekomstscenario's te bespreken; en 4) een zorgaanbieder die 
kan optreden als persoonlijk aanspreekpunt (Hoofdstuk 3). Ten derde lijken brede 
UBM's de meest belovende effecten te hebben op de kwaliteit van zorg en de zorgkosten 
(Hoofdstuk 4). Ten vierde worden dichtere netwerken geassocieerd met minder ZvP-
gerelateerde complicaties, hogere zorggebruik, maar lagere zorgkosten (Hoofdstuk 5). 
Ten slotte moet de zorg dichter bij huis worden geleverd (Hoofdstuk 6).
Onze interpretaties zijn de volgende. De zorg voor mensen met de ZvP in Nederland 
is momenteel noch naadloos, noch betaalbaar. De naden die we identificeerden, 
hebben allemaal betrekking op organisatorische aspecten en niet op biomedische 
aspecten. De geïdentificeerde naad van onverklaarde sekseverschillen bij het gebruik 
van de gezondheidszorg kan te wijten zijn aan een doctor of patient delay in het 
diagnostische proces bij vrouwen. De meest urgente naden die mensen met ZVP zelf 
melden, betreffen het sociale, emotionele of huiselijke domein. Om naden in de zorg 
te identificeren, moet het perspectief van de individuele mensen met de ZvP worden 
meegenomen, en de Voice of the Customer-methode kan daarbij een hulpmiddel zijn.
We hebben enkele suggesties gedaan om deze naden aan te pakken. Ten eerste moet 
de manier waarop zorgaanbieders zijn georganiseerd opnieuw worden bekeken. Wij 
stellen dat gespecialiseerde Parkinson-verpleegkundigen wellicht het meest geschikt 
zijn om op te treden als persoonlijke casemanager. Ten tweede kunnen videobezoeken 
en zelfcontrole-apps helpen om enkele naden in de Parkinsonzorg te overbruggen. Ten 
derde zouden we de ontwikkeling van thuiszorgprogramma's voor mensen met de ZvP 
verwelkomen, in plaats van de meer ziekenhuisgebaseerde modellen van de huidige 
zorg.
Wat betreft het betalingsmodel voor Parkinsonzorg stellen we een experimentele 
brede UBM voor die financiële prikkels koppelt aan kwaliteitsindicatoren die relevant 
zijn voor mensen met de ZvP. 'Dichtheid' van zorgaanbiedersnetwerken zou in dit 
nieuwe model als kwaliteitsindicator kunnen fungeren, omdat een hoge dichtheid 
gunstige effecten heeft op de kwaliteit van zorg en de zorgkosten.
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ocorrência de complicações relacionadas com a DP (por exemplo, pneumonia, lesão 
ortopédica e hospitalização devido à DP), internamento em lares de idosos e óbito.
A análise incluiu dados de 13.518 homens e 8.775 mulheres com DP recém diagnosticada. 
Afigura-se que, após o diagnóstico, as mulheres consultaram o seu clínico geral em 
média 10 dias e o seu fisioterapeuta em média 89 dias mais cedo do que os homens. 
Quanto a consultas a neurologistas, a diferença entre homens e mulheres foi pouca. 
Aproximadamente dois anos após o diagnóstico, ocorre a primeira complicação 
relacionada com a DP (mulheres: 1,8 anos; homens: 2,3 anos). Em cinco anos, 37,9% 
das mulheres haviam consultado pelo menos uma vez um terapeuta ocupacional 
e 18,5% um terapeuta da fala. Os números correspondentes para os homens foram 
33,1% e 23,7%. Além disso, 72,9% das mulheres e 68,7% dos homens experimentaram 
pelo menos uma complicação relacionada com a DP; 27,5% das mulheres e 22,5% 
dos homens foram internados num lar de idosos. No período de cinco anos após o 
diagnóstico, 14,6% das mulheres e 18,3% dos homens faleceram. Esta diferença entre 
sexos pode ser devido a um atraso do médico ou paciente no processo de diagnóstico 
em mulheres, e não devido a uma progressão mais agressiva da doença nas mulheres.
Capítulo 3
No Capítulo 3, identificamos as principais necessidades dos pacientes com DP 
usando a abordagem Voz do Cliente (VoC): esta é uma nova metodologia desenvolvida 
originalmente no campo da indústria para sondar as necessidades dos clientes. 
Um grupo de 12 entrevistadores realizou entrevistas a pacientes com DP (n = 20), 
parentes (n = 12) e profissionais de saúde (n = 11). Os entrevistadores identificaram 
dez necessidades frequentemente mencionadas e combinaram as citações mais 
informativas num vídeo abrangente, que foi mostrado aos entrevistados numa reunião 
de consenso. Nessa reunião, os entrevistados prioritizaram as dez necessidades 
identificadas, atribuindo no máximo três pontos a cada uma das diferentes 
necessidades. Era possível alocar todos os três pontos a uma única necessidade ou 
dividi-los entre duas ou três necessidades. O número total de pontos representa a 
importância do tema.
A abordagem de VoC revelou que as necessidades mais urgentes do paciente diziam 
respeito ao domínio social, emocional ou doméstico, e não aos aspectos biomédicos 
da doença. As principais necessidades não atendidas foram: (1) maior autogestão; 
(2) melhor colaboração interdisciplinar entre diferentes prestadores de saúde; (3) 
mais tempo para discutir os cenários futuros e possíveis; e (4) um prestador de saúde 
atuando como gerente de caso pessoal, seja para resolver problemas diretamente ou 
para direcionar os pacientes com DP ao profissional mais bem equipado para resolver 
o problema em questão. Esses resultados podem servir para otimizar o atendimento 
aos pacientes com DP.
Resumo
Capítulo 1
A Doença de Parkinson (DP) é uma doença neurodegenerativa progressiva crónica, 
caracterizada por uma ampla gama de sintomas. Muitos prestadores de saúde 
diferentes estão envolvidos no tratamento de pacientes com DP, o que acarreta custos 
substanciais. Para atingir os melhores resultados, o atendimento aos pacientes com 
DP deve ser contínuo e sustentável. Nesta tese utilizamos as seguintes definições: 
cuidado contínuo é cuidado consistente e coerente, marcado por uma relação das partes 
ordenada, lógica e consistente, sem descontinuidades ou disparidades, uniformes em 
qualidade e combinados de forma imperceptível. Cuidado sustentável é o cuidado que 
pode ser sustentado ao longo do tempo, que é eficiente e não drena recursos finitos 
desnecessários.
Apesar dos esforços, o cuidado atual de pacientes com DP está frequentemente longe 
de ser contínuo e sustentável. Em primeiro lugar, os cuidados que os pacientes com DP 
recebem são bastante variáveis, o que implica que os cuidados não são "consistentes", 
"coerentes" ou "uniformes em qualidade". Em segundo lugar, os pacientes com 
DP não consideram os seus cuidados como "marcados por uma relação ordenada, 
lógica e consistente das partes". Terceiro, as questões financeiras nos sistemas de 
saúde impedem a prestação de cuidados contínuos e sustentáveis. E, finalmente, o 
atendimento aos pacientes com DP é prestado por profissionais de saúde dispersos, 
complicando a colaboração multidisciplinar e, como resultado, os profissionais de 
saúde tratam poucos pacientes com DP e não se tornam especialistas.
O objetivo desta tese é estudar medidas potenciais para alcançar um cuidado contínuo 
e sustentável de pacientes com DP. Isso resulta nas seguintes questões de pesquisa: 
Como é a percurso atual do paciente com DP? Quais são as descontinuidades atuais 
no atendimento aos pacientes com DP? Os modelos de pagamento baseados em 
resultados podem contribuir para um cuidado contínuo e sustentável de pacientes 
com DP? O cuidado de pacientes com DP será mais contínuo e sustentável se os 
prestadores partilharem mais pacientes?
Capítulo 2 
No Capítulo 2, usamos o banco de dados nacional de reclamações médicas holandês 
para reconstruir o percurso de pacientes com PD por sexo durante os primeiros cinco 
anos após o diagnóstico. Numa análise tempo-para-evento usando dados dos seguros 
de saúde de todos os pacientes com diagnóstico de DP entre 2012 e 2016 nos Países 
Baixos, identificamos os momentos em que esses pacientes receberam cuidados de 
neurologistas, terapeutas de saúde aliados e médicos de clínica geral. Da mesma forma, 
identificamos os momentos em que marcos clínicos relevantes foram alcançados: a 
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como um proxy para a densidade da sua colaboração (pontuação de densidade). 
Calculámos a pontuação de densidade média por paciente com DP e por população 
hospitalar. Visualizámos gráficos de colaboração dos três hospitais com pontuações 
mais altas e mais baixas, utilizando t-distributed Stochastic Neighbour Embedding 
(t-SNE). Usando análises de regressão logística e linear, estimámos a relação entre 
densidade e resultados de saúde, utilização de saúde e custos de saúde.
A pontuação de densidade média variou consideravelmente por paciente (média 6,7; 
desvio padrão 8,2), bem como por hospital (média 3,9; desvio padrão 8,2). Ajustados 
para variáveis de confusão, as pontuações de densidade mais altas foram associadas 
a um menor risco de complicações relacionadas com DP e a menores custos de saúde, 
embora não com mortalidade. Pontuações de densidade mais altas foram associados 
a envolvimento mais frequente de neurologistas, fisioterapeutas e terapeutas 
ocupacionais, mas a um envolvimento menos frequente de psicólogos. Portanto, 
propomos o uso de pontuações de densidade como indicador de qualidade em redes 
de prestadores de saúde.
Capítulo 6
No Capítulo 6, discutimos como poderíamos melhorar o atendimento de pacientes 
com DP, transferindo-o para a casa do paciente. O cuidado de pacientes com DP 
é frequentemente mal planeado: pacientes com DP que estão hospitalizados 
frequentemente sofrem atrasos no tratamento, medicamentos contraindicados, 
imobilidade prolongada, estadias prolongadas e alta mortalidade. Apesar dos 
benefícios documentados de receber cuidados de médicos com experiência em DP, 
muitos pacientes com DP não recebem esses cuidados especializados. Além disso, 
os modelos de cuidado atuais frequentemente exigem que os indivíduos mais velhos 
com mobilidade, cognição e capacidade de condução de veículos prejudicadas sejam 
transportados por cuidadores informais para grandes centros médicos urbanos.
Mover o atendimento para a casa do paciente tornaria o atendimento de DP mais 
centrado no paciente. Fatores demográficos, incluindo o envelhecimento da 
população, e fatores sociais, como a fragmentação familiar, aumentarão a necessidade 
de cuidados domiciliares. Os avanços tecnológicos, principalmente a capacidade de 
avaliar e prestar cuidados remotamente, possibilitarão a transição do cuidado para o 
domicílio. No entanto, apesar de ser promissora, esta próxima geração de atendimento 
domiciliar terá que superar barreiras, incluindo modelos de seguro desatualizados e 
uma divisão tecnológica. Uma vez iniciado, o atendimento domiciliar aumentará o 
acesso a atendimento de alta qualidade para o número crescente de pacientes com DP.
Capítulo 4
O Capítulo 4 descreve uma revisão dos efeitos dos modelos de pagamento baseados em 
resultados (OBPMs) na qualidade do atendimento e nos custos de saúde. Em primeiro 
lugar, desenvolvemos uma definição para OBPMs: um modelo de pagamento em saúde 
em que os pagamentos de incentivos relacionados ao desempenho dos prestadores de 
saúde dependem em pelo menos 10% dos resultados do atendimento prestado, sendo 
especialmente pensado para estimular efeitos favoráveis em termos de qualidade de 
cuidados ou custos de saúde. Em seguida, pesquisamos quatro fontes de dados para 
identificar os modelos: 1) bancos de dados de literatura científica; 2) sites de agências 
governamentais e científicas relevantes; 3) listas de referências dos artigos incluídos; 
4) especialistas na área. Selecionamos apenas estudos que examinaram o impacto do 
modelo de pagamento na qualidade e / ou custos. Uma síntese de evidências foi usada 
para vincular características específicas aos efeitos sobre a qualidade do atendimento 
ou custos de saúde.
Incluímos 88 artigos, descrevendo 12 OBPMs. Nenhum deles focava especificamente 
a DP, embora todos os modelos tenham como alvo populações com condições 
crónicas. Distinguem-se dois grupos de OBPMs quanto à suas especificidades: OBPMs 
restritos, que contêm apenas incentivos financeiros explícitos para um desempenho 
de qualidade medido objetivamente; e OBPMs amplos, que combinam orçamentos 
globais e partilha de riscos para grupos de fornecedores multidisciplinares com 
incentivos financeiros explícitos para qualidade. A maioria (5 dos 9) OBPMs restritos 
mostrou efeitos positivos na qualidade; os outros tiveram efeitos mistos (2) ou 
negativos (2). Os efeitos dos OBPMs restritos sobre a utilização ou custos de saúde, 
no entanto, foram desfavoráveis (3) ou desconhecidos (6). Os três OBPMs amplos 
mostraram todos os efeitos positivos na qualidade do atendimento, ao mesmo tempo 
em que reduziram o crescimento dos custos de saúde. Embora apenas três OBPMs 
amplos puderam ser incluídos nesta análise, estes foram os que tiveram efeitos mais 
favoráveis na qualidade do atendimento e na utilização/custo dos cuidados de saúde.
Capítulo 5
No capítulo 5, observamos que os pacientes com DP criam as chamadas "redes de 
partilha de pacientes" de prestadores de saúde ao escolher os seus próprios presta-
dores de saúde. Essas redes diferem em "densidade": o número de pacientes que os 
prestadores partilham. Quisemos descobrir se redes mais densas de prestadores de 
serviços de saúde estavam relacionadas com melhores resultados para os pacientes, 
menor utilização de serviços de saúde e menores custos de saúde de DP. Usámos dados 
de seguros de saúde de todos os pacientes com DP nos Países Baixos entre 2012 e 2016. 
Incluímos todas as consultas a prestadores de saúde mais frequentemente envolvidos 
no atendimento a pacientes com DP. Para avaliar a densidade das redes de prestadores 
de saúde, usámos o número médio de pacientes que os prestadores de saúde partilham 
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Resumindo os pontos fortes e as limitações da pesquisa, parece-nos que o uso de 
uma combinação de metodologias de pesquisa é um ponto forte importante. Outros 
pontos fortes são as grandes amostras de nossas análises e a abrangência da nossa 
revisão sistemática. Uma limitação é a não inclusão de efeitos de longo prazo; ou 
seja, além dos cinco primeiros anos após o diagnóstico. Uma segunda limitação é que 
nossa revisão sobre OBPMs, que não é específica para PD. E, finalmente, as atividades 
do ParkinsonNet podem ter influenciado a generalização das nossas descobertas em 
vários capítulos.
Quanto ao futuro, defendemos mais pesquisas sobre atrasos de médicos ou pacientes 
específicos por sexo em DP para explicar o uso "precoce" de vários serviços de saúde em 
mulheres com DP. Recomendamos um teste-piloto em que enfermeiras especializadas 
em DP atuem como gerente de caso pessoal para pacientes com DP, para confirmar 
se isso pode tornar o cuidado aos pacientes com DP mais contínuo. Gostaríamos de 
otimizar o uso de inovações tecnológicas, como aplicativos de automonitorização. 
Sugerimos modelos de cuidado inovadores que atendam pacientes com DP mais perto 
de casa. E, por fim, defendemos o desenvolvimento de um OBPM para o atendimento 
de DP com densidade como indicador de qualidade incorporado. Incentivamos um 
teste-piloto para estudar os efeitos desse modelo na qualidade do atendimento e 
nos custos de saúde. Uma prestação de cuidados de DP melhor, mais contínua e mais 
sustentável pode servir como um exemplo de modelo para outras condições crónicas.
Capítulo 7
No Capítulo 7, interpretamos as nossas constatações e formulamos conclusões. 
Começamos com uma visão geral das principais descobertas. Primeiro, a reconstrução 
do percurso do paciente com Parkinson durante os primeiros cinco anos após o 
diagnóstico revelou profundas diferenças entre sexos: as mulheres consultam a 
maioria dos profissionais de saúde antes do diagnóstico e com mais frequência do que 
os homens (Capítulo 2). Em segundo lugar, as principais necessidades não atendidas 
dos pacientes são: : (1) maior autogestão; (2) melhor colaboração interdisciplinar 
entre diferentes prestadores de saúde; (3) mais tempo para discutir os cenários 
futuros e possíveis; e (4) um prestador de saúde atuando como gerente de caso 
pessoal (Capítulo 3). Terceiro, OBPMs amplos parecem ter os efeitos mais promissores 
quanto à qualidade do atendimento e custos de saúde (Capítulo 4). Quarto, redes mais 
densas de prestadores de saúde estão associadas a menor ocorrência de complicações 
relacionadas com DP, maior utilização de saúde, mas menores custos (Capítulo 5). 
Finalmente, os cuidados devem ser oferecidos mais perto da casa do paciente (Capítulo 
6).
As nossas interpretações são as seguintes. O cuidado de pacientes com DP nos 
Países Baixos não é nem contínuo nem sustentável. Todas as descontinuidades 
identificadas dizem respeito a aspectos organizacionais, e não a aspectos biomédicos. 
A descontinuidade identificada de diferenças inexplicáveis de sexo no uso de 
cuidados de saúde pode ser devido ao atraso do médico ou do paciente no processo de 
diagnóstico em mulheres. As descontinuidades mais urgentes relatadas pelos próprios 
pacientes com DP dizem respeito ao domínio social, emocional ou doméstico. Para 
identificar descontinuidades no atendimento, a perspectiva dos pacientes com DP 
deve ser incluída, e o método Voz do Cliente pode auxiliar.
Oferecemos algumas sugestões sobre como lidar com essas descontinuidades. 
Primeiro, a forma como os prestadores estão organizados e dividem tarefas deve ser 
repensada. Argumentamos que enfermeiras especializadas em Parkinson são as mais 
adequadas para atuar como gerentes de casos pessoais. Em segundo lugar, as visitas de 
vídeo e os aplicativos de automonitorização podem ajudar a superar algumas falhas 
no tratamento de DP. Terceiro, gostaríamos de desenvolver programas de cuidados 
domiciliares para DP, em vez dos modelos de cuidados atuais mais baseados em 
hospitais.
Com relação ao modelo de pagamento para atendimento em DP, sugerimos um OBPM 
amplo experimental que vincule incentivos financeiros a indicadores de qualidade 
relevantes para DP. A 'densidade' poderia, portanto, atuar como um indicador de 
qualidade neste novo modelo, em que uma densidade alta teria efeitos favoráveis na 
qualidade dos cuidados e nos custos de saúde.
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